FCRN antibodies and methods of use

JP2023548858A5Inactive Publication Date: 2024-11-14MOMENTA PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526977
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-07-07
Filing Date
2021-11-05
Publication Date
2024-11-14
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Methods for administering antibodies against human neonatal Fc receptor (FcRn) are described. Anti-FcRn antibodies are useful, for example, to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, for example, to block immune complex-based activation of an immune response in a subject, or to treat an immune disease (e.g., an autoimmune disease) in a subject.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] (Cross - Reference to Related Applications) This application claims priority to U.S. Provisional Patent Application No. 63 / 110,884, filed on November 6, 2020; U.S. Provisional Patent Application No. 63 / 137,972, filed on January 15, 2021; U.S. Provisional Patent Application No. 63 / 173,126, filed on April 9, 2021; U.S. Provisional Patent Application No. 63 / 173,919, filed on April 12, 2021; U.S. Provisional Patent Application No. 63 / 174,423, filed on April 13, 2021; U.S. Provisional Patent Application No. 63 / 175,440, filed on April 15, 2021; U.S. Provisional Patent Application No. 63 / 203,075, filed on July 7, 2021; U.S. Provisional Patent Application No. 63 / 203,077, filed on July 7, 2021; and U.S. Provisional Patent Application No. 63 / 219,155, filed on July 7, 2021, each of which is hereby incorporated by reference in its entirety.

[0002] (Background) Therapeutic proteins, such as therapeutic antibodies, have rapidly become a clinically important drug class for patients with immune diseases. A number of autoimmune and alloimmune diseases are mediated by pathogenic antibodies.

[0003] There is a need for new methods of treating immune diseases.

[0004] (Summary) The present disclosure features methods for dosing an antibody against the human neonatal Fc receptor (FcRn). Anti - FcRn antibodies are useful, for example, for promoting clearance of autoantibodies in a subject, for suppressing antigen presentation in a subject, for blocking an immune response, for example, for blocking immune complex - based activation of an immune response in a subject, or for treating an immune disease (e.g., an autoimmune disease) in a subject.

[0005] This specification describes methods for treating various disorders, including intravenous or subcutaneous administration of anti-FcRn antibodies described herein at doses of approximately 15 mg / kg to approximately 60 mg / kg to the target. The methods described herein may include an initial dose at a first dose level (e.g., a loading dose or induction dose), followed by subsequent doses at different dose levels or maintenance dose levels.

[0006] In some embodiments, a method is provided for treating myasthenia gravis in a patient requiring treatment for myasthenia gravis, comprising administering an initial loading dose of anti-FcRn antibody at approximately 30 mg / kg to approximately 60 mg / kg, followed by a maintenance dose of anti-FcRn antibody at approximately 15 mg / kg to approximately 30 mg / kg, wherein the anti-FcRn antibody comprises a heavy chain including HCDR1 of SEQ ID NO: 6, HCDR2 of SEQ ID NO: 7, and HCDR3 of SEQ ID NO: 8, and a light chain including LCDR1 of SEQ ID NO: 3, LCDR2 of SEQ ID NO: 4, and LCDR3 of SEQ ID NO: 5, wherein the administration reduces serum IgG in the patient by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of baseline serum IgG.

[0007] In some embodiments, a method is provided for treating myasthenia gravis in a patient requiring treatment for myasthenia gravis, comprising administering an initial loading dose of anti-FcRn antibody at approximately 30 mg / kg to approximately 60 mg / kg, followed by a maintenance dose of anti-FcRn antibody at approximately 15 mg / kg to approximately 30 mg / kg, wherein the anti-FcRn antibody comprises a heavy chain including HCDR1 of SEQ ID NO: 6, HCDR2 of SEQ ID NO: 7, and HCDR3 of SEQ ID NO: 8, and a light chain including LCDR1 of SEQ ID NO: 3, LCDR2 of SEQ ID NO: 4, and LCDR3 of SEQ ID NO: 5, wherein the administration reduces baseline serum autoantibodies by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 50%, or at least 25%.

[0008] In some embodiments, a method is provided for treating or reducing the severity of myasthenia gravis in a subject, comprising administering an initial loading dose of anti-FcRn antibody in the range of approximately 5 mg / kg to approximately 120 mg / kg to the subject, followed by a maintenance dose of anti-FcRn antibody in the range of approximately 5 mg / kg to approximately 60 mg / kg, wherein the anti-FcRn antibody comprises a heavy chain including HCDR1 of SEQ ID NO: 6, HCDR2 of SEQ ID NO: 7, and HCDR3 of SEQ ID NO: 8, and a light chain including LCDR1 of SEQ ID NO: 3, LCDR2 of SEQ ID NO: 4, and LCDR3 of SEQ ID NO: 5.

[0009] In some embodiments, a pharmaceutical composition is provided for administration to a patient suffering from myasthenia gravis, wherein the anti-FcRn antibody is administered to the patient at an initial loading dose of about 30 mg / kg to about 60 mg / kg, followed by a maintenance dose of about 15 mg / kg to about 30 mg / kg, and the anti-FcRn antibody comprises a heavy chain including HCDR1 of SEQ ID NO: 6, HCDR2 of SEQ ID NO: 7, and HCDR3 of SEQ ID NO: 8, and a light chain including LCDR1 of SEQ ID NO: 3, LCDR2 of SEQ ID NO: 4, and LCDR3 of SEQ ID NO: 5. [Brief explanation of the drawing]

[0010] [Figure 1] This graph shows the mean (SD) FcRn receptor occupancy in circulating monocytes after a single administration of M281 at concentrations of 0.3 mg / kg, 3 mg / kg, 10 mg / kg, 30 mg / kg, and 60 mg / kg. [Figure 2] This graph shows the mean (SD) serum IgG levels after a single dose of M281 at concentrations of 0.3 mg / kg, 3 mg / kg, 10 mg / kg, 30 mg / kg, and 60 mg / kg. [Figure 3A] This graph shows the mean (SD) FcRn receptor occupancy rate in monocytes in MAD cohorts at 30 mg / kg (Figure 3A) and 15 mg / kg (Figure 3B), divided by the number of doses administered. [Figure 3B]This graph shows the mean (SD) FcRn receptor occupancy rate in monocytes in MAD cohorts at 30 mg / kg (Figure 3A) and 15 mg / kg (Figure 3B), divided by the number of doses administered. [Figure 4A] This graph shows the mean (SD) serum IgG levels in the MAD cohorts at 30 mg / kg (Figure 4A) and 15 mg / kg (Figure 4B), divided by the number of doses administered. [Figure 4B] This graph shows the mean (SD) serum IgG levels in the MAD cohorts at 30 mg / kg (Figure 4A) and 15 mg / kg (Figure 4B), divided by the number of doses administered. [Figure 5A] This graph shows the results of a model designed to predict the effects of various doses of M281 on serum IgG during Q4W (Figure 5A) or Q2W (Figure 5B). [Figure 5B] This graph shows the results of a model designed to predict the effects of various doses of M281 on serum IgG during Q4W (Figure 5A) or Q2W (Figure 5B). [Figure 6] This graph shows the results of a model designed to predict the effects of various doses of M281 on MG-ADL compared to placebo. [Figure 7A] This graph shows the results of a model designed to predict the effects of various doses of M281 on serum IgG (Figure 7A) and MG-ADL (Figure 7B) compared to placebo. [Figure 7B] This graph shows the results of a model designed to predict the effects of various doses of M281 on serum IgG (Figure 7A) and MG-ADL (Figure 7B) compared to placebo. [Figure 8A] This is an enlarged view of the graphs in Figures 7A and 7B for weeks 1-4, showing the results of a model designed to predict the effects of various doses of M281 on serum IgG (Figure 8A) and MG-ADL (Figure 8B) compared to placebo. [Figure 8B]This is an enlarged view of the graphs in Figures 7A and 7B for weeks 1-4, showing the results of a model designed to predict the effects of various doses of M281 on serum IgG (Figure 8A) and MG-ADL (Figure 8B) compared to placebo. [Figure 9] This graph shows the results of a model designed to predict the effects of various doses of M281 on serum albumin levels. [Figure 10] This graph shows the results of a model designed to predict IgG reduction and MG-ADL improvement in adult patients with gMG following maintenance dosing of 15 mg / kg and 30 mg / kg for q2w. [Figure 11] This graph shows the results of a model designed to predict IgG reduction and MG-ADL improvement with a 30 mg / kg loading dose in adult patients with gMG. [Figure 12] This graph shows the mean (±SE) percentage relative to baseline IgG over time. [Figure 13] This graph shows the arithmetic mean (±SE) of AChR-binding antibodies and IgG relative to baseline over time.

[0011] (Detailed description) definition As used herein, the terms “a” and “an” mean “at least one” or “one or more” unless the context explicitly indicates otherwise.

[0012] Where used herein, the term “approximately” means that a number is an approximation and small variations will not significantly affect the implementation of the disclosed embodiments. Where numerical limitations are used, unless otherwise indicated by the context, “approximately” means that a number may vary by + / - 10% and remain within the scope of the disclosed embodiments. In addition, values ​​may be preceded by the term “approximately,” but exact values ​​are also provided herein, i.e., without the term “approximately.”

[0013] As used herein, the term "antibody" is used in the broadest sense and encompasses various antibody structures including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, as long as they exhibit FcRn antigen-binding activity.

[0014] "Antibody fragment" includes a portion of an intact antibody that includes the antigen-binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab’, F(ab’)2, and Fv fragments, diabodies, linear antibodies, single-chain antibody molecules, and multispecific antibodies.

[0015] As used herein, the term "isolated antibody" refers to an antibody that has been separated and / or recovered from the components of its production host cell environment, where the contaminating components of the production host cell environment are substances that interfere with the research, diagnostic, or therapeutic use of the antibody. Contaminating components can include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In some embodiments, for example, as determined by the Lowry method, (1) greater than 95% by weight of the antibody, and in some embodiments greater than 99% by weight, (2) to an extent sufficient to obtain at least 15 residues of the N-terminus or internal amino acids, for example, by use of a spinning cup sequencer, or (3) to homogeneity by SDS-PAGE under reducing or non-reducing conditions using, for example, Coomassie blue or silver staining. Isolated antibodies include antibodies in situ within recombinant cells. However, typically isolated antibodies are prepared by at least one purification step. Pharmaceutical preparations of isolated antibodies typically have less than 250 ppm (e.g., less than 200 ppm, 150 ppm, 100 ppm) of host cell protein (HCP) as determined by an ELISA-based HCP assay performed as recommended by FDA "Guidance for Industry" documents.

[0016] As used herein, the term "baseline" with respect to the amount, concentration or level of a molecule refers to the amount, concentration or level of the molecule prior to administration of a therapeutic agent (e.g., an antibody) provided herein.

[0017] As used herein, "comprising" (and any form of comprising such as "comprise", "comprises" and "comprised"), "having" (and any form of having such as "have" and "has"), "including" (and any form of including such as "includes" and "include"), or "containing" (and any form of containing such as "contains" and "contain") are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. Any step or composition using the transitional phrase "comprise" or "comprising" can also be said to describe the same thing as the transitional phrase "consisting of" or "consists of".

[0018] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous population of antibodies, i.e., the individual antibodies in the population have the same primary sequence except for naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific and are directed against a single antigenic site (i.e., an epitope on human FcRn). In contrast to polyclonal antibody preparations, which typically contain different antibodies directed against different epitopes, each monoclonal antibody is directed against a single epitope on an antigen. The modifier "monoclonal" indicates the characteristic of an antibody obtained from a substantially homogeneous population of antibodies and should not be construed as requiring production of the antibody by any particular method.

[0019] As used herein, the terms “variable region” and “variable domain” refer to portions of the light and heavy chains of an antibody that include the amino acid sequences of complementarity-determining regions (CDRs, e.g., CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, and CDR H3) and framework regions (FRs). According to the methods used herein, the amino acid positions assigned to the CDRs and FRs are defined according to Kabat. Using this numbering system, the actual linear amino acid sequence may include fewer or additional amino acids corresponding to the shortening or insertion into the CDRs (as further defined herein) or FRs of the variable region. For example, the heavy chain variable region may include a single inserted residue after residue 52 of the CDR H2 (i.e., residue 52a according to Kabat) and a residue inserted after residue 82 of the heavy chain FR (e.g., residues 82a, 82b, 82c, etc. according to Kabat). The Kabat numbering of residues can be determined for a given antibody by aligning its sequence with a "standard" Kabat numbered sequence in homologous regions.

[0020] As used herein, the terms “complementarity-determining region” and “CDR” refer to regions of antibody variable domains or variable regions whose sequences are hypervariable and / or form structurally defined loops. CDRs are also known as hypervariable regions. The light chain and heavy chain variable regions each have three CDRs. The light chain variable region contains CDR L1, CDR L2, and CDR L3. The heavy chain variable region contains CDR H1, CDR H2, and CDR H3. Each CDR may contain amino acid residues derived from the complementarity-determining region as defined by Kabat (i.e., approximately residues 24-34 (CDR L1), 50-56 (CDR L2), and 89-97 (CDR L3) in the light chain variable region, and approximately residues 31-35 (CDR H1), 50-65 (CDR H2), and 95-102 (CDR H3) in the heavy chain variable region).

[0021] As used herein, the term "FcRn" refers to the neonatal Fc receptor that binds to the Fc region of an IgG antibody, such as an IgG1 antibody. An exemplary FcRn is the human FcRn with UniProt ID number P55899. Human FcRns are thought to be involved in maintaining the half-life of IgG by constitutively binding to internalized IgG for its reuse, returning it to the cell surface for transport.

[0022] As used herein, the terms “affinity” and “binding affinity” refer to the strength of the binding interaction between two molecules. Generally, binding affinity refers to the strength of the combined non-covalent interactions between a single binding site of a molecule and its binding partner, for example, an isolated antibody and its target (e.g., an isolated anti-FcRn antibody and human FcRn). Unless otherwise stated, binding affinity refers to the intrinsic binding affinity, which reflects the 1:1 interaction between members of a binding pair. The binding affinity between two molecules is generally expressed using the dissociation constant (K). D ) or affinity constant (K A As described by ), two molecules with low binding affinity to each other generally tend to bind slowly and dissociate easily, and large K D This shows that two molecules with high affinity for each other generally tend to bind easily and remain bound for longer periods, and a small K D This indicates.

[0023] As used herein, the term "inhibits IgG binding to FcRn" refers to the ability of an anti-FcRn antibody to block or inhibit the binding of IgG (e.g., IgG1) to human FcRn. In some embodiments, the anti-FcRn antibody binds to FcRn at a site on the human FcRn where IgG would normally bind. Thus, the anti-FcRn antibody can inhibit the binding of IgG (e.g., the autoantibody of the subject) to FcRn. In some embodiments, the molecule (e.g., the anti-FcRn antibody of this disclosure) substantially or completely inhibits binding to IgG. In some embodiments, IgG binding is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or even 100%.

[0024] As used herein, the term "inhibits the binding of pathogenic antibodies to FcRn" refers to the ability of an anti-FcRn antibody to block or inhibit the binding of pathogenic antibodies (e.g., pathogenic IgG antibodies) to human FcRn. In some embodiments, the anti-FcRn antibody binds to FcRn at a site on human FcRn where pathogenic antibodies bind, for example. Thus, the anti-FcRn antibody can inhibit the binding of pathogenic antibodies (e.g., pathogenic IgG antibodies) to FcRn. In some embodiments, the molecule (e.g., anti-FcRn antibody) substantially or completely inhibits binding to pathogenic antibodies. In some embodiments, the binding of pathogenic antibodies to FcRn is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or even 100%.

[0025] As used herein, the term “hydrophobic amino acid” refers to an amino acid that has relatively low water solubility. Examples of hydrophobic amino acids include, but are not limited to, leucine, isoleucine, alanine, phenylalanine, valine, and proline. In some embodiments, the hydrophobic amino acids in this disclosure are alanine, leucine, isoleucine, and valine.

[0026] As used herein, the term “polar amino acid” refers to an amino acid whose side chain has chemical polarity induced by atoms with different electronegativity. The polarity of a polar amino acid depends on the electronegativity between atoms in the amino acid's side chain and the structural asymmetry of the side chain. Examples of polar amino acids include, but are not limited to, serine, threonine, cysteine, methionine, tyrosine, tryptophan, asparagine, and glutamine. In some embodiments, the polar amino acids in this disclosure are serine, threonine, asparagine, glutamine, cysteine, and tyrosine.

[0027] As used herein, the term “acidic amino acid” refers to an amino acid whose side chain contains a carboxylic acid group having a pKa of 3.5 to 4.5. In some embodiments, the acidic amino acids are aspartic acid and glutamic acid.

[0028] As used herein, the term “basic amino acid” refers to an amino acid whose side chain contains an amino group having a pKa of 9.5 to 13. In some embodiments, the basic amino acids are histidine, lysine, and arginine.

[0029] As used herein, the term “identity percentage (%)” means the percentage of amino acid (or nucleic acid) residues of a candidate sequence, e.g., amino acid (or nucleic acid) residues of the anti-FcRn antibody of this disclosure, after the sequences have been aligned and gaps introduced as necessary to achieve the maximum identity percentage (i.e., gaps can be introduced in one or both of the candidate sequence and the reference sequence for optimal alignment, and non-homologous sequences can be ignored for comparison purposes). Alignment for the purpose of determining identity percentage can be achieved using various methods within the scope of skill in the art, e.g., using publicly available computer software such as BLAST, ALIGN, or Megalign (DNASTAR) software. A person skilled in the art can determine appropriate parameters for measuring alignment, including any algorithm necessary to achieve the maximum alignment over the entire length of the sequences being compared. In some embodiments, the percentage of amino acid (or nucleic acid) sequence identity between a given reference sequence, a given candidate sequence with respect to a given reference sequence, or a given candidate sequence that opposes a given reference sequence (or alternatively, a given candidate sequence that has or contains a certain percentage of amino acid (or nucleic acid) sequence identity between a given reference sequence, a given reference sequence, or a given candidate sequence that opposes a given reference sequence) is calculated as follows: 100 × (Ratio of A / B) A is the number of amino acid (or nucleic acid) residues scored as identical in the alignment of the candidate sequence and the reference sequence, and B is the total number of amino acid (or nucleic acid) residues in the reference sequence. In some embodiments where the length of the candidate sequence is not equal to the length of the reference sequence, the percentage of amino acid (or nucleic acid) sequence identity of the candidate sequence to the reference sequence is not equal to the percentage of amino acid (or nucleic acid) sequence identity of the reference sequence to the candidate sequence.

[0030] In certain embodiments, a reference sequence aligned for comparison with a candidate sequence may demonstrate that the candidate sequence exhibits 50% to 100% identity over its entire length or a selected portion of consecutive amino acid (or nucleic acid) residues. The length of the candidate sequence aligned for comparison purposes is at least 30%, e.g., at least 40%, e.g., at least 50%, 60%, 70%, 80%, 90%, or 100% of the length of the reference sequence. The molecules are identical at a position when that position in the candidate sequence is occupied by the same amino acid (or nucleic acid) residue as the corresponding position in the reference sequence. Positions can be altered by substitution, deletion, or insertion. Substitutions, deletions, or insertions may involve a specific number of amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more). When describing substitutions, deletions, or insertions of n or fewer amino acids, this means that the substitutions, deletions, or insertions contain, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or n amino acids. The number of substitutions, deletions, or insertions may be a percentage of the entire sequence (e.g., 1%, 5%, 10%, 15%, 20%, or more), and the number of substitutions, deletions, or insertions may change the total number of amino acids in the entire sequence by 5%, 10%, 15%, 20%, or more.

[0031] As used herein, the term “fetal and neonatal alloimmunity and / or autoimmune disorder” refers to an immune disorder in the fetus and / or neonatal caused by the transplacental transfer of maternal antibodies (e.g., pathogenic maternal antibodies) directed against fetal and / or neonatal antigens. For example, antibodies targeted by pregnancy (e.g., pathogenic antibodies) may react with antigens in the fetus (e.g., antigens inherited by the fetus from the fetal father). Examples of fetal and neonatal alloimmunity and / or autoimmune disorders are provided herein.

[0032] As used herein, the term “pathogenic antibody” refers to an antibody that causes one or more immune diseases or disorders in a subject (e.g., a pregnant subject), the fetus of the pregnant subject, and / or the newborn. In some embodiments, the pathogenic antibody is an autoantibody produced in the subject (e.g., a pregnant subject) against one or more of the subject's own proteins, and therefore causes an autoimmune disease or disorder in the subject. In some embodiments, the pathogenic antibody in the pregnant subject crosses the placenta to the fetus and reacts with fetal antigens (e.g., antigens inherited by the fetus from the father), and therefore may cause, for example, alloimmunity and / or autoimmune disorders in the fetus and the newborn.

[0033] As used herein, “antibody-mediated enhancement of viral disease” refers to a viral disease in which an antibody can facilitate viral entry into a host cell, thus leading to increased or enhanced infectivity in the cell. In some embodiments, the antibody may bind to a viral surface protein, and the antibody / virus complex may bind to an FcRn receptor on the cell surface via an interaction between the antibody and the receptor. The antibody / virus complex may then be internalized within the cell.

[0034] As used herein, the term “gestational age” describes how far along a pregnancy is. Gestational age can be expressed in weeks. Methods for determining gestational age are known in the art (e.g., Committee on Obstetric Practice, American Institute of Ultrasound in Medicine, Society for Maternal-Fetal Medicine, Committee Opinion, Number 700, May 2017, which is incorporated herein in its entirety). In some cases, gestational age can be determined by ultrasound, the number of weeks from the first day of the last menstrual period (LMP), or a combination thereof.

[0035] As used herein, the term “pharmaceutical composition” refers to a pharmaceutical or pharmaceutically acceptable preparation comprising an active ingredient and one or more excipients and diluents for making the active ingredient suitable for a method of administration. The pharmaceutical compositions of this disclosure contain a pharmaceutically acceptable ingredient compatible with an anti-FcRn antibody. The pharmaceutical compositions may be in aqueous form for intravenous or subcutaneous administration, or in tablet or capsule form for oral administration.

[0036] As used herein, the term “pharmaceutically acceptable carrier” refers to an excipient or diluent in a pharmaceutical composition. A pharmaceutically acceptable carrier must be compatible with the other components of the formulation and must not be harmful to the recipient. In this disclosure, a pharmaceutically acceptable carrier must provide adequate pharmaceutically stable for the Fc construct. The properties of the carrier vary depending on the mode of administration. For example, aqueous solution carriers are commonly used for intravenous administration, and solid carriers are commonly used for oral administration.

[0037] As used herein, the term “therapeutic dose” means an amount effective in inducing a desired biological effect in a subject or patient, or in treating a patient with a condition or disorder described herein, such as a pharmaceutical dose. It should also be understood that “therapeutic dose” may be interpreted herein as an amount that, when administered alone or in combination with other therapeutic agents, or when taken in any dose or route, produces the desired therapeutic effect.

[0038] As used herein, the term “not more” means the following quantities, which may be integers. For example, two or fewer permutations may mean 0, 1, or 2 permutations.

[0039] As used herein, the terms “treatment” or “to treat” mean reducing, decreasing, reducing the risk of, or reducing the side effects of a particular disease or condition. This reduction, decrease, risk reduction, or reduction of side effects is compared to a subject who did not receive treatment, e.g., a control, baseline, or a known control level or measurement.

[0040] This specification describes a method for administering an anti-FcRn antibody, preferably such as nipocalimab. The method may include initiating weekly, bi-weekly, quarterly, or monthly doses at a lower maintenance dose (e.g., approximately 75%, 50%, 25%, 20%, 15%, 10%, or 5% of the loading dose) one, two, three, or four weeks after the administration of a loading dose. The antibody can be administered relatively rapidly but safely by IV or subcutaneously.

[0041] I. Anti-FcRn antibody Methods for treating various disorders, including the injection of anti-FcRn antibodies at doses of approximately 5 mg / kg to approximately 120 mg / kg into a subject, are described herein. In some embodiments, the injection is intravenous or subcutaneous.

[0042] In some embodiments, the method includes intravenous administration of an initial loading dose of approximately 60 mg / kg followed by bi-weekly intravenous administration of a maintenance dose of approximately 30 mg / kg. In some embodiments, the method includes intravenous administration of an initial loading dose of approximately 60 mg / kg followed by bi-weekly intravenous administration of a maintenance dose of approximately 15 mg / kg. In some embodiments, the method includes intravenous administration of an initial loading dose of approximately 30 mg / kg followed by bi-weekly intravenous administration of a maintenance dose of approximately 30 mg / kg. In some embodiments, the method includes intravenous administration of an initial loading dose of approximately 30 mg / kg followed by bi-weekly intravenous administration of a maintenance dose of approximately 15 mg / kg. In some embodiments, the method includes intravenous administration of an initial loading dose of approximately 60 mg / kg followed by monthly intravenous administration of a maintenance dose of approximately 30 mg / kg. In some embodiments, the method includes intravenous administration of an initial loading dose of approximately 60 mg / kg followed by monthly intravenous administration of a maintenance dose of approximately 15 mg / kg. In some embodiments, the method includes an intravenous administration of an initial loading dose of approximately 30 mg / kg, followed by monthly intravenous administration of a maintenance dose of approximately 30 mg / kg. In some embodiments, the method includes an intravenous administration of an initial loading dose of approximately 30 mg / kg, followed by monthly intravenous administration of a maintenance dose of approximately 15 mg / kg.

[0043] In some embodiments, the method includes subcutaneous administration of an initial loading dose of approximately 60 mg / kg followed by bi-weekly subcutaneous administration of a maintenance dose of approximately 30 mg / kg. In some embodiments, the method includes subcutaneous administration of an initial loading dose of approximately 60 mg / kg followed by bi-weekly subcutaneous administration of a maintenance dose of approximately 15 mg / kg. In some embodiments, the method includes subcutaneous administration of an initial loading dose of approximately 30 mg / kg followed by bi-weekly subcutaneous administration of a maintenance dose of approximately 30 mg / kg. In some embodiments, the method includes subcutaneous administration of an initial loading dose of approximately 30 mg / kg followed by bi-weekly subcutaneous administration of a maintenance dose of approximately 15 mg / kg. In some embodiments, the method includes subcutaneous administration of an initial loading dose of approximately 60 mg / kg followed by monthly subcutaneous administration of a maintenance dose of approximately 30 mg / kg. In some embodiments, the method includes subcutaneous administration of an initial loading dose of approximately 60 mg / kg followed by monthly subcutaneous administration of a maintenance dose of approximately 15 mg / kg. In some embodiments, the method includes a subcutaneous administration of an initial loading dose of approximately 30 mg / kg, followed by a monthly subcutaneous administration of a maintenance dose of approximately 30 mg / kg. In some embodiments, the method includes a subcutaneous administration of an initial loading dose of approximately 30 mg / kg, followed by a monthly subcutaneous administration of a maintenance dose of approximately 15 mg / kg.

[0044] In some embodiments, the method includes intravenous administration of an initial loading dose of approximately 60 mg / kg, followed by bi-weekly subcutaneous administration of a maintenance dose of approximately 30 mg / kg. In some embodiments, the method includes intravenous administration of an initial loading dose of approximately 60 mg / kg, followed by bi-weekly subcutaneous administration of a maintenance dose of approximately 15 mg / kg. In some embodiments, the method includes intravenous administration of an initial loading dose of approximately 30 mg / kg, followed by bi-weekly subcutaneous administration of a maintenance dose of approximately 30 mg / kg. In some embodiments, the method includes intravenous administration of an initial loading dose of approximately 30 mg / kg, followed by bi-weekly subcutaneous administration of a maintenance dose of approximately 15 mg / kg. In some embodiments, the method includes intravenous administration of an initial loading dose of approximately 60 mg / kg, followed by monthly subcutaneous administration of a maintenance dose of approximately 30 mg / kg. In some embodiments, the method includes intravenous administration of an initial loading dose of approximately 60 mg / kg, followed by monthly subcutaneous administration of a maintenance dose of approximately 15 mg / kg. In some embodiments, the method includes an intravenous administration of an initial loading dose of approximately 30 mg / kg, followed by monthly subcutaneous administration of a maintenance dose of approximately 30 mg / kg. In some embodiments, the method includes an intravenous administration of an initial loading dose of approximately 30 mg / kg, followed by monthly subcutaneous administration of a maintenance dose of approximately 15 mg / kg.

[0045] In some embodiments, the anti-FcRn antibody is M281. In some embodiments, the anti-FcRn antibody is nipocalimab. In some embodiments, M281 and nipocalimab have the same amino acid sequence. In some embodiments, M281 and nipocalimab have the same heavy chain and light chain amino acid sequence. In some embodiments, M281 and nipocalimab have the same variable heavy chain and variable light chain amino acid sequence. As used herein, "M281" and "nipocalimab" refer to the same antibody and can be used interchangeably. In preferred embodiments, the anti-FcRn antibody is M281.

[0046] In some embodiments, the anti-FcRn antibody is M281 and comprises or consists of a light chain with the sequence: QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMIYGDSERPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 1), and the sequence: EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKG PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFP A heavy chain containing or consisting of PKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (Sequence ID 2), or comprising them.

[0047] In some embodiments, the anti-FcRn antibody comprises (a) a light chain sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1, wherein LCDR1 comprises the sequence TGTGSDVGSYNLVS (SEQ ID NO: 3), LCDR2 comprises the sequence GDSERPS (SEQ ID NO: 4), and LCDR3 comprises the sequence SSYAGSGIYV (SEQ ID NO: 5); and (b) a heavy chain sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2, wherein HCDR1 comprises the sequence TYAMG (SEQ ID NO: 6), HCDR2 comprises the sequence SIGASGSQTRYADS (SEQ ID NO: 7), and HCDR3 comprises the sequence LAIGDSY (SEQ ID NO: 8).

[0048] In some embodiments, the anti-FcRn antibody includes a light chain variable region containing an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMIYGDSERPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTKVTVL (SEQ ID NO: 9). In some embodiments, the light chain variable region contains LCDR1 having the sequence TGTGSDVGSYNLVS (SEQ ID NO: 3), LCDR2 having the sequence GDSERPS (SEQ ID NO: 4), and LCDR3 having the sequence SSYAGSGIYV (SEQ ID NO: 5).

[0049] In some embodiments, the anti-FcRn antibody includes a heavy chain variable region containing an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSS (SEQ ID NO: 10). In some embodiments, the heavy chain variable region contains HCDR1 having the sequence TYAMG (SEQ ID NO: 6), HCDR2 having the sequence SIGASGSQTRYADS (SEQ ID NO: 7), and HCDR3 having the sequence LAIGDSY (SEQ ID NO: 8).

[0050] In some embodiments, the anti-FcRn antibody comprises a heavy chain and a light chain, the heavy chain comprising HCDR1 of SEQ ID NO: 6, HCDR2 of SEQ ID NO: 7, and HCDR3 of SEQ ID NO: 8, and the light chain comprising LCDR1 of SEQ ID NO: 3, LCDR2 of SEQ ID NO: 4, and LCDR3 of SEQ ID NO: 5.

[0051] In some embodiments, the variable region heavy chain includes an amino acid sequence having at least 90% identity with the sequence of SEQ ID NO: 10, and the variable region light chain includes an amino acid sequence having at least 90% identity with the sequence of SEQ ID NO: 9. In some embodiments, the variable region heavy chain includes an amino acid sequence having at least 95% identity with the sequence of SEQ ID NO: 10, and the variable region light chain includes an amino acid sequence having at least 95% identity with the sequence of SEQ ID NO: 9. In some embodiments, the variable region heavy chain includes an amino acid sequence having at least 99% identity with the sequence of SEQ ID NO: 10, and the variable region light chain includes an amino acid sequence having at least 99% identity with the sequence of SEQ ID NO: 9.

[0052] In some embodiments, the heavy chain includes an amino acid sequence having at least 90% identity with the sequence of SEQ ID NO: 2, and the light chain includes an amino acid sequence having at least 90% identity with the sequence of SEQ ID NO: 1. In some embodiments, the heavy chain includes an amino acid sequence having at least 95% identity with the sequence of SEQ ID NO: 2, and the light chain includes an amino acid sequence having at least 95% identity with the sequence of SEQ ID NO: 1. In some embodiments, the heavy chain includes an amino acid sequence having at least 99% identity with the sequence of SEQ ID NO: 2, and the light chain includes an amino acid sequence having at least 99% identity with the sequence of SEQ ID NO: 1.

[0053] In some embodiments, the variable region heavy chain comprises the amino acid sequence of SEQ ID NO: 10, and the variable region light chain comprises the amino acid sequence of SEQ ID NO: 9.

[0054] In some embodiments, the heavy chain comprises the amino acid sequence of SEQ ID NO: 2, and the light chain comprises the amino acid sequence of SEQ ID NO: 1.

[0055] The antibodies described herein may further contain amino acid substitutions, additions, and / or deletions outside the CDR (i.e., the framework region (FR)). The amino acid substitutions, additions, and / or deletions may be substitutions, additions, and / or deletions of one or more amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or more). The amino acid substitutions, additions, and / or deletions may be substitutions, additions, and / or deletions of 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, or 2 or fewer single amino acids.

[0056] In some embodiments, the antibodies described herein may include amino acid substitutions, additions, and / or deletions in the constant region of the antibody (e.g., the Fc region) that result in reduced effector function, such as reduced complement-dependent cytolysis (CDC), antibody-dependent cell-mediated cytolysis (ADCC), and / or reduced antibody-dependent cell-mediated phagocytosis (ADCP), and / or reduced B cell killing. The constant region does not directly participate in the binding of the antibody to its target, but exhibits various effector functions, such as the antibody's involvement in antibody-dependent cytotoxicity. In some embodiments, the antibodies described herein are characterized by reduced binding (i.e., absence of binding) to human complement factor C1q and / or human Fc receptors on natural killer (NK) cells. In other embodiments, the antibody is characterized by reduced binding (i.e., absence of binding) to human FcγRI, FcγRIIA, and / or FcγRIIIA. To modify or reduce antibody-dependent effector functions such as CDC, ADCC, ADCP, and / or B cell killing, the antibodies described herein may be of the IgG class and may contain one or more amino acid substitutions E233, L234, G236, D265, D270, N297, E318, K320, K322, A327, A330, P331, and / or P329 (numbered in the EU system). In some embodiments, the antibodies described herein contain the mutation L234A / L235A or D265A / N297A (numbered in the EU system). In some embodiments, the antibodies described herein contain asparagine (N) at position 297 (numbered in the EU system). In some embodiments, the anti-FcRn antibodies described herein are aglycosylated at position 297 (as numbered according to the EU system).In some cases, the anti-FcRn antibodies described herein lack an N at position 297 (EU numbering) in any one of SEQ ID NOs. 2 and 23-26, so that the antibody is aglycosylated at that position. The resulting effectorless antibodies exhibit little binding to complement or Fc receptors (i.e., complement C1q binding) and low CDC activity.

[0057] In some embodiments, the isolated anti-FcRn antibodies described herein include LCDR1 having the sequence TGTGSDVGSYNLVS (SEQ ID NO: 3), LCDR2 having the sequence GDSERPS (SEQ ID NO: 4), LCDR3 having the sequence SSYAGSGIYV (SEQ ID NO: 5), HCDR1 having the sequence NYAMG (SEQ ID NO: 12), HCDR2 having the sequence SIGASGAQTRYADS (SEQ ID NO: 14), and HCDR3 having the sequence LAIGDSY (SEQ ID NO: 8).

[0058] In some embodiments, the isolated anti-FcRn antibodies described herein include LCDR1 having the sequence TGTGSDVGSYNLVS (SEQ ID NO: 3), LCDR2 having the sequence GDSERPS (SEQ ID NO: 4), LCDR3 having the sequence SSYAGSGIYV (SEQ ID NO: 5), HCDR1 having the sequence TYAMG (SEQ ID NO: 6), HCDR2 having the sequence SIGASGGQTRYADS (SEQ ID NO: 15), and HCDR3 having the sequence LAIGDSY (SEQ ID NO: 8).

[0059] In some embodiments, the light chain of the isolated anti-FcRn antibody is It contains a sequence that has at least 90% identity with the sequence of QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMIYGDSERPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS (Sequence ID 1).

[0060] In some embodiments, the heavy chain of the isolated anti-FcRn antibody is EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGSSGAQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTK GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL It contains a sequence that has at least 90% identity with the sequence of FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (Sequence ID 23).

[0061] In other embodiments, the heavy chain of the isolated anti-FcRn antibody is EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTK GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL It contains a sequence that has at least 90% identity with the sequence of FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (sequence number 24).

[0062] In other embodiments, the heavy chain of the isolated anti-FcRn antibody is EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMGWVRQAPGKGLEWVSSIGASGAQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTK GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL It contains a sequence that has at least 90% identity with the sequence of FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (Sequence ID 25).

[0063] In some embodiments, the heavy chain of the isolated anti-FcRn antibody is EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGGQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTK GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL It contains a sequence that has at least 90% identity with the sequence of FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (sequence number 26).

[0064] In some embodiments, the isolated anti-FcRn antibody has a light chain and a heavy chain, and the light chain is The heavy chain contains a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity with the sequence of QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMIYGDSERPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 1), and the heavy chain is EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGSSGAQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFP LAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI The sequence contains a sequence that has at least 90%, 95%, 96%, 97%, 98%, or 99% identity with the sequence of SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (Sequence ID 23).

[0065] In some embodiments, the isolated anti-FcRn antibody has a light chain and a heavy chain, and the light chain is The heavy chain contains a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity with the sequence of QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMIYGDSERPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 1), and the heavy chain is EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFP LAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI The sequence contains a sequence that has at least 90%, 95%, 96%, 97%, 98%, or 99% identity with the sequence of SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (Sequence ID 24).

[0066] In some embodiments, the isolated anti-FcRn antibody has a light chain and a heavy chain, and the light chain is The heavy chain contains a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity with the sequence of QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMIYGDSERPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 1), and the heavy chain is EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMGWVRQAPGKGLEWVSSIGASGAQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFP LAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI The sequence contains a sequence that has at least 90%, 95%, 96%, 97%, 98%, or 99% identity with the sequence of SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (Sequence ID 25).

[0067] In some embodiments, the isolated anti-FcRn antibody has a light chain and a heavy chain, and the light chain is The heavy chain contains a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity with the sequence of QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMIYGDSERPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 1), and the heavy chain is EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGGQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFP LAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI The sequence contains a sequence that has at least 90%, 95%, 96%, 97%, 98%, or 99% identity with the sequence of SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (Sequence ID 26).

[0068] In some embodiments, the heavy chain of the isolated anti-FcRn antibody contains a sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity with any one of the sequences of SEQ ID NOs. 23-26. In other embodiments, the light chain of the isolated anti-FcRn antibody contains a sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the sequence of SEQ ID NO. 1.

[0069] In some embodiments, the heavy chain of the isolated anti-FcRn antibody contains a sequence having 5, 4, 3, 2, or 1 or fewer single amino acid substitutions relative to the amino acid sequence of SEQ ID NO: 2. In some embodiments, the light chain of the isolated anti-FcRn antibody contains a sequence having 5, 4, 3, 2, or 1 or fewer single amino acid substitutions relative to the sequence of SEQ ID NO: 1.

[0070] In some embodiments, the isolated anti-FcRn antibody contains the amino acid substitution N297A compared to any one of the sequences in Sequence ID No. 2 (numbered in the EU system). In some embodiments, the isolated anti-FcRn antibody contains asparagine (N) at position 297 compared to any one of the sequences in Sequence ID No. 2 (numbered in the EU system).

[0071] In some embodiments, the isolated anti-FcRn antibody further comprises amino acid substitutions D355E and L357M compared to any one of the sequences in SEQ ID NO: 2 (according to EU numbering).

[0072] In some embodiments, the isolated anti-FcRn antibody lacks the C-terminal lysine at residue 446 compared to the sequence of SEQ ID NO: 2.

[0073] In some embodiments, the isolated anti-FcRn antibody has a light chain and a heavy chain, and the light chain is The sequence QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMIYGDSERPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS (Sequence ID 1) is included or consists of the heavy chain, EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGSSGAQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSA STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLG It contains or consists of the sequence GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (sequence number 23).

[0074] In some embodiments, the isolated anti-FcRn antibody has a light chain and a heavy chain, and the light chain is The sequence QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMIYGDSERPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 1) is included, and the heavy chain is, EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSA STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLG It contains or consists of the sequence GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (sequence number 24).

[0075] In some embodiments, the isolated anti-FcRn antibody has a light chain and a heavy chain, and the light chain is The sequence QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMIYGDSERPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 1) is included, and the heavy chain is, EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMGWVRQAPGKGLEWVSSIGASGAQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSA STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLG It contains or consists of the sequence GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (sequence number 25).

[0076] In some embodiments, the isolated anti-FcRn antibody has a light chain and a heavy chain, and the light chain is The sequence QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMIYGDSERPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS (Sequence ID 1) is included or consists of the heavy chain, EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGGQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSA STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLG It contains or consists of the sequence GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (sequence number 26).

[0077] While not bound by any particular theory, anti-FcRn antibodies are thought to compete with and inhibit the binding of IgG to human FcRn. Epitope mapping of the antibody by hydrogen-deuterium exchange shows that the antibody binds to epitopes on FcRn located within and / or adjacent to the Fc-FcRn interaction interface, suggesting that the antibody blocks IgG binding to FcRn by direct inhibition. Furthermore, the epitope-mapped binding sites are far from the albumin-binding sites of FcRn. Therefore, serum albumin binding should not be inhibited, and serum albumin levels should not be reduced beyond approximately 35%, 30%, or 25%.

[0078] In some embodiments, the anti-FcRn antibody is nipocalimab, RVT-1401 (HL161), rozanolixizumab (UCB7665), ALXN1830, ABY-039, or efgultigimod. RVT-1401 (also referred to as HL161BKN) is described in International Publication No. 2020097099, rozanolixizumab is described in International Publication No. 2014019727, and efgultigimod (ARGX-113) is described in International Publication No. 2015100299, each of which is incorporated herein by reference in whole. In some embodiments, the anti-FcRn antibody is a biosimilar of any of the anti-FcRn antibodies provided herein. In preferred embodiments, the anti-FcRn antibody is nipocalimab.

[0079] In some embodiments, the Fc domain of the antibody is not fucosylated. In some embodiments of all the methods described herein, the Fc domain of the antibody is not glycosylated. In some embodiments of all the methods described herein, the antibody lacks effector function. In some embodiments of all the methods described herein, the antibody is an IgG1 antibody.

[0080] II. FcRn Inhibition FcRn is a type I transmembrane protein that functions as an IgG and serum albumin-binding intracellular vesicle transport protein. FcRn is expressed in endothelial cells, luminal epithelial cells, hepatocytes, podocytes, granulocytes, monocytes, macrophages, dendritic cells, and NK cells, but not on B cells or T cells. FcRn maintains the half-life of IgG by constitutively binding to internalized IgG and transporting it back to the cell surface. Binding of both Fc and serum albumin by FcRn occurs in early endosomes at pH 6.0, followed by sorting of FcRn into vesicles, which transport FcRn-bound IgG or albumin back to the cell surface, where FcRn rapidly releases IgG or albumin at pH 7.4. This transport cycle maintains the half-lives of both IgG and albumin by recirculating them in the circulation, preventing transport to lysosomes for degradation. FcRn also captures internalized IgG Fc in epithelial cells and transports them bidirectionally to the opposing apical or basolateral membranes. This function enables the transport of IgG into the lumen of organs such as the gastrointestinal tract, or the transport of IgG or IgG-antigen complexes from the lumen to vascular or lymphoid tissues in the interstitial layer.

[0081] To study the contribution of FcRn to IgG homeostasis, mice were engineered in which parts of the light and heavy chains of FcRn were "knocked out" to prevent the expression of these proteins (Junghans et al., Proc Natl Acad Sci USA 93:5512, 1996). In these mice, the serum half-life and concentration of IgG were dramatically reduced, suggesting an FcRn-dependent mechanism of IgG homeostasis. Studies in rodent models, such as those discussed above, suggest that blocking FcRn may increase IgG catabolism, including the catabolism of pathogenic autoantibodies, thereby inhibiting the development of disease (e.g., autoimmune diseases). FcRn may also contribute to antigen presentation through antigen degradation and the transport of immune complexes to the MHC loading compartment.

[0082] This disclosure provides isolated anti-FcRn antibodies that bind to human FcRn with high affinity. The anti-FcRn antibodies compete with and effectively inhibit the binding of other anti-FcRn antibodies (e.g., IgG, IgG autoantibodies) to FcRn, thereby increasing the catabolism of other anti-FcRn antibodies (e.g., IgG, IgG autoantibodies) and reducing their half-life. Anti-FcRn antibodies may be used in methods to treat or reduce immune complex-based activation of immune responses in a target, such as immune responses induced by autoantibodies in autoimmune diseases.

[0083] Placental transfer of maternal IgG antibodies to the fetus is an important FcRn-dependent mechanism that provides protection to the newborn, while its humoral response is inefficient. During the fetal period, FcRns in the syncytial trophoblast layer of the placenta are involved in the transfer of maternal IgG antibodies to the fetus. Pathogenic maternal antibodies (e.g., pathogenic maternal IgG antibodies) can also cross the placenta by binding to FcRns, potentially causing alloimmune and / or autoimmune disorders in the fetus and neonatal population. In some embodiments, pathogenic antibodies in a pregnant subject cause alloimmune and / or autoimmune disorders in the fetus of the pregnant subject. The anti-FcRn antibodies described herein can compete with and inhibit the binding of maternal pathogenic antibodies (e.g., maternal pathogenic IgG antibodies) to FcRns, thereby increasing the catabolism and reducing the half-life of these pathogenic antibodies.

[0084] This disclosure provides isolated anti-FcRn antibodies that bind to human FcRn. Anti-FcRn antibodies can compete with and inhibit the binding of other anti-FcRn antibodies (e.g., IgG, IgG autoantibodies) to FcRn, thereby increasing the catabolism and reducing the half-life of other anti-FcRn antibodies (e.g., IgG, IgG autoantibodies). Anti-FcRn antibodies may be used in methods to treat or reduce immune complex-based activation of immune responses in subjects, such as immune responses induced by autoantibodies in autoimmune diseases. Reducing an immune response may be described as reducing the immune response compared to an untreated subject (e.g., a control subject). Anti-FcRn antibodies may also be used in methods to reduce pathogenic antibody transport across the placenta of pregnant subjects (e.g., pathogenic maternal IgG antibody transport), increase pathogenic antibody catabolism in pregnant subjects, and treat antibody-mediated enhancement of viral diseases in fetuses or neonates by administering isolated antibodies that bind to human FcRn to pregnant subjects. Reducing the transport of pathogenic antibodies across the placenta of a pregnant subject may be described as reducing the transport of pathogenic antibodies compared to an untreated subject (e.g., a control subject). In another embodiment, the present disclosure is characterized by a method for treating antibody-mediated enhancement of a viral disease in a fetus or neonatal, comprising, comprising, or comprising an antibody described herein, to a pregnant subject, wherein the antibody comprises, comprising, a light chain and a heavy chain, the light chain comprises, comprising, or comprising the sequence of SEQ ID NO: 1, and the heavy chain comprises, comprising, or comprising the sequence of SEQ ID NO: 2.In another aspect, the Disclosure features a method for treating antibody-mediated enhancement of a viral disease in a fetus or neonatal, comprising or essentially comprising administering an antibody to a pregnant subject, wherein the antibody comprises, comprises, or essentially comprises a light chain and a heavy chain, the light chain comprising, comprising, or essentially comprising a sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the sequence of SEQ ID NO: 1, and the heavy chain comprising, comprising, or essentially comprising a sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the sequence of SEQ ID NO: 2.

[0085] III. Vectors, host cells, and antibody production Anti-FcRn antibodies can be produced from host cells. Host cells refer to a vehicle containing the necessary cellular components, such as organelles, required to express the polypeptides and constructs described herein from their corresponding nucleic acids. The nucleic acids may be contained in nucleic acid vectors that can be introduced into host cells by conventional techniques known in the art (e.g., transformation, transfection, electroporation, calcium phosphate precipitation, direct microinjection, infection, etc.). The selection of nucleic acid vectors depends in part on the host cells used. Generally, host cells are either of prokaryotic (e.g., bacteria) or eukaryotic (e.g., mammals) origin.

[0086] nucleic acid vector constructs and host cells The nucleic acid sequences encoding the amino acid sequences of anti-FcRn antibodies can be prepared by various methods known in the art. These methods include, but are not limited to, oligonucleotide-mediated (or site-directed) mutagenesis and PCR mutagenesis. The nucleic acid molecules encoding anti-FcRn antibodies can be obtained using standard techniques, such as gene synthesis. Alternatively, nucleic acid molecules encoding wild-type anti-FcRn antibodies can be mutated to contain specific amino acid substitutions using standard techniques in the art, such as QuikChange® mutagenesis. The nucleic acid molecules can be synthesized using nucleotide synthesis factors or PCR techniques.

[0087] A nucleic acid sequence encoding an anti-FcRn antibody can be inserted into a vector capable of replicating and expressing nucleic acid molecules in prokaryotic or eukaryotic host cells. Many vectors are available in the art and can be used for the purposes of this disclosure. Each vector may contain various components that can be regulated and optimized for compatibility with specific host cells. For example, vector components may include, but are not limited to, an origin of replication, a selection marker gene, a promoter, a ribosome binding site, a signal sequence, a nucleic acid sequence encoding the protein of interest, and a transcription termination sequence.

[0088] In some embodiments, mammalian cells are used as host cells for the present disclosure. Examples of mammalian cell types include, but are not limited to, human embryonic kidney (HEK) (e.g., HEK293, HEK293F), Chinese hamster ovary (CHO), HeLa, COS, PC3, Vero, MC3T3, NS0, Sp2 / 0, VERY, BHK, MDCK, W138, BT483, Hs578T, HTB2, BT20, T47D, NS0 (a mouse myeloma cell line that does not endogenously produce any immunoglobulin chains), CRL7O3O, and HsS78Bst cells. In other embodiments, E. coli cells are used as host cells for the present disclosure. Examples of E. coli strains include, but are not limited to, E. coli294 (ATCC® 31,446), E. coliλ1776 (ATCC® 31,537), E. coliBL21(DE3) (ATCC® BAA-1025), and E. coliRV308 (ATCC® 31,608). Different host cells have characteristic and specific mechanisms for post-translational processing and modification of protein products. By selecting an appropriate cell line or host system, the correct modification and processing of the expressed anti-FcRn antibody can be ensured. The expression vectors described above can be introduced into appropriate host cells using conventional techniques in the art (e.g., transformation, transfection, electroporation, calcium phosphate precipitation, and direct microinjection). Once the vector is introduced into host cells for protein production, the host cells are cultured in conventional nutrient media that are appropriately modified to induce a promoter, select a transformant, or amplify a gene encoding a desired sequence.Methods for expressing therapeutic proteins are known in the art; see, for example, Paulina Balbas, Argelia Lorence (eds.) Recombinant Gene Expression: Reviews and Protocols (Methods in Molecular Biology), Humana Press; 2nd ed. 2004 (July 20, 2004) and Vladimir Voynov and Justin A. Caravella (eds.) Therapeutic Proteins: Methods and Protocols (Methods in Molecular Biology), Humana Press; 2nd ed. 2012 (June 28, 2012).

[0089] Protein production, recovery, and purification Host cells used to produce anti-FcRn antibodies are known in the art and can be grown in a culture medium suitable for the selected host cells. Examples of suitable media for mammalian host cells include Minimal Essential Medium (MEM), Dulbecco's Modified Eagle's Medium (DMEM), Expi293® expression medium, DMEM supplemented with fetal bovine serum (FBS), and RPMI-1640. Examples of suitable media for bacterial host cells include Luria broth (LB) + selective agents, such as ampicillin, as needed supplements. Host cells are cultured at a suitable temperature of approximately 20°C to approximately 39°C, for example, 25°C to approximately 37°C, or approximately 37°C, and at a CO2 level of 5-10% (approximately 8%). The pH of the medium is generally approximately 6.8-7.4, for example, 7.0, depending mainly on the host organism. When an inducible promoter is used in the expression vector of this disclosure, protein expression is induced under conditions favorable for promoter activation.

[0090] Protein recovery typically involves disturbing host cells by means such as permeable shock, sonic treatment, or lysis. Once the cells are disturbed, cellular debris may be removed by centrifugation or filtration. The protein may be further purified. Anti-FcRn antibodies can be purified by any method known in the art of protein purification, for example, by protein A affinity, other chromatography (e.g., ion exchange, affinity, and size exclusion column chromatography), centrifugation, solubility difference, or any other standard technique for protein purification. In some cases, anti-FcRn antibodies may be conjugated to marker sequences such as peptides to facilitate purification. An example of a marker amino acid sequence is the hexa-histidine peptide (His tag), which conjugates to a nickel-functionalized agarose affinity column with micromolar affinity. Other peptide tags useful for purification include, but are not limited to, the hemagglutinin "HA" tag, which corresponds to an epitope derived from influenza hemagglutinin protein.

[0091] Alternatively, anti-FcRn antibodies may be produced by cells of a subject (e.g., human) in a therapeutic context by administering a vector containing a nucleic acid molecule encoding the anti-FcRn antibody of this disclosure (e.g., retroviral vectors, adenovirus vectors, poxvirus vectors (e.g., vaccinia virus vectors such as Modified Vaccinia Ankara (MVA)), adeno-associated virus vectors, and alphavirus vectors). Once the vector enters the cells of the subject (e.g., by transformation, transfection, electroporation, calcium phosphate precipitation, direct microinjection, infection, etc.), it promotes the expression of anti-FcRn antibodies, which are then secreted from the cells. If the treatment of a disease or disorder is the desired outcome, further treatment may not be necessary. If protein collection is desired, blood may be collected from the subject, and the protein may be purified from the blood by methods known in the art.

[0092] IV. Pharmaceutical Compositions and Preparations The composition for injection is a physiologically compatible aqueous composition (e.g., buffered to physiological pH and substantially isotonic). The composition may include, for example, sodium chloride, trehalose, and the surfactant polysorbate (PS) 80, as well as a buffer. The composition may include both an ionic osmolite stabilizer (sodium chloride) and a nonionic osmolite stabilizer (trehalose).

[0093] In certain embodiments, a preferred formulation may comprise about 25 mM sodium phosphate, about 25 mM sodium chloride, about 90.5 mg / ml trehalose, about 0.01% polysorbate (PS) 80, and about 10 mg / ml, about 15 mg / ml, or about 30 mg / ml of the antibody described herein, buffered at pH 6.5. In certain embodiments, a preferred formulation may comprise about 25 mM sodium succinate, about 25 mM sodium chloride, about 90.5 mg / ml trehalose, about 0.01% polysorbate (PS) 80, and about 10 mg / ml, about 15 mg / ml, or about 30 mg / ml of the antibody described herein, buffered at pH 6.6 or pH 6.5. In certain embodiments, a preferred formulation may comprise about 25 mM sodium succinate, about 25 mM sodium chloride, about 90.5 mg / ml trehalose, about 0.01% polysorbate (PS) 80, and about 10 mg / ml, about 15 mg / ml, or about 30 mg / ml of the antibody described herein, buffered at pH 5 to pH 8. In certain embodiments, a preferred formulation may comprise about 25 mM sodium succinate, about 25 mM sodium chloride, about 90.5 mg / ml trehalose, about 0.01% polysorbate (PS) 80, and about 10 mg / ml, about 15 mg / ml, or about 30 mg / ml of the antibody described herein, buffered at pH 6 to pH 7.

[0094] This disclosure features a pharmaceutical composition comprising one or more anti-FcRn antibodies as described herein. In addition to a therapeutically effective amount of antibody, the pharmaceutical composition may contain one or more pharmaceutically acceptable carriers or excipients, which can be formulated by methods known to those skilled in the art.

[0095] Acceptable carriers and excipients in a pharmaceutical composition are non-toxic to the recipient at the dosage and concentration used. Acceptable carriers and excipients may include buffers, antioxidants, preservatives, polymers, amino acids, and carbohydrates. Pharmaceutical compositions can be administered parenterally in the form of injectable formulations. Injectable pharmaceutical compositions can be formulated using sterile solutions or any pharmaceutically acceptable liquid as a vehicle. Examples of pharmaceutically acceptable vehicles include, but are not limited to, sterile water, physiological saline, and cell culture media (e.g., Dulbecco's modified Eagle medium (DMEM), α-modified Eagle medium (α-MEM), F-12 medium). Formulation methods are known in the art, for example, See Banga (ed.) Therapeutic Peptides and Proteins: Formula, Processing and Delivery Systems (2nd ed.) Taylor & Francis Group, CRC Press (2006).

[0096] In some embodiments, the composition is administered parenterally. In some embodiments, the composition is administered intravenously or subcutaneously. In some embodiments, the composition is administered intraperitoneally, intradermally, or intramuscularly. In some embodiments, the composition is administered intravenously. In some embodiments, the composition is administered subcutaneously. In some embodiments, the composition is administered using an infusion pump. In some embodiments, the composition is administered using an auto-injector. In some embodiments, the composition is administered using a patch pump syringe. In some embodiments, the composition is administered using a wearable syringe. In some embodiments, the composition is administered using a Sorrel® pump. In some embodiments, the composition is administered using a pump such as the one in U.S. Patent No. 9,943,642 (which is incorporated herein by reference in its entirety).

[0097] In some embodiments, formulations are prepared using different concentrations of sodium chloride, trehalose, and the surfactant polysorbate (PS) 80, and buffers, and may be buffered at different pH levels (pH 5-8, pH 6-7, or pH 5-7). In some embodiments, the composition includes both an ionic osmolite stabilizer (sodium chloride) and a nonionic osmolite stabilizer (trehalose). The stability of formulations and compositions can be evaluated over time by appearance, pH, protein concentration, size purity, charge distribution, and thermal stability. These stability parameters can be measured by analytical techniques including pH, UV-Vis, size exclusion chromatography, ion exchange chromatography, CE-SDS, and differential scanning calorimetry.

[0098] The composition for injection may be an aqueous composition that is physiologically compatible (e.g., buffered to physiological pH and substantially isotonic). The composition may include, for example, sodium chloride, trehalose, and the surfactant polysorbate (PS) 80, as well as a buffer. The composition may include both an ionic osmolite stabilizer (sodium chloride) and a nonionic osmolite stabilizer (trehalose).

[0099] In some embodiments, the injection is the injection of a composition comprising about 10 mg / ml to about 60 mg / ml of the antibody described herein, about 20 mM to about 30 mM sodium phosphate, about 20 mM to about 30 mM sodium chloride, about 80 mg / ml to about 100 mg / ml trehalose, and about 0.1% w / v to about 0.005% w / v polysorbate 80. In certain embodiments, the antibody described herein is administered at about 5 mg / kg to about 30 mg / kg. In certain embodiments, the concentration of the antibody described herein in intravenous injection is about 10 mg / ml to about 30 mg / ml. In certain embodiments, the concentration of the antibody described herein in subcutaneous injection is about 10 mg / ml to about 30 mg / ml.

[0100] In some embodiments, a preferred formulation may comprise about 25 mM sodium phosphate, about 25 mM sodium chloride, about 90.5 mg / ml trehalose, about 0.01% polysorbate (PS) 80, and about 10 mg / ml, about 15 mg / ml, or about 30 mg / ml of the antibody described herein, buffered at pH 6.5. In certain embodiments, a preferred formulation may comprise about 25 mM sodium succinate, about 25 mM sodium chloride, about 90.5 mg / ml trehalose, about 0.01% polysorbate (PS) 80, and about 10 mg / ml, about 15 mg / ml, or about 30 mg / ml of the antibody described herein, buffered at pH 6.6 or pH 6.5. The stability of the two formulations described above can be further tested in the presence of selected mechanical, thermal, and chemical stresses. In some embodiments, the stability of the composition can be maintained for more than 30 months for formulations of the antibody disclosed herein in concentrations of about 10 mg / ml, about 15 mg / ml, or about 30 mg / ml, buffered at pH 6.5 with about 25 mM sodium phosphate, about 25 mM sodium chloride, about 90.5 mg / ml trehalose, about 0.01% polysorbate (PS) 80. In various embodiments, the formulation may contain the antibody disclosed herein buffered at pH 6.5 with about 25 mM sodium phosphate, about 25 mM sodium chloride, about 90.5 mg / ml trehalose, and different amounts of polysorbate 80. In some embodiments, the pharmaceutical composition comprises an antibody disclosed herein having up to five single amino acid insertions, substitutions, or deletions at approximately 10 mg / ml or 30 mg / ml, approximately 20 mM to approximately 30 mM sodium phosphate, approximately 20 mM to approximately 30 mM sodium chloride, approximately 80 mg / ml to approximately 100 mg / ml trehalose, and approximately 0.10% w / v to approximately 0.005% w / v polysorbate 80 buffered at pH 6.5. In some embodiments, a preferred formulation may comprise approximately 25 mM sodium phosphate, approximately 25 mM sodium chloride, approximately 90.5 mg / ml trehalose, approximately 0.01% polysorbate (PS) 80, and approximately 10 mg / ml, approximately 15 mg / ml, or approximately 30 mg / ml of the antibody described herein buffered at pH 5 to pH 8.In certain embodiments, a preferred formulation may comprise about 25 mM sodium succinate, about 25 mM sodium chloride, about 90.5 mg / ml trehalose, about 0.01% polysorbate (PS) 80, and about 10 mg / ml, about 15 mg / ml, or about 30 mg / ml of the antibody described herein, buffered at pH 5 to pH 7. In some embodiments, the stability of the composition can be maintained for more than 30 months for formulations of about 25 mM sodium phosphate, about 25 mM sodium chloride, about 90.5 mg / ml trehalose, about 0.01% polysorbate (PS) 80, and about 10 mg / ml, about 15 mg / ml, or about 30 mg / ml of the antibody described herein, buffered at pH 6 to pH 7. In some embodiments, the stability of the composition can be maintained for more than 30 months for formulations of the antibody disclosed herein in concentrations of about 10 mg / ml, about 15 mg / ml, or about 30 mg / ml, buffered at pH 5–pH 8 with about 25 mM sodium phosphate, about 25 mM sodium chloride, about 90.5 mg / ml trehalose, about 0.01% polysorbate (PS) 80, and pH 5–pH 8. In various embodiments, the formulation may contain the antibody disclosed herein buffered at pH 5–pH 8, pH 6–7, or pH 5–pH 7 with about 25 mM sodium phosphate, about 25 mM sodium chloride, about 90.5 mg / ml trehalose, and different amounts of polysorbate 80. In some embodiments, the pharmaceutical composition comprises an antibody disclosed herein having up to five single amino acid insertions, substitutions, or deletions at approximately 10 mg / ml or 30 mg / ml, approximately 20 mM to approximately 30 mM sodium phosphate, approximately 20 mM to approximately 30 mM sodium chloride, approximately 80 mg / ml to approximately 100 mg / ml trehalose, and approximately 0.10% w / v to approximately 0.005% w / v polysorbate 80 buffered at pH 5 to pH 8, or pH 5 to pH 7.

[0101] V. Route, Dosage, and Administration A pharmaceutical composition containing one or more anti-FcRn antibodies as a therapeutic protein can be formulated for intravenous or subcutaneous administration. In a preferred embodiment, the pharmaceutical composition comprises nipocalimab.

[0102] Methods for treating various disorders are described herein, including intravenous or subcutaneous administration of an anti-FcRn antibody described herein at doses of approximately 5 mg / kg to approximately 120 mg / kg to a subject. In some embodiments, the anti-FcRn antibody comprises a heavy chain including HCDR1 of SEQ ID NO: 6, HCDR2 of SEQ ID NO: 7, and HCDR3 of SEQ ID NO: 8, and a light chain including LCDR1 of SEQ ID NO: 3, LCDR2 of SEQ ID NO: 4, and LCDR3 of SEQ ID NO: 5. In preferred embodiments, the anti-FcRn antibody is nipocalimab. The methods described herein include an initial dose at a first dose level (e.g., a loading dose or induction dose), followed by subsequent doses at different dose levels or maintenance dose levels.

[0103] In some embodiments, the anti-FcRn antibody is administered every other week at a maintenance dose of approximately 5 mg / kg to approximately 60 mg / kg, following an initial loading dose of approximately 5 mg / kg to approximately 120 mg / kg. In some embodiments, the anti-FcRn antibody is administered every other week at a maintenance dose of approximately 5 mg / kg to approximately 30 mg / kg, following an initial loading dose of approximately 5 mg / kg to approximately 60 mg / kg. In some embodiments, the anti-FcRn antibody is administered every other week at a maintenance dose of approximately 30 mg / kg, following an initial loading dose of approximately 60 mg / kg. In some embodiments, the anti-FcRn antibody is administered every other week at a maintenance dose of approximately 15 mg / kg, following an initial loading dose of approximately 60 mg / kg. In some embodiments, the anti-FcRn antibody is administered every other week at a maintenance dose of approximately 30 mg / kg, following an initial loading dose of approximately 30 mg / kg. In some embodiments, the anti-FcRn antibody is administered every other week with an initial loading dose of approximately 30 mg / kg followed by a maintenance dose of approximately 15 mg / kg. In some embodiments, the anti-FcRn antibody is administered every four weeks with an initial loading dose of approximately 5 mg / kg to approximately 120 mg / kg followed by a maintenance dose of approximately 5 mg / kg to approximately 60 mg / kg. In some embodiments, the anti-FcRn antibody is administered every four weeks with an initial loading dose of approximately 5 mg / kg to approximately 60 mg / kg followed by a maintenance dose of approximately 5 mg / kg to approximately 30 mg / kg. In some embodiments, the anti-FcRn antibody is administered every four weeks with an initial loading dose of approximately 60 mg / kg followed by a maintenance dose of approximately 30 mg / kg. In some embodiments, the anti-FcRn antibody is administered every four weeks with an initial loading dose of approximately 60 mg / kg followed by a maintenance dose of approximately 15 mg / kg. In some embodiments, the anti-FcRn antibody is administered every four weeks at a maintenance dose of approximately 30 mg / kg, following an initial loading dose of approximately 30 mg / kg. In some embodiments, the anti-FcRn antibody is administered every four weeks at a maintenance dose of approximately 15 mg / kg, following an initial loading dose of approximately 30 mg / kg. In some embodiments, the anti-FcRn antibody is administered monthly at a maintenance dose of approximately 5 mg / kg to approximately 60 mg / kg, following an initial loading dose of approximately 5 mg / kg to approximately 120 mg / kg.In some embodiments, the anti-FcRn antibody is administered monthly in a maintenance dose of approximately 5 mg / kg to approximately 30 mg / kg, following an initial loading dose of approximately 5 mg / kg to approximately 60 mg / kg. In some embodiments, the anti-FcRn antibody is administered monthly in a maintenance dose of approximately 5 mg / kg to approximately 15 mg / kg, following an initial loading dose of approximately 5 mg / kg to approximately 60 mg / kg. In some embodiments, the anti-FcRn antibody is administered monthly in a maintenance dose of approximately 5 mg / kg to approximately 15 mg / kg, following an initial loading dose of approximately 5 mg / kg to approximately 60 mg / kg. In some embodiments, the anti-FcRn antibody is administered monthly in a maintenance dose of approximately 15 mg / kg, following an initial loading dose of approximately 60 mg / kg. In some embodiments, the anti-FcRn antibody is administered monthly in a maintenance dose of approximately 30 mg / kg, following an initial loading dose of approximately 60 mg / kg. In preferred embodiments, the anti-FcRn antibody is administered monthly in an initial loading dose of approximately 30 mg / kg followed by a maintenance dose of approximately 15 mg / kg. In some embodiments, the anti-FcRn antibody is administered monthly in an initial loading dose of approximately 30 mg / kg followed by a maintenance dose of approximately 30 mg / kg. In preferred embodiments, the anti-FcRn antibody is preferably nipocalimab. In some embodiments, the anti-FcRn antibody is administered intravenously. In some embodiments, the anti-FcRn antibody is administered subcutaneously. In some embodiments, the initial loading dose is administered intravenously and the maintenance dose is administered subcutaneously.

[0104] In some embodiments, the methods described herein include administering an anti-FcRn antibody to an adult subject or patient. The terms “adult subject” and “adult patient” can be used interchangeably. As used herein, an adult subject is a subject aged 18 years or older, and for example, in certain embodiments, an adult subject is 18–100 years, 19–90 years, for example, at least 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95 years.

[0105] In some embodiments, the methods described herein include administering an anti-FcRN antibody to a pediatric subject or patient. The terms “pediatric subject” and “pediatric patient” can be used interchangeably. In some embodiments, the pediatric subject is under 18 years of age. In some embodiments, the pediatric subject is about 12 to under 18 years of age. In some embodiments, the pediatric subject is about to about 12 years of age. In some embodiments, the pediatric subject is under 12 years of age. In some embodiments, the pediatric subject is 2 to 12 years of age. In some embodiments, the pediatric patient is an adolescent pediatric patient. In some embodiments, the adolescent pediatric patient is 12 to under 18 years of age.

[0106] In some embodiments, the antibody is administered in an initial dose of 60 mg / kg. In some embodiments, the antibody is administered in an initial dose of 30 mg / kg. In some embodiments, the antibody is administered in doses of approximately 5 mg / kg to approximately 60 mg / kg, approximately 5 mg / kg to approximately 15 mg / kg, approximately 15 mg / kg to approximately 60 mg / kg, or approximately 30 mg / kg to approximately 60 mg / kg. In some embodiments, the antibody is administered in doses of approximately 5 mg / kg, approximately 15 mg / kg, approximately 30 mg / kg, approximately 45 mg / kg, or approximately 60 mg / kg. In some embodiments, the antibody is administered in exactly or approximately 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 mg / kg. In some embodiments, the antibody is administered in a single dose, or in initial loading doses and maintenance doses. In some embodiments, the initial loading dose and maintenance dose are the same dose. In some embodiments, the loading dose and the maintenance dose are not the same. In preferred embodiments, the loading dose is greater than the maintenance dose. In some embodiments, the loading dose is administered at doses of approximately 5 mg / kg to approximately 60 mg / kg, approximately 5 mg / kg to approximately 15 mg / kg, approximately 15 mg / kg to approximately 60 mg / kg, or approximately 30 mg / kg to approximately 60 mg / kg. In some embodiments, the loading dose is administered at a dose of 60 mg / kg. In some embodiments, the loading dose is administered at a dose of 30 mg / kg. In some embodiments, the maintenance dose is administered at doses of approximately 5 mg / kg to approximately 60 mg / kg, approximately 5 mg / kg to approximately 15 mg / kg, approximately 15 mg / kg to approximately 60 mg / kg, or approximately 30 mg / kg to approximately 60 mg / kg. In some embodiments, the maintenance dose is administered at doses of approximately 5 mg / kg, approximately 15 mg / kg, approximately 30 mg / kg, approximately 45 mg / kg, or approximately 60 mg / kg. In some embodiments, the maintenance dose is administered at a dose of 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 mg / kg. In some embodiments, the maintenance dose is administered at a dose of 15 mg / kg. In some embodiments, the loading dose is administered at a dose of approximately 30 mg / kg and a maintenance dose of approximately 15 mg / kg. In preferred embodiments, the loading dose is administered at a dose of 30 mg / kg and a maintenance dose of 15 mg / kg.

[0107] In some embodiments, the administration reduces serum IgG in the patient by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of baseline serum IgG. In some embodiments, the method may include administering a loading dose that reduces serum IgG by at least 65% to at least 85% compared to baseline. The method may include administering a loading dose that reduces serum IgG by at least 36% to at least 64% compared to baseline. The method may include administering a loading dose that reduces serum IgG by at least 15% to at least 35% compared to baseline. The loading dose reduces IgG levels by at least 20% to at least 35% (e.g., at least 20%, at least 25%, at least 30%, at least 35%) from baseline within about the first 1 to 2 weeks of treatment.

[0108] A loading dose may be followed by a maintenance dose of approximately 75%, 50%, 25%, 20%, 15%, 10%, or 5% of the loading dose. In certain embodiments, the maintenance dose is administered every two weeks, every three weeks, or every four weeks. The maintenance dose maintains serum IgG levels at a reduced level below baseline (e.g., maintaining serum IgG at a level of at least 65%–85%, at least 36%–64%, or at least 15%–35% of baseline). In certain embodiments, the maintenance dosing method maintains serum IgG at a level of at least 20%–35% of baseline (e.g., at least 20%, at least 25%, at least 30%, at least 35%).

[0109] In some embodiments, the initial loading dose is 60 mg / kg administered intravenously, followed by a bi-weekly (Q2W) administration of a maintenance dose of 15 mg / kg administered intravenously after 1, 2, 3, or 4 weeks. In some embodiments, the initial loading dose is 60 mg / kg administered intravenously, followed by a bi-weekly (Q2W) administration of a maintenance dose of 30 mg / kg administered intravenously after 1, 2, 3, or 4 weeks. In some embodiments, the initial loading dose is 30 mg / kg administered intravenously, followed by a bi-weekly (Q2W) administration of a maintenance dose of 15 mg / kg administered intravenously after 1, 2, 3, or 4 weeks. In some embodiments, the initial loading dose is 30 mg / kg administered intravenously, followed by a bi-weekly (Q2W) administration of a maintenance dose of 30 mg / kg administered intravenously after 1, 2, 3, or 4 weeks.

[0110] In some embodiments, the initial loading dose is 60 mg / kg administered intravenously, followed by monthly administrations of a maintenance dose of 15 mg / kg administered intravenously after 1, 2, 3, or 4 weeks. In some embodiments, the initial loading dose is 60 mg / kg administered intravenously, followed by monthly administrations of a maintenance dose of 30 mg / kg administered intravenously after 1, 2, 3, or 4 weeks. In some embodiments, the initial loading dose is 30 mg / kg administered intravenously, followed by monthly administrations of a maintenance dose of 15 mg / kg administered intravenously after 1, 2, 3, or 4 weeks. In some embodiments, the initial loading dose is 30 mg / kg administered intravenously, followed by monthly administrations of a maintenance dose of 30 mg / kg administered intravenously after 1, 2, 3, or 4 weeks.

[0111] In some embodiments, the initial loading dose is 60 mg / kg administered intravenously, followed by a bi-weekly (Q2W) subcutaneous maintenance dose of 15 mg / kg after 1, 2, 3, or 4 weeks. In some embodiments, the initial loading dose is 60 mg / kg administered intravenously, followed by a bi-weekly (Q2W) subcutaneous maintenance dose of 30 mg / kg after 1, 2, 3, or 4 weeks. In some embodiments, the initial loading dose is 30 mg / kg administered intravenously, followed by a bi-weekly (Q2W) subcutaneous maintenance dose of 15 mg / kg after 1, 2, 3, or 4 weeks. In some embodiments, the initial loading dose is 30 mg / kg administered intravenously, followed by a bi-weekly (Q2W) subcutaneous maintenance dose of 30 mg / kg after 1, 2, 3, or 4 weeks.

[0112] In some embodiments, the initial loading dose is 60 mg / kg administered intravenously, followed by monthly subcutaneous maintenance doses of 15 mg / kg after 1, 2, 3, or 4 weeks. In some embodiments, the initial loading dose is 60 mg / kg administered intravenously, followed by monthly subcutaneous maintenance doses of 30 mg / kg after 1, 2, 3, or 4 weeks. In some embodiments, the initial loading dose is 30 mg / kg administered intravenously, followed by monthly subcutaneous maintenance doses of 15 mg / kg after 1, 2, 3, or 4 weeks. In some embodiments, the initial loading dose is 30 mg / kg administered intravenously, followed by monthly subcutaneous maintenance doses of 30 mg / kg after 1, 2, 3, or 4 weeks.

[0113] In some embodiments, the initial loading dose is 60 mg / kg administered subcutaneously, followed by a maintenance dose of 15 mg / kg administered subcutaneously every other week (Q2W) after 1, 2, 3, or 4 weeks. In some embodiments, the initial loading dose is 60 mg / kg administered subcutaneously, followed by a maintenance dose of 30 mg / kg administered subcutaneously every other week (Q2W) after 1, 2, 3, or 4 weeks. In some embodiments, the initial loading dose is 30 mg / kg administered subcutaneously, followed by a maintenance dose of 15 mg / kg administered subcutaneously every other week (Q2W) after 1, 2, 3, or 4 weeks. In some embodiments, the initial loading dose is 30 mg / kg administered subcutaneously, followed by a maintenance dose of 30 mg / kg administered subcutaneously every other week (Q2W) after 1, 2, 3, or 4 weeks.

[0114] In some embodiments, the initial loading dose is 60 mg / kg administered subcutaneously, followed by monthly subcutaneous maintenance doses of 15 mg / kg after 1, 2, 3, or 4 weeks. In some embodiments, the initial loading dose is 60 mg / kg administered subcutaneously, followed by monthly subcutaneous maintenance doses of 30 mg / kg after 1, 2, 3, or 4 weeks. In some embodiments, the initial loading dose is 30 mg / kg administered subcutaneously, followed by monthly subcutaneous maintenance doses of 15 mg / kg after 1, 2, 3, or 4 weeks. In some embodiments, the initial loading dose is 30 mg / kg administered subcutaneously, followed by monthly subcutaneous maintenance doses of 30 mg / kg after 1, 2, 3, or 4 weeks.

[0115] In some embodiments, the antibody is administered by intravenous infusion. In some embodiments, the antibody is administered by subcutaneous infusion. In some embodiments, the antibody is administered in doses of about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, or about 60 mg / kg. In some embodiments, the antibody is administered at least weekly, every two weeks, every three weeks, or every four weeks (i.e., once a month).

[0116] In some embodiments, the first antibody infusion is administered at a loading dose of approximately 60 mg / kg, and the second antibody infusion is administered weekly at a maintenance dose of 15 mg / kg. In some embodiments, the first antibody infusion is administered at a loading dose of approximately 60 mg / kg, and the second antibody infusion is administered every two weeks at a maintenance dose of 15 mg / kg. In some embodiments, the first antibody infusion is administered at a loading dose of approximately 60 mg / kg, and the second antibody infusion is administered every three weeks at a maintenance dose of 15 mg / kg. In some embodiments, the first antibody infusion is administered at a loading dose of approximately 60 mg / kg, and the second antibody infusion is administered every four weeks at a maintenance dose of 15 mg / kg.

[0117] In some embodiments, the first antibody infusion is administered at a loading dose of approximately 30 mg / kg, and the second antibody infusion is administered weekly at a maintenance dose of 15 mg / kg. In some embodiments, the first antibody infusion is administered at a loading dose of approximately 30 mg / kg, and the second antibody infusion is administered every two weeks at a maintenance dose of 15 mg / kg. In some embodiments, the first antibody infusion is administered at a loading dose of approximately 30 mg / kg, and the second antibody infusion is administered every three weeks at a maintenance dose of 15 mg / kg. In some embodiments, the first antibody infusion is administered at a loading dose of approximately 30 mg / kg, and the second antibody infusion is administered every four weeks at a maintenance dose of 15 mg / kg.

[0118] In some embodiments, the first antibody infusion is administered at a loading dose of approximately 60 mg / kg, and the second antibody infusion is administered weekly at a maintenance dose of 30 mg / kg. In some embodiments, the first antibody infusion is administered at a loading dose of approximately 60 mg / kg, and the second antibody infusion is administered every two weeks at a maintenance dose of 30 mg / kg. In some embodiments, the first antibody infusion is administered at a loading dose of approximately 60 mg / kg, and the second antibody infusion is administered every three weeks at a maintenance dose of 30 mg / kg. In some embodiments, the first antibody infusion is administered at a loading dose of approximately 60 mg / kg, and the second antibody infusion is administered every four weeks at a maintenance dose of 30 mg / kg.

[0119] In some embodiments, the first antibody infusion is administered at a loading dose of approximately 30 mg / kg, and the second antibody infusion is administered weekly at a maintenance dose of 30 mg / kg. In some embodiments, the first antibody infusion is administered at a loading dose of approximately 30 mg / kg, and the second antibody infusion is administered every two weeks at a maintenance dose of 30 mg / kg. In some embodiments, the first antibody infusion is administered at a loading dose of approximately 30 mg / kg, and the second antibody infusion is administered every three weeks at a maintenance dose of 30 mg / kg. In some embodiments, the first antibody infusion is administered at a loading dose of approximately 30 mg / kg, and the second antibody infusion is administered every four weeks at a maintenance dose of 30 mg / kg.

[0120] In some embodiments, additional infusions are administered at a maintenance dose of 15 mg / kg. In some embodiments, additional infusions are administered at a maintenance dose of 30 mg / kg. In some embodiments, infusions (including the first, second, and / or additional) are administered every two weeks, every three weeks, or every four weeks. In some embodiments, the method includes an initial (loading) dose followed by a maintenance dose every two weeks (e.g., every two weeks). In some embodiments, the method includes an initial (loading) dose followed by a maintenance dose every three weeks. In some embodiments, the method includes an initial (loading) dose followed by a monthly maintenance dose. In some embodiments, the initial dose is higher than the bi-weekly maintenance dose. In some embodiments, the loading dose provides a stronger 1-2 week IgG reduction (e.g., a greater decrease in IgG levels).

[0121] The pharmaceutical composition is administered in a manner and at a rate suitable for the administered formulation. In some embodiments, the subject receives a single dose of approximately 30 mg / kg or approximately 60 mg / kg of antibody by intravenous infusion over 90 minutes or less. In some embodiments, the intravenous infusion is performed over 60 minutes or less, 45 minutes or less, 30 minutes or less, 15 minutes or less, or 7 minutes or less. In some embodiments, the subject receives a single dose of approximately 30 mg / kg or approximately 60 mg / kg of antibody by subcutaneous infusion over 90 minutes or less. In some embodiments, the subcutaneous infusion is performed over 60 minutes or less, 45 minutes or less, 30 minutes or less, 15 minutes or less, or 7 minutes or less. In some embodiments, the antibody dose is infused over a period of approximately 7 to 90 minutes, 7 to 60 minutes, 7 to 45 minutes, 7 to 30 minutes, 10 to 90 minutes, 10 to 60 minutes, 10 to 45 minutes, 10 to 30 minutes, 15 to 30 minutes, 30 to 90 minutes, or 15 to 60 minutes.

[0122] In some embodiments, the initial loading dose is infused into the subject over approximately 30 to 90 minutes. In some embodiments, the maintenance dose is infused into the subject over approximately 15 to 60 minutes. In some embodiments, the subject receives a dose of approximately 30 mg / kg of antibody by intravenous infusion over 15 minutes. In some embodiments, the subject receives a dose of approximately 30 mg / kg of antibody by intravenous infusion over 30 minutes. In some embodiments, the subject receives a dose of approximately 45 mg / kg of antibody by intravenous infusion over 15 minutes. In some embodiments, the subject receives a dose of approximately 45 mg / kg of antibody by intravenous infusion over 30 minutes. In some embodiments, the subject receives a dose of approximately 60 mg / kg of antibody by intravenous infusion over 30 minutes. In some embodiments, the subject receives a dose of approximately 30 mg / kg of antibody by intravenous infusion over 60 minutes. In some embodiments, the subject receives a dose of approximately 30 mg / kg to approximately 60 mg / kg by intravenous infusion over a first period for the first infusion and a second period for the second infusion. In some cases, the first period is longer than the second period. In some cases, the second infusion is a second dose of the antibody. In some cases, the subject receives a dose of approximately 30 mg / kg by intravenous infusion over a 30-minute period for the first infusion and a 15-minute period for the second infusion. In some cases, the subject receives a dose of approximately 45 mg / kg by intravenous infusion over a 30-minute period for the first infusion and a 15-minute period for the second infusion. In some cases, the subject receives a dose of approximately 60 mg / kg by intravenous infusion over a 60-minute period for the first infusion and a 30-minute period for the second infusion. In some embodiments, the subject receives a dose of antibody of approximately 30 mg / kg by subcutaneous injection over 15 minutes. In some embodiments, the subject receives a dose of antibody of approximately 30 mg / kg by subcutaneous injection over 30 minutes. In some embodiments, the subject receives a dose of antibody of approximately 45 mg / kg by subcutaneous injection over 15 minutes. In some embodiments, the subject receives a dose of antibody of approximately 45 mg / kg by subcutaneous injection over 30 minutes.In some embodiments, the subject receives a dose of approximately 60 mg / kg of antibody by subcutaneous infusion over 30 minutes. In some embodiments, the subject receives a dose of approximately 30 mg / kg of antibody by subcutaneous infusion over 60 minutes. In some embodiments, the subject receives a dose of approximately 30 mg / kg to approximately 60 mg / kg by subcutaneous infusion over a first period for a first infusion and a second period for a second infusion. In some cases, the first period is longer than the second period. In some cases, the second infusion is a second administration of antibody. In some cases, the subject receives a dose of approximately 30 mg / kg by subcutaneous infusion over 30 minutes in the first period for the first infusion and 15 minutes in the second period for the second infusion. In some cases, the subject receives a dose of approximately 45 mg / kg by subcutaneous infusion over 30 minutes in the first period for the first infusion and 15 minutes in the second period for the second infusion. In some cases, the subject receives a dose of approximately 60 mg / kg by subcutaneous injection over a first period of 60 minutes for the first infusion and a second period of 30 minutes for the second infusion. The dosage and administration rate of the pharmaceutical composition depend on factors including the subject's previous treatment, the disease being treated, and the subject's physical characteristics, such as age, weight, and overall health status.

[0123] [Table 1]

[0124] [Table 2]

[0125] In some embodiments of all the methods described herein, the injection is an injection of a composition containing about 15 mg / ml to about 60 mg / ml of antibody. In some embodiments of all the methods described herein, the injection is an injection of a composition containing about 15 mg / ml, about 30 mg / ml, about 45 mg / ml, or about 60 mg / ml of antibody. In some embodiments of all the methods described herein, the injection is an injection of a composition containing about 15 mg / ml of antibody. In some embodiments of all the methods described herein, the injection is an injection of a composition containing about 30 mg / ml of antibody. In some embodiments of all the methods described herein, the injection is an injection of a composition containing about 60 mg / ml of antibody. In preferred embodiments, the antibody is an anti-FcRn antibody, and most preferably, the anti-FcRn antibody is nipocalimab. In some embodiments, the anti-FcRn antibody comprises a variable region heavy chain containing a sequence having at least 95%, 96%, 97%, 98%, 99%, or 100% identity with the sequence of SEQ ID NO: 10, and a variable region light chain containing a sequence having at least 95%, 96%, 97%, 98%, 99%, or 100% identity with the sequence of SEQ ID NO: 9. In some embodiments, the anti-FcRn antibody comprises a heavy chain containing a sequence having at least 95%, 96%, 97%, 98%, 99%, or 100% identity with the sequence of SEQ ID NO: 2, and a light chain containing a sequence having at least 95%, 96%, 97%, 98%, 99%, or 100% identity with the sequence of SEQ ID NO: 1.

[0126] In some embodiments, the injection is the injection of a composition comprising approximately 15 mg / ml to approximately 60 mg / ml (or approximately 15 mg / ml, approximately 20 mg / ml, approximately 30 mg / ml, approximately 40 mg / ml, approximately 50 mg / ml, approximately 60 mg / ml) of the antibodies described herein, approximately 20 mM to approximately 30 mM sodium phosphate, approximately 20 mM to approximately 30 mM sodium chloride, approximately 80 mg / ml to approximately 100 mg / ml trehalose, and approximately 0.1% w / v to approximately 0.005% w / v polysorbate 80 at pH 6.5. In some embodiments, the injection is the injection of a composition comprising approximately 15 mg / ml to approximately 60 mg / ml (or approximately 15 mg / ml, approximately 20 mg / ml, approximately 30 mg / ml, approximately 40 mg / ml, approximately 50 mg / ml, approximately 60 mg / ml) of the antibodies described herein, approximately 20 mM to approximately 30 mM sodium phosphate, approximately 20 mM to approximately 30 mM sodium chloride, approximately 80 mg / ml to approximately 100 mg / ml trehalose, and approximately 0.1% w / v to approximately 0.005% w / v polysorbate 80 at pH 5 to pH 8. In some embodiments, the injection is the injection of a composition comprising approximately 15 mg / ml to approximately 60 mg / ml (or approximately 15 mg / ml, approximately 20 mg / ml, approximately 30 mg / ml, approximately 40 mg / ml, approximately 50 mg / ml, approximately 60 mg / ml) of the antibodies described herein, approximately 20 mM to approximately 30 mM sodium phosphate, approximately 20 mM to approximately 30 mM sodium chloride, approximately 80 mg / ml to approximately 100 mg / ml trehalose, and approximately 0.1% w / v to approximately 0.005% w / v polysorbate 80 at pH 6 to pH 7. In some embodiments, the injection is the injection of a composition comprising approximately 15 mg / ml to approximately 60 mg / ml (or approximately 15 mg / ml, approximately 20 mg / ml, approximately 30 mg / ml, approximately 40 mg / ml, approximately 50 mg / ml, approximately 60 mg / ml) of the antibodies described herein, approximately 20 mM to approximately 30 mM sodium phosphate, approximately 20 mM to approximately 30 mM sodium chloride, approximately 80 mg / ml to approximately 100 mg / ml trehalose, and approximately 0.1% w / v to approximately 0.005% w / v polysorbate 80 at pH 5 to pH 7.

[0127] In some embodiments of all the methods described herein, the antibody is administered at a dose of approximately 15 mg / kg to approximately 30 mg / kg. In some embodiments of all the methods described herein, the antibody is administered at a dose of approximately 30 mg / kg to approximately 60 mg / kg. In some embodiments of all the methods described herein, the concentration of the antibody in intravenous infusion is approximately 15 mg / ml to approximately 30 mg / ml. In some embodiments of all the methods described herein, the concentration of the antibody in intravenous infusion is approximately 30 mg / ml to approximately 60 mg / ml. In some embodiments of all the methods described herein, the concentration of the antibody in subcutaneous infusion is approximately 15 mg / ml to approximately 30 mg / ml. In some embodiments of all the methods described herein, the concentration of the antibody in subcutaneous infusion is approximately 30 mg / ml to approximately 60 mg / ml.

[0128] In some embodiments of all the methods described herein, the second and third fusion times are the same and are performed over a period of 60 minutes or less, 45 minutes or less, 30 minutes or less, 15 minutes or less, or 7 minutes or less, and the subsequent injection time is shortened.

[0129] In some embodiments of all the methods described herein, the first injection and second fusion times are the same and are carried out over 90 minutes or less, 60 minutes or less, 45 minutes or less, 30 minutes or less, or 15 minutes or less, with subsequent injection times being shortened. In some embodiments of all the methods described herein, both the first injection and the second fusion are carried out over 60 minutes, with subsequent injections carried out over 45 minutes or less, 30 minutes or less, or 15 minutes or less, or both the first injection and the second fusion are carried out over 45 minutes, with subsequent injections carried out over 30 minutes or less, or 15 minutes or less, or both the first injection and the second fusion are carried out over 30 minutes, with subsequent injections carried out over 15 minutes or less. In some embodiments, the injection times are the same and are carried out over 90 minutes or less, 60 minutes or less, 45 minutes or less, 30 minutes or less, 15 minutes or less, or 7 minutes or less. In various embodiments of all methods, the first injection is performed over a period of 90 minutes or less, 60 minutes or less, 45 minutes or less, 30 minutes or less, or 15 minutes or less, and subsequent injection times are shortened. In some embodiments, the second and third fusion times are the same and are performed over a period of 60 minutes or less, 45 minutes or less, 30 minutes or less, 15 minutes or less, or 7 minutes or less, and subsequent injection times are shortened. In some embodiments of all methods, the first injection and second fusion times are the same and are performed over a period of 90 minutes or less, 60 minutes or less, 45 minutes or less, 30 minutes or less, or 15 minutes or less, and subsequent injection times are shortened. In various aspects of all methods, the first infusion is administered over 60 minutes, followed by subsequent infusions lasting 45 minutes or less, 30 minutes or less, or 15 minutes or less; or the first infusion is administered over 45 minutes, followed by subsequent infusions lasting 30 minutes or less or 15 minutes or less; or the first infusion is administered over 30 minutes, followed by subsequent infusions lasting 15 minutes or less.In various aspects of all methods, both the first injection and the second fusion are performed over a period of 60 minutes, followed by a subsequent injection over a period of 45 minutes or less, 30 minutes or less, or 15 minutes or less; or both the first injection and the second fusion are performed over a period of 45 minutes, followed by a subsequent injection over a period of 30 minutes or less, or 15 minutes or less; or both the first injection and the second fusion are performed over a period of 30 minutes, followed by a subsequent injection over a period of 15 minutes or less.

[0130] In some embodiments, the composition is administered parenterally. In some embodiments, the composition is administered intravenously or subcutaneously. In some embodiments, the composition is administered intraperitoneally, intradermally, or intramuscularly. In some embodiments, the composition is administered intravenously. In some embodiments, the composition is administered subcutaneously. In some embodiments, the composition is administered using an infusion pump. In some embodiments, the composition is administered using an auto-injector. In some embodiments, the composition is administered using a patch pump syringe. In some embodiments, the composition is administered using a wearable syringe. In some embodiments, the composition is administered using a Sorrel® pump. In some embodiments, the composition is administered using a pump such as the one in U.S. Patent No. 9,943,642 (which is incorporated herein by reference in its entirety).

[0131] In some embodiments, the anti-FcRn antibody is administered at the rates disclosed herein without the subject experiencing any serious adverse events or reactions.

[0132] VI. Treatment Methods and Indications Blocking human FcRn with anti-FcRn antibodies may be therapeutically beneficial in diseases driven by IgG autoantibodies. The ability of FcRn blockade to induce overall IgG catabolism and removal of multiple autoantibodies without disrupting serum albumin, small circulating metabolites, or lipoproteins provides a way to expand the usefulness and availability of autoantibody removal strategies for patients with autoantibody-driven autoimmune disease pathology. While this disclosure is not theoretical, the primary mechanism of action of anti-FcRn antibodies may be to increase the catabolism of circulating pathogenic autoantibodies and decrease the deposition of autoantibodies and immune complexes in affected tissues.

[0133] In some embodiments of all aspects, the method treats a pregnant subject, the fetus of the pregnant subject, and / or a combination thereof.

[0134] The Specified Provision also describes methods for reducing the risk of or developing autoimmune disorders or alloimmune disorders, including, consisting of, or essentially derived from, intravenous administration of the FcRn antibodies described herein to pregnant subjects.

[0135] In some cases, the approach may include discontinuing administration if the subject exhibits hypoalbuminemia (e.g., serum albumin levels below 30 g / l, 25 g / l, or 20 g / l). In some cases, serum albumin levels may decrease by 25% or less from baseline during treatment.

[0136] Pharmaceutical compositions and methods containing one or more anti-FcRn antibodies are useful for treating immunological conditions or diseases in a subject by promoting the catabolism and clearance of pathogenic antibodies, such as IgG and IgG autoantibodies, reducing the immune response, blocking immune complex-based activation of the immune response, for example. In particular, pharmaceutical compositions and methods are useful for reducing or treating immune complex-based activation of acute or chronic immune responses. Acute immune responses can be activated by medical conditions selected from the group consisting of pemphigus vulgaris, lupus nephritis, myasthenia gravis, Guillain-Barré syndrome, antibody-mediated rejection, fulminant antiphospholipid syndrome, immune complex-mediated vasculitis, glomerulitis, channel disease, neuromyelitis optica, autoimmune hearing loss, idiopathic thrombocytopenia purpura (ITP), autoimmune hemolytic anemia (AIHA), immune neutropenia, dilated cardiomyopathy, and serum sickness. For example, in some embodiments, the acute immune response is activated by the medical condition in the pregnant subject. For example, in some embodiments, the acute immune response is activated in the fetus or neonatal in the medical condition in the pregnant subject. In some embodiments of all embodiments, the acute immune response is activated by the medical condition in the pregnant subject. In some embodiments of all embodiments, the acute immune response is activated in the fetus or neonatal in the medical condition in the pregnant subject. In some embodiments of all aspects, the acute immune response is activated by idiopathic thrombocytopenic purpura. In some embodiments of all aspects, the acute immune response is activated by pemphigus vulgaris. In some embodiments of all aspects, the acute immune response is activated by fulminant antiphospholipid syndrome. In some embodiments of all aspects, the acute immune response is activated by neuromyelitis optica. In some embodiments of all aspects, the acute immune response is activated by antibody-mediated rejection. In some embodiments of all aspects, the acute immune response is activated by myasthenia gravis.Chronic immune responses can be activated by medical conditions selected from the group consisting of chronic inflammatory demyelinating polyneuropathy (CIDP), systemic lupus, chronic forms of disorders indicated for acute treatment, reactive arthropathy, primary biliary cirrhosis, ulcerative colitis, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. In some embodiments of all aspects, the chronic immune response is activated by chronic inflammatory demyelinating polyneuropathy.

[0137] In some embodiments, the pharmaceutical compositions and methods are used for lupus nephritis (LN), myasthenia gravis (MG), idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, chronic inflammatory demyelinating polyneuropathy (CIPD), bullous pemphigoid (BP), dermatomyositis, polymyositis, rheumatoid arthritis (RA), Sjögren's syndrome, systemic lupus erythematosus (SLE), hemolytic disease of the fetus and newborn (HDFN), warm autoimmune hemolytic anemia (wAIHA), maternal fetal medicine (MFM), or polymyositis and dermatomyositis. It is useful in reducing or treating disorders selected from the group consisting of dermatomyositis (PMDM) and other conditions.

[0138] In some embodiments, pharmaceutical compositions and methods are useful for reducing or treating lupus nephritis (LN).

[0139] In some embodiments, pharmaceutical compositions and methods are useful for reducing or treating myasthenia gravis (MG).

[0140] In some embodiments, pharmaceutical compositions and methods are useful for reducing or treating chronic inflammatory demyelinating polyneuropathy (CIPD).

[0141] In some embodiments, pharmaceutical compositions and methods are useful for reducing or treating bullous pemphigoid (BP).

[0142] In some embodiments, pharmaceutical compositions and methods are useful for reducing or treating rheumatoid arthritis (RA).

[0143] In some embodiments, pharmaceutical compositions and methods are useful for reducing or treating Sjögren's syndrome.

[0144] In some embodiments, pharmaceutical compositions and methods are useful for reducing or treating systemic lupus erythematosus (SLE).

[0145] In some embodiments, pharmaceutical compositions and methods are useful for reducing or treating hemolytic diseases (HDFN) in fetuses and neonates.

[0146] In some embodiments, pharmaceutical compositions and methods are useful for reducing or treating warm autoimmune hemolytic anemia (wAIHA).

[0147] In some embodiments, pharmaceutical compositions and methods are useful for reducing or treating maternal-fetal medicine (MFM).

[0148] In some embodiments, pharmaceutical compositions and methods are useful for reducing or treating polymyositis and dermatomyositis (PMDM).

[0149] In some embodiments, the pharmaceutical compositions and methods are used for alopecia areata, ankylosing spondylitis, antiphospholipid antibody syndrome, Addison's disease, autoimmune hemolytic anemia (AIHA) (including warm AIHA), hemolytic anemia, autoimmune hepatitis, hepatitis, Behçet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue dermatitis, chronic fatigue immune deficiency syndrome, chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, scarring pemphigoid, focal scleroderma (CREST syndrome), cold agglutinin disease, Crohn's disease, dermatomyositis, discoid lupus, and essential mixed type. Cryoglobulinemia, fibromyalgia, fibromyositis, Graves' disease, Hashimoto's thyroiditis, hypothyroidism, inflammatory bowel disease, autoimmune lymphoproliferative syndrome, idiopathic pulmonary fibrosis, IgA nephropathy, insulin-dependent diabetes mellitus, juvenile arthritis, lichen planus, lupus, Meniere's disease, mixed connective tissue disease, multiple sclerosis, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndrome, polymyalgia rheumatica, polymyalgia It is useful in reducing or treating disorders selected from the group consisting of myositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcomatoidosis, scleroderma, Sjögren's syndrome, Stiffman syndrome, Takayasu's arteritis, temporal arteritis, ulcerative colitis, uveitis, vitiligo, chronic inflammatory nephropathy, myasthenia gravis, hemolytic disease of the fetus and neonatal infestation (HDFN), demyelinating polyneuropathy (CIDP), membranous nephropathy, Goodpasture disease, polymyositis, idiopathic thrombocytopenic purpura (ITP, also known as "immune thrombocytopenic purpura"), scleroderma, relapsing rheumatoid arthritis, Graves' disease, autoimmune thyroiditis, polyglandular autoimmune syndrome, glomerulonephritis, lupus nephritis, systemic lupus erythematosus (SLE), type 1 diabetes mellitus, and Wegener's granulomatosis.

[0150] In some embodiments, pharmaceutical compositions and methods are useful for reducing or treating immune responses activated by systemic lupus erythematosus, antiphospholipid syndrome, pemphigus vulgaris / bullous pemphigoid, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, myasthenia gravis, or neuromyelitis optica.

[0151] In some embodiments, the pharmaceutical compositions and methods are useful in reducing the risk of anemia in the fetus or in reducing the risk of developing it. In some embodiments, the pharmaceutical compositions and methods are useful in reducing or avoiding the need for intrauterine transfusion (IUT). In some embodiments, the pharmaceutical compositions and methods are useful in reducing or avoiding the need for prenatal PP+IVIg, postnatal transfusion, IVIg, and / or phototherapy.

[0152] In some embodiments, pharmaceutical compositions and methods are useful for reducing or treating immune responses activated by autoimmune diseases. Autoimmune diseases include alopecia areata, ankylosing spondylitis, antiphospholipid antibody syndrome (e.g., antiphospholipid antibody syndrome), Addison's disease, hemolytic anemia (e.g., warm autoimmune hemolytic anemia), autoimmune hepatitis, hepatitis, Behçet's disease, bullous pemphigoid, cardiomyopathy, celiac plue dermatitis, chronic fatigue immune dysfunction syndrome, chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, scarring pemphigoid, focal scleroderma (CREST syndrome), cold agglutinin disease, Crohn's disease, dermatomyositis, discoid lupus, essential mixed cryoglobulinemia, epidermolysis bullosa; fibromyalgia, fibromyositis, Graves' disease, Hashimoto's thyroiditis, hypothyroidism, inflammatory bowel disease The group may be selected from colitis, autoimmune lymphoproliferative syndrome, idiopathic pulmonary fibrosis, IgA nephropathy, insulin-dependent diabetes mellitus, juvenile arthritis, lichen planus, lupus, membranous nephropathy, Meniere's disease, mixed connective tissue disease, multiple sclerosis, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndrome, polymyalgia rheumatica, polymyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcomatoid, scleroderma, Sjögren's syndrome, Stiffman syndrome, Takayasu's arteritis, temporal arteritis, ulcerative colitis, uveitis, vitiligo, and Wegener's granulomatosis. In some embodiments, the pharmaceutical compositions and methods are useful for reducing or treating immune responses in fetuses or neonates. In some embodiments, pharmaceutical compositions and methods are useful for reducing or treating immune responses in fetuses or neonates activated by autoimmune diseases in pregnant mothers.

[0153] In some embodiments, the pharmaceutical compositions and methods are useful for reducing or treating immune responses activated by systemic lupus erythematosus, antiphospholipid syndrome, pemphigus vulgaris / bullous pemphigoid, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, myasthenia gravis, or neuromyelitis optica. In some embodiments, the pharmaceutical compositions and methods are useful for reducing or treating immune responses in fetuses or neonates. In some embodiments, the pharmaceutical compositions and methods are useful for reducing or treating immune responses activated by systemic lupus erythematosus, antiphospholipid syndrome, pemphigus vulgaris / bullous pemphigoid, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, myasthenia gravis, or neuromyelitis optica in pregnant mothers.

[0154] The pharmaceutical compositions and methods are useful in reducing the transport of pathogenic antibodies across the placenta of a pregnant subject (e.g., transport of pathogenic maternal IgG antibodies), increasing pathogenic antibody catabolism in the pregnant subject, and treating antibody-mediated enhancement of viral diseases in the fetus or neonatal period by administering isolated antibodies that bind to human FcRn to the pregnant subject. Diseases and disorders that may benefit from FcRn inhibition by the isolated anti-FcRn antibodies described herein include diseases and disorders in the fetus and / or neonatal period caused by the transport of maternal pathogenic antibodies (e.g., maternal pathogenic IgG antibodies) across the placenta from the pregnant subject to the fetus and / or neonatal period.

[0155] In some embodiments, diseases and disorders that may benefit from FcRn inhibition by isolated anti-FcRn antibodies described herein are fetal and neonatal alloimmune and / or autoimmune disorders. Fetal and neonatal alloimmune disorders are disorders in the fetus and / or neonatal caused by pathogenic antibodies in the pregnant subject. Pathogenic antibodies in the pregnant subject can attack fetal antigens (e.g., antigens inherited by the fetus from the fetal father) to cause the fetus or neonatal to have fetal and neonatal alloimmune and / or autoimmune disorders.

[0156] In some embodiments of all aspects, antibodies associated with immune disorders are detected in a biological sample obtained from a pregnant subject. In some embodiments of all aspects, the biological sample is a blood or urine sample. In some embodiments of all aspects, the biological sample is a blood sample.

[0157] In some embodiments, the present disclosure provides a method for treating or reducing the risk of developing alloimmune disorders and / or autoimmune disorders in a fetus and neonatal, comprising an intravenous administration to a pregnant woman of a composition comprising an antibody (referred to as M281) having a light chain having the amino acid sequence of SEQ ID NO: 1 and a heavy chain having the amino acid sequence of SEQ ID NO: 2, wherein the administration of M281 is terminated after 34 weeks of gestation.

[0158] In some embodiments, the present disclosure provides a method for treating or reducing the risk of developing alloimmune disorders and / or autoimmune disorders in a fetus and neonatal, comprising administering to a pregnant woman a composition comprising an antibody (referred to as M281) having a light chain having the amino acid sequence of SEQ ID NO: 1 and a heavy chain having the amino acid sequence of SEQ ID NO: 2, wherein the administration of M281 is completed at least one week before delivery.

[0159] Examples of fetal and neonatal alloimmune disorders and / or autoimmune disorders that can be treated by the methods described herein include, but are not limited to, fetal and neonatal alloimmune thrombocytopenia (FNAIT), hemolytic disease of the fetus and newborn (HDFN), alloimmune panthrombocytopenia, congenital heart block, fetal joint contractures, neonatal myasthenia gravis, neonatal autoimmune hemolytic anemia, neonatal antiphospholipid syndrome, neonatal polymyositis, dermatomyositis, neonatal lupus, neonatal scleroderma, Behçet's disease, neonatal Graves' disease, neonatal Kawasaki disease, neonatal autoimmune thyroid disease, and neonatal type 1 diabetes mellitus. In some embodiments of all aspects, the fetal and neonatal autoimmune and / or autoimmune disorder is a hemolytic disease of the fetus and newborn. In some embodiments of all aspects, the fetal and neonatal autoimmune and / or autoimmune disorder is fetal and neonatal alloimmune thrombocytopenia. In some embodiments of all aspects, the fetal and neonatal autoimmune and / or autoimmune disorder is congenital heart block. In some embodiments, the treatment reduces the risk of miscarriage. In some embodiments of all aspects, the subject has a medical history of having previously had fetal and neonatal alloimmune and / or autoimmune disorder. For example, in some embodiments, the pregnant subject has been pregnant before, and the fetus or neonatal had fetal and neonatal alloimmune and / or autoimmune disorder. In some embodiments of all aspects, the subject is at risk of having fetal and neonatal alloimmune and / or autoimmune disorder.

[0160] In some embodiments, diseases and disorders that may benefit from FcRn inhibition by isolated anti-FcRn antibodies described herein are viral diseases in which the antibody facilitates viral entry into host cells, resulting in increased or enhanced infectivity in the cells, e.g., antibody-mediated enhancement of viral diseases. In some embodiments, the antibody may bind to a viral surface protein, and the antibody / virus complex may bind to FcRn on the cell surface via an interaction between the antibody and the receptor. The antibody / virus complex may then be internalized into the cell. For example, a virus may enter fetal cells and / or tissues by forming a complex with maternal IgG antibodies. The maternal IgG antibodies may bind to viral surface proteins, and the IgG / virus complex may bind to FcRn in syncytial trophoblastic cells of the placenta, which then transfers the complex to the fetus.

[0161] In some embodiments, the methods described herein may be used to treat antibody-mediated enhancement of viral diseases. In some embodiments, viral diseases enhanced by pathogenic antibodies (e.g., pathogenic IgG antibodies) include alphavirus infection, flavivirus infection, Zika virus infection, chikungunya virus infection, Ross River virus infection, severe acute respiratory syndrome coronavirus infection, Middle East respiratory syndrome, avian influenza infection, influenza virus infection, human respiratory syncytial virus infection, Ebola virus infection, yellow fever virus infection, dengue virus infection, human immunodeficiency virus infection, respiratory syncytial virus infection, hantavirus infection, getavirus infection, Sindbisvirus infection, Bunyamwella virus infection, This includes, but is not limited to, viral diseases caused by West Nile virus infection, Japanese encephalitis virus B infection, rabbitpox virus infection, lactate dehydrogenase-heavy virus infection, reovirus infection, rabies virus infection, foot-and-mouth disease virus infection, porcine reproductive and respiratory syndrome virus infection, monkey hemorrhagic fever virus infection, equine infectious anemia virus infection, goat arthritis virus infection, African swine fever virus infection, lentivirus infection, BK papova virus infection, Murray Valley encephalitis virus infection, enterovirus infection, cytomegalovirus infection, pneumonia virus infection, morbillivirus infection, and measles virus infection.

[0162] In some embodiments of all aspects, viral diseases include alphavirus infection, flavivirus infection, Zika virus infection, chikungunya virus infection, Ross River virus infection, severe acute respiratory syndrome coronavirus infection, Middle East respiratory syndrome, avian influenza infection, influenza virus infection, human respiratory syncytial virus infection, Ebola virus infection, yellow fever virus infection, dengue fever virus infection, human immunodeficiency virus infection, respiratory syncytial virus infection, hantavirus infection, getavirus infection, Sindbisvirus infection, Bunyamwella virus infection, and West Nile virus infection. It is caused by a virus selected from the group consisting of infection, Japanese encephalitis virus B infection, rabbitpox virus infection, lactate dehydrogenase-heavy virus infection, reovirus infection, rabies virus infection, foot-and-mouth disease virus infection, porcine reproductive and respiratory syndrome virus infection, monkey hemorrhagic fever virus infection, equine infectious anemia virus infection, goat arthritis virus infection, African swine fever virus infection, lentivirus infection, BK papovavirus infection, Murray Valley encephalitis virus infection, enterovirus infection, cytomegalovirus infection, pneumonia virus infection, morbillivirus infection, and measles virus infection.

[0163] Blocking human FcRn with anti-FcRn antibodies may be therapeutically beneficial in diseases driven by pathogenic antibodies (e.g., pathogenic IgG antibodies). The ability of FcRn blockade to induce overall pathogenic antibody catabolism and the removal of multiple pathogenic antibodies, microcirculation metabolites, or lipoproteins provides a way to expand the usefulness and applicability of pathogenic antibody removal strategies for patients with pathogenic antibody-driven autoimmune disease pathology. While not theoretically bound, the primary mechanism of action of anti-FcRn antibodies may be to increase the catabolism of circulating pathogenic antibodies and reduce the deposition of pathogenic antibodies and immune complexes in affected tissues.

[0164] The anti-FcRn antibodies described herein may be administered to pregnant subjects who have, or are at risk of having, a medical condition that activates an immune response in the pregnant subject. In some embodiments, the pregnant subject may have a medical condition that has activated an immune response in the pregnant subject in the past. In some embodiments, the pregnant subject has a medical history of having had a previous fetus or neonatal with alloimmunity and / or autoimmune disorder in the fetus and neonatal. In some embodiments, if pathogenic antibodies associated with an immune disorder are detected in a biological sample (e.g., blood or urine sample) obtained from the pregnant subject, the anti-FcRn antibodies described herein may be administered to the pregnant subject. In some embodiments, pathogenic antibodies detected in the biological sample of the pregnant subject are known to bind to fetal antigens in the pregnant subject (e.g., antigens inherited by the fetus from the fetal father).

[0165] In some embodiments, the anti-FcRn antibodies described herein may be administered to subjects planning to become pregnant who have, or are at risk of having, a medical condition that activates an immune response in the pregnant subject, and / or who have previously had a medical condition that activates an immune response in the pregnant subject. In some embodiments, the subject is planning to become pregnant and has a medical history of having had a previous fetus or neonatal with alloimmunity and / or autoimmune disorder in the fetus and neonatal. In some embodiments, the anti-FcRn antibodies described herein may be administered to subjects planning to become pregnant whose biological samples contain pathogenic antibodies associated with an immune disorder.

[0166] In some embodiments, the anti-FcRn antibodies described herein may be administered to a subject (e.g., a pregnant subject) to reduce or treat immune complex-based activation of an acute or chronic immune response in the subject. Acute immune responses may be activated by medical conditions (e.g., pemphigus vulgaris, lupus nephritis, myasthenia gravis, Guillain-Barré syndrome, antibody-mediated rejection, fulminant antiphospholipid syndrome, immune complex-mediated vasculitis, glomerulitis, channel disease, neuromyelitis optica, autoimmune hearing loss, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, immune neutropenia, dilated cardiomyopathy, serum sickness, chronic inflammatory demyelinating polyneuropathy, systemic lupus, reactive arthropathy, primary biliary cirrhosis, ulcerative colitis, or antineutrophil cytoplasmic antigen antibody (ANCA)-associated vasculitis).

[0167] In some embodiments, the anti-FcRn antibodies described herein may be administered to subjects (e.g., pregnant subjects) to reduce or treat the immune response activated by autoimmune diseases. Autoimmune diseases include, for example, alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, Addison's disease, hemolytic anemia, warm autoimmune hemolytic anemia (wAIHA), antifactor antibodies, and heparin-induced thrombocytopenia. Thrombocytopenia (HICT), sensitized transplant, autoimmune hepatitis, hepatitis, Behçet's disease, bullous pemphigoid, cardiomyopathy, celiac plue dermatitis, chronic fatigue immune deficiency syndrome, chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, scarring pemphigoid, focal scleroderma (CREST syndrome), cold agglutinin disease, Crohn's disease, dermatomyositis, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia, fibromyalgia, Graves' disease, Hashimoto's thyroiditis, hypothyroidism, inflammatory bowel disease, autoimmune lymphoproliferative syndrome, idiopathic It may be pulmonary fibrosis, IgA nephropathy, insulin-dependent diabetes mellitus, juvenile arthritis, lichen planus, lupus, Meniere's disease, mixed connective tissue disease, multiple sclerosis, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndrome, polymyalgia rheumatica, polymyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcomatoid, scleroderma, Sjögren's syndrome, Stiffman syndrome, Takayasu's arteritis, temporal arteritis, ulcerative colitis, uveitis, vitiligo, or Wegener's granulomatosis.

[0168] In some embodiments, the subject is a pregnant woman. In certain embodiments, the maintenance dose is based on the pregnant woman's weight at the time of the first loading dose and is not adjusted upward based on weight gain by the pregnant woman. In certain embodiments, the maintenance dose is determined per dose and may be adjusted upward based on the pregnant woman's weight at the time of administration and on weight gain by the pregnant woman. In certain embodiments, the maintenance dose is administered at least every other week, the maintenance dose is administered at least weekly, and the maintenance dose is administered weekly. In certain embodiments, the subject is a pregnant woman and the first loading dose is administered during the first trimester of pregnancy, the subject is a pregnant woman and the first loading dose is administered during the second trimester of pregnancy, and the subject is a pregnant woman and the first loading dose is administered during the third trimester of pregnancy. In certain embodiments, the subject is a pregnant woman with an obstetric history of severe fetal anemia; the subject is a pregnant woman with an obstetric history of hemolytic disease of the fetus and neonatal; the subject is a pregnant woman with elevated anti-RhD, anti-Rhc, or anti-Kell immunoglobulin alloantibody titers; the subject is a pregnant woman with elevated anti-Rhc or anti-Kell immunoglobulin alloantibody titers; the subject is a pregnant woman with anti-Lua, Lub, Bg, Kna, Yta, EcKCw, Fya, cE, ce, D, Ce, cE, K, Kpa, Kpb, Fya, M, N, S, Lea, Leb, Fy, Jka. The subjects are pregnant women who have elevated immunoglobulin alloantibody titers against one or more antibodies selected from the group consisting of Diego, P, and Mia / Mur; pregnant women who have a history of severe fetal anemia or stillbirth within 24 weeks of gestation, have elevated anti-D or anti-Kell IgG alloantibody titers, and are pregnant with an antigen-positive fetus; pregnant women whose first dose is administered between 12 and 16 weeks of gestation; and pregnant women whose first dose is administered during the 14th week of gestation.

[0169] In some embodiments, a method for treating myasthenia gravis in a patient is provided. In some embodiments, the myasthenia gravis is generalized myasthenia gravis. In some embodiments, the patient is an adult patient or a pediatric patient. In some embodiments, the method involves administering a pharmaceutical composition containing an anti-FcRn antibody to the target.

[0170] In some embodiments, a method is provided for treating myasthenia gravis in a patient requiring treatment for myasthenia gravis, comprising administering an initial loading dose of anti-FcRn antibody at approximately 30 mg / kg to approximately 60 mg / kg, followed by a maintenance dose of anti-FcRn antibody at approximately 15 mg / kg to approximately 30 mg / kg, wherein the anti-FcRn antibody comprises a heavy chain including HCDR1 of SEQ ID NO: 6, HCDR2 of SEQ ID NO: 7, and HCDR3 of SEQ ID NO: 8, and a light chain including LCDR1 of SEQ ID NO: 3, LCDR2 of SEQ ID NO: 4, and LCDR3 of SEQ ID NO: 5, wherein the administration reduces serum IgG in the patient by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of baseline serum IgG.

[0171] In some embodiments, a method is provided for treating myasthenia gravis in a patient requiring treatment for myasthenia gravis, comprising administering an initial loading dose of anti-FcRn antibody at approximately 30 mg / kg to approximately 60 mg / kg, followed by a maintenance dose of anti-FcRn antibody at approximately 15 mg / kg to approximately 30 mg / kg, wherein the anti-FcRn antibody comprises a heavy chain including HCDR1 of SEQ ID NO: 6, HCDR2 of SEQ ID NO: 7, and HCDR3 of SEQ ID NO: 8, and a light chain including LCDR1 of SEQ ID NO: 3, LCDR2 of SEQ ID NO: 4, and LCDR3 of SEQ ID NO: 5, wherein the administration reduces baseline serum autoantibodies by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 50%, or at least 25%.

[0172] In some embodiments, a method is provided for treating or reducing the severity of myasthenia gravis in a subject, comprising administering an initial loading dose of anti-FcRn antibody in the range of approximately 5 mg / kg to approximately 120 mg / kg to the subject, followed by a maintenance dose of anti-FcRn antibody in the range of approximately 5 mg / kg to approximately 60 mg / kg, wherein the anti-FcRn antibody comprises a heavy chain including HCDR1 of SEQ ID NO: 6, HCDR2 of SEQ ID NO: 7, and HCDR3 of SEQ ID NO: 8, and a light chain including LCDR1 of SEQ ID NO: 3, LCDR2 of SEQ ID NO: 4, and LCDR3 of SEQ ID NO: 5.

[0173] In some embodiments, the anti-FcRn antibody is as provided herein. In some embodiments, the anti-FcRn antibody is nipokalimab, RVT-1401 (HL161), rozanolixizumab (UCB7665), ALXN1830, ABY-039, or efgultigimod. RVT-1401 (also referred to as HL161BKN) is described in WO2020 / 097099, rozanolixizumab is described in WO2014 / 019727, and efgultigimod (ARGX-113) is described in WO2015 / 100299, each of which is incorporated herein in whole by reference. In some embodiments, the anti-FcRn antibody is a biosimilar of any of the anti-FcRn antibodies provided herein. In a preferred embodiment, the anti-FcRn antibody is nipocalimab.

[0174] In some embodiments, the anti-FcRn antibody comprises a heavy chain and a light chain, the heavy chain comprising HCDR1 of SEQ ID NO: 6, HCDR2 of SEQ ID NO: 7, and HCDR3 of SEQ ID NO: 8, and the light chain comprising LCDR1 of SEQ ID NO: 3, LCDR2 of SEQ ID NO: 4, and LCDR3 of SEQ ID NO: 5. In some embodiments, the heavy chain comprises a variable region heavy chain containing an amino acid sequence having at least 90% identity to the sequence of SEQ ID NO: 10, and the light chain comprises a variable region light chain containing an amino acid sequence having at least 90% identity to the sequence of SEQ ID NO: 9. In some embodiments, the heavy chain comprises a variable region heavy chain containing an amino acid sequence having at least 95% identity to the sequence of SEQ ID NO: 10, and the light chain comprises a variable region light chain containing an amino acid sequence having at least 95% identity to the sequence of SEQ ID NO: 9. In some embodiments, the heavy chain comprises a variable region heavy chain containing an amino acid sequence having at least 99% identity to the sequence of SEQ ID NO: 10, and the light chain comprises a variable region light chain containing an amino acid sequence having at least 99% identity to the sequence of SEQ ID NO: 9. In some embodiments, the heavy chain includes an amino acid sequence having at least 90% identity with the sequence of SEQ ID NO: 2, and the light chain includes an amino acid sequence having at least 90% identity with the sequence of SEQ ID NO: 1. In some embodiments, the heavy chain includes an amino acid sequence having at least 95% identity with the sequence of SEQ ID NO: 2, and the light chain includes an amino acid sequence having at least 95% identity with the sequence of SEQ ID NO: 1. In some embodiments, the heavy chain includes an amino acid sequence having at least 99% identity with the sequence of SEQ ID NO: 2, and the light chain includes an amino acid sequence having at least 99% identity with the sequence of SEQ ID NO: 1. In some embodiments, the heavy chain includes a variable region heavy chain containing the amino acid sequence of SEQ ID NO: 10, and the light chain includes a variable region light chain containing the amino acid sequence of SEQ ID NO: 9. In some embodiments, the heavy chain includes the amino acid sequence of SEQ ID NO: 2, and the light chain includes the amino acid sequence of SEQ ID NO: 1.

[0175] In some embodiments, a method for treating myasthenia gravis in a subject involves administering a pharmaceutical composition comprising approximately 10 mg / ml to approximately 60 mg / ml of anti-FcRn antibody, approximately 20 mM to approximately 30 mM of sodium phosphate, approximately 20 mM to approximately 30 mM of sodium chloride, approximately 80 mg / ml to approximately 100 mg / ml of trehalose, and approximately 0.1% w / v to approximately 0.005% w / v of polysorbate 80.

[0176] In some embodiments, a method for treating myasthenia gravis in a subject includes administering an initial dose and a maintenance dose of an anti-FcRn antibody. In some embodiments, the initial loading dose is approximately 60 mg / kg. In some embodiments, the initial loading dose is approximately 30 mg / kg. In some embodiments, the maintenance dose is approximately 15 mg / kg, approximately 30 mg / kg, approximately 45 mg / kg, or approximately 60 mg / kg. In some embodiments, the maintenance dose is approximately 15 mg / kg. In some embodiments, the maintenance dose is approximately 30 mg / kg. In some embodiments, the maintenance dose is 45 mg / kg. In some embodiments, the maintenance dose is administered one, two, three, or four weeks after the administration of the initial loading dose. In some embodiments, the maintenance dose is administered one, two, three, or four weeks after the preceding maintenance dose. In some embodiments, the initial loading dose is infused into the subject over approximately 30 to 90 minutes. In some embodiments, the maintenance dose is administered to the subject over a period of approximately 15 to 60 minutes.

[0177] In some embodiments, subjects receiving treatment for myasthenia gravis have or indicate a reduction in one or more immunoglobulin isotypes or total IgG. In some embodiments, subjects receiving treatment for myasthenia gravis or moderate to severe active myasthenia gravis have or indicate a reduction in one or more immunoglobulin isotypes or total IgG. In some embodiments, the reduction is about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1–20%, 5–20%, 5–25%, 10–30%, 15–35%, 20–40%, 40–60%, or about or at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, or 90%. In some embodiments, administration of anti-FcRn antibody reduces serum IgG by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of baseline serum IgG. In some embodiments, administration of anti-FcRn antibody reduced serum IgG in patients by at least 90% of baseline. In some embodiments, administration of anti-FcRn antibody reduces serum IgG in patients by at least 80% of baseline. In some embodiments, administration of anti-FcRn antibody reduces serum IgG in patients by at least 70% of baseline. In some embodiments, the reduced immunoglobulin isotype is IgG1, IgG2, IgG3, IgG4, or any combination thereof. In some embodiments, administration of anti-FcRn antibody reduces serum IgG1 by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of baseline serum IgG1. In some embodiments, administration of anti-FcRn antibody reduced serum IgG1 in patients by at least 90% of baseline. In some embodiments, administration of anti-FcRn antibody reduces serum IgG1 in patients by at least 80% of baseline. In some embodiments, administration of anti-FcRn antibody reduces serum IgG1 in patients by at least 70% of baseline.In some embodiments, administration of anti-FcRn antibody reduces serum IgG2 by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of baseline serum IgG2. In some embodiments, administration of anti-FcRn antibody reduced serum IgG2 in patients by at least 90% of baseline. In some embodiments, administration of anti-FcRn antibody reduces serum IgG2 in patients by at least 80% of baseline. In some embodiments, administration of anti-FcRn antibody reduces serum IgG2 in patients by at least 70% of baseline. In some embodiments, administration of anti-FcRn antibody reduces serum IgG3 by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of baseline serum IgG3. In some embodiments, administration of anti-FcRn antibodies reduces serum IgG3 in patients by at least 90% from baseline. In some embodiments, administration of anti-FcRn antibodies reduces serum IgG3 in patients by at least 80% from baseline. In some embodiments, administration of anti-FcRn antibodies reduces serum IgG3 in patients by at least 70% from baseline. In some embodiments, administration of anti-FcRn antibodies reduces serum IgG4 by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% from baseline serum IgG4. In some embodiments, administration of anti-FcRn antibodies reduced serum IgG4 in patients by at least 90% from baseline. In some embodiments, administration of anti-FcRn antibodies reduces serum IgG4 in patients by at least 80% from baseline. In some embodiments, administration of anti-FcRn antibodies reduces serum IgG4 in patients by at least 70% from baseline.

[0178] In some embodiments, administration of an anti-FcRn antibody reduces serum albumin by up to 18%, up to 16%, up to 14%, up to 12%, up to 10%, up to 8%, up to 6%, up to 4%, or up to 2% of baseline serum albumin. In some embodiments, administration of an anti-FcRn antibody reduces serum albumin by up to 18% of baseline serum albumin. In some embodiments, administration of an anti-FcRn antibody reduces serum albumin by up to 16% of baseline serum albumin. In some embodiments, administration of an anti-FcRn antibody reduces serum albumin by up to 14% of baseline serum albumin. In some embodiments, administration of an anti-FcRn antibody reduces serum albumin by up to 12% of baseline serum albumin. In some embodiments, administration of an anti-FcRn antibody reduces serum albumin by up to 10% of baseline serum albumin. In some embodiments, administration of anti-FcRn antibody reduces serum albumin by up to 8% above baseline. In some embodiments, administration of anti-FcRn antibody reduces serum albumin by up to 6% above baseline. In some embodiments, administration of anti-FcRn antibody reduces serum albumin by up to 4% above baseline. In some embodiments, administration of anti-FcRn antibody reduces serum albumin by up to 2% above baseline.

[0179] In some embodiments, subjects receiving treatment for myasthenia gravis have or demonstrate a reduction in autoantibodies. In some embodiments, the reduction is about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1–20%, 5–20%, 5–25%, 10–30%, 15–35%, 20–40%, 40–60%, or about or at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, or 95%. In some embodiments, the reduced autoantibody is selected from the group consisting of anti-acetylcholine receptor (AChR), anti-muscle-specific kinase (MuSK), anti-low-density lipoprotein receptor-associated protein 4 (LRP4), anti-agrin, anti-titin, anti-Kv1.4, anti-ryanodine receptor, anti-collagen Q, and anti-cortactin. In some embodiments, the autoantibody is anti-AChR or anti-MuSK antibody. In some embodiments, administration of anti-FcRn antibody reduces anti-AChR antibody by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 50%, or at least 25% of baseline anti-AChR antibody. In some embodiments, administration of anti-FcRn antibody reduces anti-AChR antibody by at least 95% of baseline anti-AChR antibody. In some embodiments, administration of anti-FcRn antibody reduces anti-AChR antibody by at least 90% of baseline anti-AChR antibody. In some embodiments, administration of anti-FcRn antibody reduces anti-AChR antibody by at least 85% compared to baseline anti-AChR antibody. In some embodiments, administration of anti-FcRn antibody reduces anti-AChR antibody by at least 80% compared to baseline anti-AChR antibody. In some embodiments, administration of anti-FcRn antibody reduces anti-AChR antibody by at least 75% compared to baseline anti-AChR antibody. In some embodiments, administration of anti-FcRn antibody reduces anti-AChR antibody by at least 50% compared to baseline anti-AChR antibody. In some embodiments, administration of anti-FcRn antibody reduces anti-AChR antibody by at least 25% compared to baseline anti-AChR antibody.In some embodiments, administration of an anti-FcRn antibody reduces anti-MuSK antibody by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 50%, or at least 25% of baseline anti-MuSK antibody. In some embodiments, administration of an anti-FcRn antibody reduces anti-MuSK antibody by at least 95% of baseline anti-MuSK antibody. In some embodiments, administration of an anti-FcRn antibody reduces anti-MuSK antibody by at least 90% of baseline anti-MuSK antibody. In some embodiments, administration of an anti-FcRn antibody reduces anti-MuSK antibody by at least 85% of baseline anti-MuSK antibody. In some embodiments, administration of an anti-FcRn antibody reduces anti-MuSK antibody by at least 80% of baseline anti-MuSK antibody. In some embodiments, administration of an anti-FcRn antibody reduces anti-MuSK antibody by at least 75% of baseline anti-MuSK antibody. In some embodiments, administration of anti-FcRn antibody reduces anti-MuSK antibody by at least 50% of baseline anti-MuSK antibody. In some embodiments, administration of anti-FcRn antibody reduces anti-MuSK antibody by at least 25% of baseline anti-MuSK antibody. In some embodiments, administration of anti-FcRn antibody reduces anti-AChR antibody by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 50%, or at least 25% of baseline anti-AChR antibody, and reduces anti-MuSK antibody by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 50%, or at least 25% of baseline anti-MuSK antibody.

[0180] In some embodiments, the method comprises administering a pharmaceutical composition, which includes administering an anti-FcRn antibody to a subject. In some embodiments, the anti-FcRn antibody is nipocalimab, RVT-1401 (HL161), rozanolixizumab (UCB7665), ALXN1830, ABY-039, or efgartigimod. In some embodiments, the anti-FcRn antibody is as provided herein. In some embodiments, the subject has or is suspected of having myasthenia gravis. In preferred embodiments, the anti-FcRn antibody is nipocalimab.

[0181] In some embodiments, administration of anti-FcRN antibodies to subjects with myasthenia gravis treats or improves ocular myasthenia, ptosis, difficulty chewing, dysphagia, dysarthria, dyspnea, difficulty breathing, inability to keep the mouth closed, onset of sadness or drowsiness, difficulty keeping the head upright, double eyelids, dysarthria, dysphagia, facial changes, shortness of breath, weakness of the arms, weakness of the hands, weakness of the fingers, weakness of the legs, and weakness of the neck.

[0182] In some embodiments, subjects treated for myasthenia gravis show improvement in one or more of the following assays, scores, or criteria that can be used to assess improvement or condition in subjects with myasthenia gravis. In some embodiments, subjects show improvement in one or more of the following: MG-ADL score, QMG score, MG-QoL15r score, Neuro-QoL-Fatigue score, EQ-5D-5L score, MGFA scale, PGI-C score, PGI-S score, C-SSRS score, and PedsQL score.

[0183] In some embodiments, treatment of MG includes improvement of clinical markers of MG progression. These markers include MG activity of daily living profile (MG-ADL) and the quantitative myasthenia gravis (QMG) score for disease severity. In certain embodiments, MG-ADL is the primary score for measuring improvement in MG.

[0184] The MG-ADL is an 8-point questionnaire focusing on symptoms and functional performance related to activities of daily living (ADL) in patients with myosophylactic shock (MG). The 8 items of the MG-ADL are derived from the symptom-based components of the original 13-item QMG to assess impairments secondary to ocular (2 items), ocular (3 items), respiratory (1 item), and gross motor or limb (2 items) impairments related to the effects of MG. In this functional status scale, each response is graded from 0 (normal) to 3 (most severe). The total MG-ADL score ranges from 0 to 24. A clinically meaningful improvement in a patient's MG-ADL is a reduction of 2 points or more in the score 57 days after treatment.

[0185] In some embodiments, patients treated by the methods provided herein experience a change from baseline in their activities of daily living (MG-ADL) score for myasthenia gravis over time or 57 days after treatment. In some embodiments, the change from baseline in the MG-ADL score is 2 points or more on the MG-ADL scale.

[0186] The current QMG scoring system consists of 13 items: eyes (2 items), face (1 item), eyeballs (2 items), gross motor skills (6 items), body axis (1 item), and respiratory system (1 item), each graded from 0 to 3, with 3 being the most severe. The total QMG score ranges from 0 to 39. The QMG scoring system is considered an objective assessment of MG treatment and is based on quantitative testing of the sentinel muscle group. Higher scores indicated greater debilitation. QMG was administered by trained and qualified healthcare professionals (e.g., physicians, physician assistants, nurse practitioners, nurses). Where possible, QMG was administered to a given subject by the same healthcare professional throughout the study and at approximately the same time throughout the study.

[0187] In some embodiments, patients treated by the methods provided herein experience a change from baseline in their activities of daily living (MG-ADL) score for myasthenia gravis over time or 22, 23, and 24 weeks after treatment. In some embodiments, the change from baseline in the MG-ADL score is 2 points or more on the MG-ADL scale.

[0188] In some embodiments, patients treated by the methods provided herein experience a change from baseline in their QMG score 57 days after treatment. In some embodiments, patients treated by the methods provided herein experience a change from baseline in their QMG score over time after the last dose. In some embodiments, the change from baseline is a reduction of at least 2, 3, 4, 5, 6, 7, or 8 points or more in the patient's QMG score over time after the last dose. In some embodiments, the change from baseline is a reduction of at least 2 points in the patient's QMG score over time after the last dose. In some embodiments, the change from baseline is a reduction of at least 3 points in the patient's QMG score over time after the last dose. In some embodiments, the change from baseline is a reduction of at least 4 points in the patient's QMG score over time after the last dose. In some embodiments, the change from baseline is a reduction of at least 5 points in the patient's QMG score over time after the last dose. In some embodiments, the change from baseline is a reduction of at least 6 points in the patient's QMG score over time after the last dose. In some embodiments, the change from baseline is a reduction of at least 7 points in the patient's QMG score over time after the last dose. In some embodiments, the change from baseline is a reduction of 8 points or more in the patient's QMG score over time after the last dose. In some embodiments, patients treated by the method provided herein experience a change from baseline in their QMG score 22, 23, and 24 weeks after treatment. In some embodiments, patients treated by the method provided herein experience a change from baseline in their QMG score over time after the last dose. In some embodiments, the change from baseline is a reduction of at least 2, 3, 4, 5, 6, 7, or 8 points or more in the patient's QMG score over time after 22, 23, and 24 weeks after treatment, or after the last dose.In some embodiments, the change from baseline is a reduction of at least 2 points in the patient's QMG score over time, 22, 23, and 24 weeks after treatment, or after the last dose. In some embodiments, the change from baseline is a reduction of at least 3 points in the patient's QMG score over time, 22, 23, and 24 weeks after treatment, or after the last dose. In some embodiments, the change from baseline is a reduction of at least 4 points in the patient's QMG score over time, 22, 23, and 24 weeks after treatment, or after the last dose. In some embodiments, the change from baseline is a reduction of at least 5 points in the patient's QMG score over time, 22, 23, and 24 weeks after treatment, or after the last dose. In some embodiments, the change from baseline is a reduction of at least 6 points in the patient's QMG score over time, 22, 23, and 24 weeks after treatment, or after the last dose. In some embodiments, the change from baseline is a reduction of at least 7 points in the patient's QMG score over time, 22, 23, and 24 weeks after treatment, or after the last dose. In some embodiments, the change from baseline is a reduction of 8 points or more in the patient's QMG score over time, 22, 23, and 24 weeks after treatment, or after the last dose.

[0189] The 15-item Myasthenia Gravis Qualify of Life (MG-QoL-15r) is a health-related quality of life assessment tool specific to individuals with MG. See Table 4. The MG-QoL-15r is designed to be easy to administer and interpret, providing information on the subject's perception of disability and impairment, as well as the degree to which disease manifestation is tolerable. The MG-QoL-15r is completed by the subject. The total score ranges from 0 to 60, with higher scores indicating a greater degree of MG-related dysfunction and greater dissatisfaction with MG-related dysfunction. The MG-QoL-15r was used to assess the limitations of subjects related to living with MG. Each of the 15 items was rated by the subject on a 3-point scale based on a recall period of "the past few weeks," with a maximum score of 30. Higher scores indicated more limitations.

[0190] In some embodiments, patients treated by the methods provided herein experience a change from baseline in their MG-QoL-15r score 57 days after treatment. In some embodiments, patients treated by the methods provided herein experience a change from baseline in their MG-QoL-15r score over time after the last dose is administered. In some embodiments, patients treated by the methods provided herein experience a change from baseline in their MG-QoL-15r score 22, 23, and 24 weeks after treatment. In some embodiments, patients treated by the methods provided herein experience a change from baseline in their MG-QoL-15r score over time after the last dose is administered. In some embodiments, patients achieve a change from baseline on the MG-QoL-15r scale, which is a reduction of at least 3, 4, 5, or 6 points in their MG-QoL-15r score. In some embodiments, patients achieve a change from baseline on the MG-QoL-15r scale, which is a reduction of at least 3 points in their MG-QoL-15r score. In some embodiments, patients achieve a change from baseline on the MG-QoL-15r scale, which is a reduction of at least 6 points on the MG-QoL-15r score.

[0191] The severity of myasthenia gravis in subjects was assessed using the Myasthenia Gravis Foundation of America Clinical Classification (MGFA). The system includes five classes of disease severity, ranging from Class I (ocular muscle weakness only) to Class V (subject is intubated). Classes II through IV are each further divided into two subclasses based on which muscle groups are primarily affected. The MGFA was administered by trained and qualified healthcare professionals (e.g., physicians, physician assistants, nurse practitioners, and nurses) and, where possible, was assessed by the same person for a given subject throughout the study.

[0192] In some embodiments, patients treated by the methods provided herein experience a shift in MGFA classification 57 days after treatment. In some embodiments, patients treated by the methods provided herein experience a shift in MGFA classification over time after the last dose is administered. In some embodiments, the shift is about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1–20%, 5–20%, 5–25%, 10–30%, 15–35%, 20–40%, 40–60%, or about or at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, or 80%. In some embodiments, patients treated by the methods provided herein experience a shift in MGFA classification 22, 23, and 24 weeks after treatment. In some embodiments, patients treated by the methods provided herein experience a shift in their MGFA classification over time after the last dose. In some embodiments, the shift is about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1–20%, 5–20%, 5–25%, 10–30%, 15–35%, 20–40%, 40–60%, or about or at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, or 95%.

[0193] In some embodiments, patients treated by the methods provided herein experience changes in quality of life (Neuro-QoL-Fatigue) in neurological disorders. Neuro-QoL-Fatigue is a reliable, effective, and short 19-item fatigue survey completed by the subject for all items. Higher scores indicate greater fatigue and a greater impact of MG on activity. Clinically significant improvements in a patient's Neuro-QoL-Fatigue score are reflected in a decrease in score over time, 22, 23, and 24 weeks after treatment, or after the last dose.

[0194] In some embodiments, patients treated by the methods provided herein experience a change from baseline in the Neuro-QoL fatigue score 22, 23, and 24 weeks after treatment. In some embodiments, patients treated by the methods provided herein experience a change from baseline in the Neuro-Fatigue Scale over time after the last dose is administered. In some embodiments, the change from baseline in Neuro-QoL fatigue indicates improvement. In some embodiments, the variation is approximately 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1-20%, 5-20%, 5-25%, 10-30%, 15-35%, 20-40%, 40-60%, or approximately or at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, or 95%.

[0195] In some embodiments, patients treated by the methods provided herein experience changes in the EuroQol Five-Dimensional Five-Level Quality of Life Questionnaire (5Q-5D-5L). EQ-5D-5L is a standardized measure of health status developed by the EuroQol Group, providing a simple general measure of health for clinical and economic assessment. As a measure of health-related quality of life, EQ-5D-5L defines health with respect to five dimensions: mobility, self-care, daily living activities, pain / discomfort, and anxiety / depression. Each dimension has three ordinal levels of severity: “No problems” (1), “Some problems” (2), and “Serious problems” (3). The overall health status is defined as a five-digit number. The health status defined by the 5-dimensional classification can be converted into a corresponding index score that quantifies the health status, where -0.594 represents “Serious problems” and 1 represents “No problems”.

[0196] In some embodiments, patients treated by the methods provided herein experience a change from baseline on the EQ-5D-5L scale. In some embodiments, the change from baseline on the EQ-5D-5L scale indicates improvement. In some embodiments, patients treated by the methods provided herein experience a change from baseline on the EQ-5D-5L scale at 22, 23, and 24 weeks of treatment, or over time after the last dose is administered. In some embodiments, the variation is approximately 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1-20%, 5-20%, 5-25%, 10-30%, 15-35%, 20-40%, 40-60%, or approximately or at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, or 95%.

[0197] In some embodiments, patients being treated by the methods provided herein experience changes in the Patient Global Impression of Change (PGI-C). The PGI-C is a patient rating of response to treatment on a 7-point Likert scale, completed at weeks 2, 4, 8, 12, 16, 20, 22, and at the end of the study (week 24).

[0198] In some embodiments, patients treated by the methods provided herein experience a change from baseline on the PGI-C scale. In some embodiments, the change from baseline on the PGI-C scale indicates improvement. In some embodiments, patients treated by the methods provided herein experience a change from baseline on the PGI-C scale at 22, 23, and 24 weeks of treatment, or over time after the last dose is administered. In some embodiments, the change is about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1-20%, 5-20%, 5-25%, 10-30%, 15-35%, 20-40%, 40-60%, or about or at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, or 95%.

[0199] In some embodiments, patients being treated by the methods provided herein experience a change in the Patient Global Impression of Severity (PGI-S). The Patient Global Impression of Severity (PGI-S) is a global index (single-state scale) that can be used to rate the severity of a particular condition. It is a simple, direct, and easy-to-use scale that is intuitively understandable to clinicians. The PGI-S is a single question that asks patients to rate how their urinary tract condition currently falls on a scale of 1 (normal) to 4 (severe).

[0200] In some embodiments, patients treated by the methods provided herein experience a change from baseline on the PGI-S scale. In some embodiments, the change from baseline on the PGI-S scale indicates improvement. In some embodiments, patients treated by the methods provided herein experience a change from baseline on the PGI-S scale at 22, 23, and 24 weeks of treatment, or over time after the last dose is administered. In some embodiments, the change is about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1-20%, 5-20%, 5-25%, 10-30%, 15-35%, 20-40%, 40-60%, or about or at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, or 95%.

[0201] In some embodiments, patients being treated by the methods provided herein experience changes on the Columbia Suicide Severity Rating Scale. The C-SSRS is used to assess the degree of a patient's suicidal ideation on a scale ranging from “no suicidal ideation” to “active suicidal ideation with specific plans and intentions.” (Posner 2011) The C-SSRS is completed at screening (visit 0), day 1, week 2, week 4, week 8, week 12, week 16, week 20, and week 24.

[0202] In some embodiments, patients treated by the methods provided herein experience a change from baseline on the C-SSRS scale. In some embodiments, the change from baseline on the C-SSRS scale indicates improvement. In some embodiments, patients treated by the methods provided herein experience a change from baseline on the C-SSRS scale at 22, 23, and 24 weeks of treatment, or over time after the last dose is administered. In some embodiments, the change is about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1-20%, 5-20%, 5-25%, 10-30%, 15-35%, 20-40%, 40-60%, or about or at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, or 95%.

[0203] In some embodiments, pediatric patients treated by the methods provided herein experience changes in the Pediatric Quality of Life Inventory Scale (PedsQL). The PedsQL measurement model is a modular approach for measuring health-related quality of life (HRQOL) in healthy children and adolescents as well as those with acute and chronic health conditions. The PedsQL measurement model seamlessly integrates both a generic core scale and disease-specific modules into a single measurement system. The 23-item PedsQL generic core scale is designed to measure the core dimensions of health described by the World Health Organization, and role (school) functioning. PedsQL is available in versions for children and adolescents aged 5–7, 8–12, and 13–18 years, and can be completed by children and adolescents. Parent-assessment versions are available for children aged 2–4, 5–7, 8–12, and 13–18 years. The PedsQL inventory takes approximately 5 minutes to complete and can be self-administered by parents, children, and adolescents aged 8–18 years after being introduced by a trained administrator. For younger children, and as an alternative in special circumstances, clinicians may perform the inventory if they read the instructions and all items word for word to the child or adolescent. Reverse score the items on the PedsQL Generic Core Scale and convert them to a 0-100 scale. Higher scores indicate better health-related quality of life: 0 ("never") = 100, 1 ("rarely") = 75, 2 ("sometimes") = 50, 3 ("frequently") = 25, and 4 ("almost always") = 0. Versions used: Teenagers report the acute version for children aged 13–18 years. Parents report the acute version for children aged 8–12 years. Parents report the acute version for children aged 5–7 years, and parents report the acute version for toddlers aged 2–4 years.

[0204] In some embodiments, pediatric patients treated by the methods provided herein experience a change from baseline on the PedsQL scale. In some embodiments, the change from baseline on the PedsQL scale indicates improvement. In some embodiments, pediatric patients treated by the methods provided herein experience a change from baseline on the PedsQL scale over time, after 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 24 weeks of treatment, or after the last dose is administered. In some embodiments, the variation is approximately 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1-20%, 5-20%, 5-25%, 10-30%, 15-35%, 20-40%, 40-60%, or approximately or at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, or 95%.

[0205] In some embodiments, the subject is also treated with an additional therapeutic agent in addition to the anti-FcRn antibody. In some embodiments, the additional therapeutic agent is an acetylcholinesterase inhibitor, pyridostigmine, pyridostigmine bromide (Mestinon), neostigmine, prednisone, azathioprine (Imuran), mycophenylate mofetil (CellCept), tacrolimus (Prograf), methotrexate, cyclosporine (Sandimmune, Neoral), and cyclophosphamide (Cytoxan, Neosar), rituximab (Rituxan), eculizumab (Soliris), IVIg, or any combination thereof. In some embodiments, the additional therapeutic agent is administered simultaneously with or immediately following (before or after) the anti-FcRn antibody.

[0206] As provided herein, in some embodiments, pharmaceutical compositions comprising an anti-FcRn antibody are provided. In some embodiments, a pharmaceutical composition comprising an anti-FcRn antibody for administration to a patient suffering from myasthenia gravis is provided, wherein the anti-FcRn antibody is administered to the patient in a therapeutically effective dose at an initial loading dose of about 30 mg / kg to about 60 mg / kg, followed by a maintenance dose of about 15 mg / kg to about 30 mg / kg, and the anti-FcRn antibody comprises a heavy chain comprising HCDR1 of SEQ ID NO: 6, HCDR2 of SEQ ID NO: 7, and HCDR3 of SEQ ID NO: 8, and a light chain comprising LCDR1 of SEQ ID NO: 3, LCDR2 of SEQ ID NO: 4, and LCDR3 of SEQ ID NO: 5. In some embodiments, the patient is an adult patient or a pediatric patient.

[0207] In some embodiments, myasthenia gravis is generalized myasthenia gravis. In some embodiments, the subject is a subject having a suboptimal response to a stable therapy for gMG. In some embodiments, the stable therapy for gMG comprises an acetylcholinesterase inhibitor, a glucocorticosteroid, and an immunosuppressant. In some embodiments, the immunosuppressant is selected from azathioprine, mycophenolate mofetil / mycophenolate, methotrexate, cyclosporine, tacrolimus, and cyclophosphamide. In some embodiments, the method comprises administering a pharmaceutical composition, which includes administering an anti-FcRN antibody to the subject. In some embodiments, the anti-FcRN antibody is nipokalimab, RVT-1401 (HL161), rozanolixizumab (UCB7665), ALXN1830, ABY-039, or efgaltigimod.

[0208] In some embodiments, the pharmaceutical composition comprises an anti-FcRn antibody including a heavy chain and a light chain, wherein the heavy chain includes HCDR1 of SEQ ID NO: 6, HCDR2 of SEQ ID NO: 7, and HCDR3 of SEQ ID NO: 8, and the light chain includes LCDR1 of SEQ ID NO: 3, LCDR2 of SEQ ID NO: 4, and LCDR3 of SEQ ID NO: 5.

[0209] In some embodiments, the pharmaceutical composition comprises an anti-FcRn antibody, the heavy chain comprising a variable region heavy chain having an amino acid sequence having at least 90% identity with the sequence of SEQ ID NO: 10, and the light chain comprising a variable region light chain having an amino acid sequence having at least 90% identity with the sequence of SEQ ID NO: 9. In some embodiments, the pharmaceutical composition comprises an anti-FcRn antibody, the heavy chain comprising a variable region heavy chain having an amino acid sequence having at least 95% identity with the sequence of SEQ ID NO: 10, and the light chain comprising a variable region light chain having an amino acid sequence having at least 95% identity with the sequence of SEQ ID NO: 9. In some embodiments, the pharmaceutical composition comprises an anti-FcRn antibody, the heavy chain comprising a variable region heavy chain having an amino acid sequence having at least 99% identity with the sequence of SEQ ID NO: 10, and the light chain comprising a variable region light chain having an amino acid sequence having at least 99% identity with the sequence of SEQ ID NO: 9. In some embodiments, the pharmaceutical composition comprises an anti-FcRn antibody, the heavy chain comprising an amino acid sequence having at least 90% identity with the sequence of SEQ ID NO: 2, and the light chain comprising an amino acid sequence having at least 90% identity with the sequence of SEQ ID NO: 1. In some embodiments, the pharmaceutical composition comprises an anti-FcRn antibody, the heavy chain comprising an amino acid sequence having at least 95% identity with the sequence of SEQ ID NO: 2, and the light chain comprising an amino acid sequence having at least 95% identity with the sequence of SEQ ID NO: 1. In some embodiments, the pharmaceutical composition comprises an anti-FcRn antibody, the heavy chain comprising an amino acid sequence having at least 99% identity with the sequence of SEQ ID NO: 2, and the light chain comprising an amino acid sequence having at least 99% identity with the sequence of SEQ ID NO: 1. In some embodiments, the pharmaceutical composition comprises an anti-FcRn antibody, the heavy chain comprising a variable region heavy chain comprising the amino acid sequence of SEQ ID NO: 10, and the light chain comprising a variable region light chain comprising the amino acid sequence of SEQ ID NO: 9. In some embodiments, the pharmaceutical composition comprises an anti-FcRn antibody, the heavy chain comprising the amino acid sequence of SEQ ID NO: 2, and the light chain comprising the amino acid sequence of SEQ ID NO: 1.

[0210] In some embodiments, the pharmaceutical composition contains a therapeutically effective amount of anti-FcRn antibody. In some embodiments, the pharmaceutical composition contains a therapeutically effective amount of anti-FcRn antibody. In some embodiments, the therapeutically effective amount is about 5 mg / kg to about 60 mg / kg, about 5 mg / kg to about 15 mg / kg, about 15 mg / kg to about 60 mg / kg, or about 30 mg / kg to about 60 mg / kg of anti-FcRn antibody. In some embodiments, the therapeutically effective amount is about 5 mg / kg, about 15 mg / kg, about 30 mg / kg, or about 60 mg / kg. In some embodiments, the therapeutically effective amount is about 5 mg / kg. In some embodiments, the therapeutically effective amount is about 15 mg / kg. In some embodiments, the therapeutically effective amount is about 30 mg / kg. In some embodiments, the therapeutically effective amount is about 60 mg / kg. In some embodiments, the pharmaceutical composition contains an initial loading dose and a maintenance dose. In some embodiments, the initial loading dose is about 60 mg / kg. In some embodiments, the initial loading dose is about 30 mg / kg. In some embodiments, the maintenance dose is about 30 mg / kg. In some embodiments, the maintenance dose is about 15 mg / kg. In some embodiments, the pharmaceutical composition is administered at an initial loading dose of about 60 mg / kg and a maintenance dose of about 30 mg / kg. In some embodiments, the pharmaceutical composition is administered at an initial loading dose of about 60 mg / kg and a maintenance dose of about 15 mg / kg. In some embodiments, the pharmaceutical composition is administered at an initial loading dose of about 30 mg / kg and a maintenance dose of about 30 mg / kg. In some embodiments, the pharmaceutical composition is administered at an initial loading dose of about 30 mg / kg and a maintenance dose of about 15 mg / kg.

[0211] In some embodiments, the pharmaceutical composition is administered weekly, every two weeks, or monthly.

[0212] In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in the patient showing improvement in the MG-ADL score, QMG score, MG-QoL15r score, Neuro-QoL-Fatigue score, EQ-5D-5L score, MGFA scale, PGI-C score, PGI-S score, C-SSRS score, and PedsQL score.

[0213] In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis treats or improves ocular myasthenia, ptosis, difficulty chewing, dysphagia, dysarthria, difficulty breathing, inability to keep the mouth closed, onset of sadness or drowsiness, difficulty keeping the head upright, double eyelids, dysarthria, dysphagia, facial changes, shortness of breath, weakness of the arms, weakness of the hands, weakness of the fingers, weakness of the legs, and weakness of the neck.

[0214] In some embodiments, administration of the pharmaceutical composition to a patient results in a reduction of one or more immunoglobulin isotypes or total IgG in the patient. In some embodiments, the isotypes are IgG1, IgG2, IgG3, or IgG4. In some embodiments, the reduction is about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1-20%, 5-20%, 5-25%, 10-30%, 15-35%, 20-40%, 40-60%, or about or at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, or 80%. In some embodiments, administration of the pharmaceutical composition reduces serum IgG by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of baseline serum IgG. In some embodiments, administration of the pharmaceutical composition reduces serum IgG in the patient by at least 90% of baseline. In some embodiments, administration of the pharmaceutical composition reduces serum IgG in the patient by at least 80% of baseline. In some embodiments, administration of the pharmaceutical composition reduces serum IgG in the patient by at least 70% of baseline. In some embodiments, the isotype of the reduced immunoglobulin is IgG1, IgG2, IgG3, IgG4, or any combination thereof. In some embodiments, administration of the pharmaceutical composition reduces serum IgG1 by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of baseline serum IgG1. In some embodiments, administration of the pharmaceutical composition reduces serum IgG1 in patients by at least 90% from baseline. In some embodiments, administration of the pharmaceutical composition reduces serum IgG1 in patients by at least 80% from baseline. In some embodiments, administration of the pharmaceutical composition reduces serum IgG1 in patients by at least 70% from baseline.In some embodiments, administration of the pharmaceutical composition reduces serum IgG2 by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of baseline serum IgG2. In some embodiments, administration of the pharmaceutical composition reduces serum IgG2 in the patient by at least 90% of baseline. In some embodiments, administration of the pharmaceutical composition reduces serum IgG2 in the patient by at least 80% of baseline. In some embodiments, administration of the pharmaceutical composition reduces serum IgG2 in the patient by at least 70% of baseline. In some embodiments, administration of the pharmaceutical composition reduces serum IgG3 by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of baseline serum IgG3. In some embodiments, administration of the pharmaceutical composition reduces serum IgG3 in the patient by at least 90% of baseline. In some embodiments, administration of the pharmaceutical composition reduces serum IgG3 in a patient by at least 80% from baseline. In some embodiments, administration of the pharmaceutical composition reduces serum IgG3 in a patient by at least 70% from baseline. In some embodiments, administration of the pharmaceutical composition reduces serum IgG4 by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% from baseline serum IgG4. In some embodiments, administration of the pharmaceutical composition reduces serum IgG4 in a patient by at least 90% from baseline. In some embodiments, administration of the pharmaceutical composition reduces serum IgG4 in a patient by at least 80% from baseline. In some embodiments, administration of the pharmaceutical composition reduces serum IgG4 in a patient by at least 70% from baseline.

[0215] In some embodiments, administration of the pharmaceutical composition reduces serum albumin by up to 18%, up to 16%, up to 14%, up to 12%, up to 10%, up to 8%, at least 6%, up to 4%, or up to 2% of baseline serum albumin. In some embodiments, administration of the pharmaceutical composition reduces serum albumin by up to 18% of baseline serum albumin. In some embodiments, administration of the pharmaceutical composition reduces serum albumin by up to 16% of baseline serum albumin. In some embodiments, administration of the pharmaceutical composition reduces serum albumin by up to 14% of baseline serum albumin. In some embodiments, administration of the pharmaceutical composition reduces serum albumin by up to 12% of baseline serum albumin. In some embodiments, administration of the pharmaceutical composition reduces serum albumin by up to 10% of baseline serum albumin. In some embodiments, administration of the pharmaceutical composition reduces serum albumin by up to 8% of baseline serum albumin. In some embodiments, administration of the pharmaceutical composition reduces serum albumin by up to 6% from baseline. In some embodiments, administration of the pharmaceutical composition reduces serum albumin by up to 4% from baseline. In some embodiments, administration of the pharmaceutical composition reduces serum albumin by up to 2% from baseline.

[0216] In some embodiments, administration of a pharmaceutical composition to a patient results in a reduction of autoantibodies in the patient. In some embodiments, the autoantibodies are selected from the group consisting of anti-acetylcholine receptor (AChR), anti-muscle-specific kinase (MuSK), anti-low-density lipoprotein receptor-related protein 4 (LRP4), anti-agrin, anti-titin, anti-Kv1.4, anti-ryanodine receptor, anti-collagen Q, and anti-cortactin. In some embodiments, the reduction is approximately 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1-20%, 5-20%, 5-25%, 10-30%, 15-35%, 20-40%, 40-60%, or approximately or at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, or 95%. In some embodiments, the autoantibody is an anti-AChR or anti-MuSK antibody. In some embodiments, administration of the pharmaceutical composition reduces the anti-AChR antibody by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 50%, or at least 25% of the baseline anti-AChR antibody. In some embodiments, administration of the pharmaceutical composition reduces anti-AChR antibody by at least 95% compared to baseline anti-AChR antibody. In some embodiments, administration of the pharmaceutical composition reduces anti-AChR antibody by at least 90% compared to baseline anti-AChR antibody. In some embodiments, administration of the pharmaceutical composition reduces anti-AChR antibody by at least 85% compared to baseline anti-AChR antibody. In some embodiments, administration of the pharmaceutical composition reduces anti-AChR antibody by at least 80% compared to baseline anti-AChR antibody. In some embodiments, administration of the pharmaceutical composition reduces anti-AChR antibody by at least 75% compared to baseline anti-AChR antibody. In some embodiments, administration of the pharmaceutical composition reduces anti-AChR antibody by at least 50% compared to baseline anti-AChR antibody. In some embodiments, administration of the pharmaceutical composition reduces anti-AChR antibody by at least 25% compared to baseline anti-AChR antibody.In some embodiments, administration of the pharmaceutical composition reduces anti-MuSK antibody by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 50%, or at least 25% of baseline anti-MuSK antibody. In some embodiments, administration of the pharmaceutical composition reduces anti-MuSK antibody by at least 95% of baseline anti-MuSK antibody. In some embodiments, administration of the pharmaceutical composition reduces anti-MuSK antibody by at least 90% of baseline anti-MuSK antibody. In some embodiments, administration of the pharmaceutical composition reduces anti-MuSK antibody by at least 85% of baseline anti-MuSK antibody. In some embodiments, administration of the pharmaceutical composition reduces anti-MuSK antibody by at least 80% of baseline anti-MuSK antibody. In some embodiments, administration of the pharmaceutical composition reduces anti-MuSK antibody by at least 75% of baseline anti-MuSK antibody. In some embodiments, administration of the pharmaceutical composition reduces anti-MuSK antibody by at least 50% of baseline anti-MuSK antibody. In some embodiments, administration of the pharmaceutical composition reduces anti-MuSK antibody by at least 25% of baseline anti-MuSK antibody. In some embodiments, administration of the pharmaceutical composition reduces anti-AChR antibody by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 50%, or at least 25% of baseline anti-AChR antibody, and reduces anti-MuSK antibody by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 50%, or at least 25% of baseline anti-MuSK antibody.

[0217] In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in the patient showing a change from baseline in the MG-ADL score. In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in a change from baseline in the MG-ADL score of 2 points or more on the MG-ADL scale. In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in the patient showing a change from baseline in the MG-ADL score. In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in a change from baseline in the MG-ADL score of 2 points or more on the MG-ADL scale. In some embodiments, administration of a pharmaceutical composition to a patient results in improvement in the patient as measured by the ACR score over time or 22, 23, and 24 weeks after administration of a first dose of the pharmaceutical composition to the patient.

[0218] In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in the patient showing a change from baseline in their QMG score after 57 days of treatment. In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in the patient showing a change from baseline in their QMG score over time after the last dose. In some embodiments, the change from baseline is a reduction of at least 2, 3, 4, 5, 6, 7, or 8 points or more in the patient's QMG score over time after the last dose of the pharmaceutical composition. In some embodiments, the change from baseline is a reduction of at least 2 points in the patient's QMG score over time after the last dose of the pharmaceutical composition. In some embodiments, the change from baseline is a reduction of at least 3 points in the patient's QMG score over time after the last dose of the pharmaceutical composition. In some embodiments, the change from baseline is a reduction of at least 4 points in the patient's QMG score over time after the last dose of the pharmaceutical composition. In some embodiments, the change from baseline is a reduction of at least 5 points in the patient's QMG score over time after the last dose of the pharmaceutical composition. In some embodiments, the change from baseline is a reduction of at least 6 points in the patient's QMG score over time after the last dose of the pharmaceutical composition. In some embodiments, the change from baseline is a reduction of at least 7 points in the patient's QMG score over time after the last dose of the pharmaceutical composition. In some embodiments, the change from baseline is a reduction of 8 points or more in the patient's QMG score over time after the last dose of the pharmaceutical composition. In some embodiments, administration of the pharmaceutical composition to a patient for the treatment of myasthenia gravis results in the patient showing a change from baseline in their QMG score over time after 22, 23, and 24 weeks of treatment, or after the last dose. In some embodiments, administration of the pharmaceutical composition to a patient for the treatment of myasthenia gravis results in the patient showing a change from baseline in their QMG score over time after the last dose.In some embodiments, the change from baseline is a reduction of at least 2, 3, 4, 5, 6, 7, or 8 points in the patient's QMG score over time, 22, 23, and 24 weeks after treatment, or after the last dose of the pharmaceutical composition. In some embodiments, the change from baseline is a reduction of at least 2 points in the patient's QMG score over time, 22, 23, and 24 weeks after treatment, or after the last dose of the pharmaceutical composition. In some embodiments, the change from baseline is a reduction of at least 3 points in the patient's QMG score over time, 22, 23, and 24 weeks after treatment, or after the last dose of the pharmaceutical composition. In some embodiments, the change from baseline is a reduction of at least 4 points in the patient's QMG score over time, 22, 23, and 24 weeks after treatment, or after the last dose of the pharmaceutical composition. In some embodiments, the change from baseline is a reduction of at least 5 points in the patient's QMG score over time, 22, 23, and 24 weeks after treatment, or after the last dose of the pharmaceutical composition. In some embodiments, the change from baseline is a reduction of at least 6 points in the patient's QMG score over time, 22, 23, and 24 weeks after treatment, or after the last dose of the pharmaceutical composition is administered. In some embodiments, the change from baseline is a reduction of at least 7 points in the patient's QMG score over time, 22, 23, and 24 weeks after treatment, or after the last dose of the pharmaceutical composition is administered. In some embodiments, the change from baseline is a reduction of 8 points or more in the patient's QMG score over time, 22, 23, and 24 weeks after treatment, or after the last dose of the pharmaceutical composition is administered.

[0219] In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in the patient showing a change from baseline in the MG-QoL15 score after 57 days of treatment. In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in the patient showing a change from baseline in the MG-QoL15 score over time after the last dose. In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in the patient showing a change from baseline in the MG-QoL15 score over time after 22, 23, and 24 weeks of treatment, or after the last dose. In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in the patient showing a change from baseline in the MG-QoL15 score over time after the last dose. In some embodiments, the patient achieves a change from baseline on the MG-QoL-15r scale, which is a reduction of at least 3, 4, 5, or 6 points in the MG-QoL-15r score. In some embodiments, the patient achieves a change from baseline on the MG-QoL-15r scale, which is a reduction of at least 3 points on the MG-QoL-15r score. In some embodiments, the patient achieves a change from baseline on the MG-QoL-15r scale, which is a reduction of at least 6 points on the MG-QoL-15r score.

[0220] In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in the patient showing a shift in MGFA classification after 57 days of treatment and over time. In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in the patient showing a shift in MGFA classification over time after administration of the last dose of the pharmaceutical composition. In some embodiments, the shift is about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1-20%, 5-20%, 5-25%, 10-30%, 15-35%, 20-40%, 40-60%, or about or at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, or 80%. In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in the patient exhibiting a shift in MGFA classification over time, 22, 23, and 24 weeks after treatment, or after the last dose. In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in the patient exhibiting a shift in MGFA classification over time, after the last dose of the pharmaceutical composition. In some embodiments, the shift is approximately 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1-20%, 5-20%, 5-25%, 10-30%, 15-35%, 20-40%, 40-60%, or approximately or at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, or 80%.

[0221] In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in a change from baseline on the Neuro-QoL-Fatigue Scale after 22, 23, and 24 weeks of treatment. In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in a change from baseline on the Neuro-QoL-Fatigue Scale over time after the last dose administration. In some embodiments, the change from baseline on Neuro-QoL-Fatigue indicates improvement.

[0222] In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in a change from baseline on the EQ-5D-5L scale. In some embodiments, the change from baseline on the EQ-5D-5L scale indicates improvement. In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in a change from baseline on the EQ-5D-5L scale over time, after 22, 23, and 24 weeks of treatment, or after the last dose is administered.

[0223] In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in a change from baseline on the PGI-C scale. In some embodiments, the change from baseline on the PGI-C scale indicates improvement. In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in a change from baseline on the PGI-C scale over time, after 22, 23, and 24 weeks of treatment, or after the last dose is administered.

[0224] In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in a change from baseline on the PGI-S scale. In some embodiments, the change from baseline on the PGI-S scale indicates improvement. In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in a change from baseline on the PGI-S scale over time, after 22, 23, and 24 weeks of treatment, or after the last dose is administered.

[0225] In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in a change from baseline on the C-SSRS scale. In some embodiments, the change from baseline on the C-SSRS scale indicates improvement. In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in a change from baseline on the C-SSRS scale over time, after 22, 23, and 24 weeks of treatment, or after the last dose is administered.

[0226] In some embodiments, administration of a pharmaceutical composition to a patient for the treatment of myasthenia gravis results in a change from baseline on the PedsQL scale. In some embodiments, the change from baseline on the PedsQL scale indicates improvement. In some embodiments, administration of a pharmaceutical composition to a pediatric patient for the treatment of myasthenia gravis results in a change from baseline on the PedsQL scale over time, after 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 24 weeks of treatment, or after the last dose administration. In some embodiments, the variation is approximately 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1-20%, 5-20%, 5-25%, 10-30%, 15-35%, 20-40%, 40-60%, or approximately or at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, or 95%.

[0227] In some embodiments, subjects treated with anti-FcRn antibodies for myasthenia gravis do not experience a significant increase in total cholesterol, high-density lipoprotein (HDL), calculated low-density lipoprotein (LDL), and triglyceride levels after treatment with the antibody. In some embodiments, the antibody is an anti-FcRn antibody. In some embodiments, the anti-FcRn antibody is as provided herein. In some embodiments, subjects treated with anti-FcRn antibodies for myasthenia gravis do not experience a significant increase in total cholesterol levels after treatment with the antibody. In some embodiments, subjects treated with anti-FcRn antibodies for myasthenia gravis do not experience a significant increase in high-density lipoprotein (HDL) levels after treatment with the antibody. In some embodiments, subjects treated with anti-FcRn antibodies for myasthenia gravis do not experience a significant increase in calculated low-density lipoprotein (LDL) levels after treatment with the antibody. In some embodiments, subjects treated with anti-FcRn antibodies for myasthenia gravis do not experience a significant increase in triglyceride levels after treatment with the antibody. In some embodiments, subjects treated with anti-FcRn antibodies for myasthenia gravis do not experience a significant increase in total cholesterol levels after treatment with the anti-FcRn antibody. In some embodiments, subjects treated with anti-FcRn antibodies for myasthenia gravis do not experience a significant increase in high-density lipoprotein (HDL) levels after treatment with the anti-FcRn antibody. In some embodiments, subjects treated with anti-FcRn antibodies for myasthenia gravis do not experience a significant increase in calculated low-density lipoprotein (LDL) levels after treatment with the anti-FcRn antibody. In some embodiments, subjects treated with anti-FcRn antibodies for myasthenia gravis do not experience a significant increase in triglyceride levels after treatment with the anti-FcRn antibody. In preferred embodiments, the anti-FcRn antibody is nipocalimab.

[0228] In some embodiments, administration of a pharmaceutical composition to a patient does not significantly increase the levels of total cholesterol, high-density lipoprotein (HDL), calculated low-density lipoprotein (LDL), and triglycerides after administration of a pharmaceutical composition containing an antibody. In some embodiments, the antibody is an anti-FcRn antibody. In some embodiments, the anti-FcRn antibody is as provided herein. In some embodiments, administration of a pharmaceutical composition to a patient does not significantly increase the levels of total cholesterol after administration of a pharmaceutical composition containing an antibody. In some embodiments, administration of a pharmaceutical composition to a patient does not significantly increase the levels of high-density lipoprotein (HDL) after administration of a pharmaceutical composition containing an antibody. In some embodiments, administration of a pharmaceutical composition to a patient does not significantly increase the levels of calculated low-density lipoprotein (LDL) after administration of a pharmaceutical composition containing an antibody. In some embodiments, administration of a pharmaceutical composition to a patient does not significantly increase the levels of triglycerides after administration of a pharmaceutical composition containing an antibody. In some embodiments, administration of the pharmaceutical composition to a patient does not significantly increase total cholesterol levels after administration of the pharmaceutical composition containing an anti-FcRn antibody. In some embodiments, administration of the pharmaceutical composition to a patient does not significantly increase high-density lipoprotein (HDL) levels after administration of the pharmaceutical composition containing an anti-FcRn antibody. In some embodiments, administration of the pharmaceutical composition to a patient does not significantly increase calculated low-density lipoprotein (LDL) levels after administration of the pharmaceutical composition containing an anti-FcRn antibody. In some embodiments, administration of the pharmaceutical composition to a patient does not significantly increase triglyceride levels after administration of the pharmaceutical composition containing an anti-FcRn antibody. In preferred embodiments, the anti-FcRn antibody is nipocalimab.

[0229] As used herein, the phrase “not significantly increased” means, when used with respect to levels (measured values) of total cholesterol, high-density lipoprotein (HDL), calculated low-density lipoprotein (LDL), or triglycerides, that any increase is no more than 30% compared to the baseline level of the antibody or composition provided herein. In some embodiments, the increase is no more than 25%, 20%, 15%, 10%, or 5%. In some embodiments, the increase is no more than about 1% to about 30%, about 5% to about 25%, about 1% to about 20%, about 1% to about 15%, about 1% to about 10%, about 5% to about 15%, about 5% to about 20%, about 10% to about 20%, about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, or about 30%.

[0230] Each and all patents, patent applications, and publications cited herein are incorporated herein by reference in their entirety. While various embodiments are disclosed with reference to specific aspects, it will be apparent that other aspects and modifications of these embodiments can be devised by those skilled in the art without departing from the true spirit and scope of the embodiments. The appended claims are intended to be construed to include all such aspects and equivalent modifications.

[0231] Other Embodiments While this disclosure is described in relation to its specific embodiments, further modifications are possible, and this application is intended to encompass any modifications, uses, or adaptations, including such deviations from this disclosure, in general principles, and it will be understood that these fall within known or customary practices in the art to which this disclosure relates and which may be applied to the essential features described herein.

[0232] In some embodiments, the embodiments provided herein also include, but are not limited to, the following: 1. A method for treating myasthenia gravis in patients requiring treatment for myasthenia gravis, comprising administering an initial loading dose of anti-FcRn antibody at approximately 30 mg / kg to approximately 60 mg / kg, followed by a maintenance dose of anti-FcRn antibody at approximately 15 mg / kg to approximately 30 mg / kg, wherein the anti-FcRn antibody is A heavy chain containing HCDR1 (SEQ ID NO: 6), HCDR2 (SEQ ID NO: 7), and HCDR3 (SEQ ID NO: 8), A light chain comprising LCDR1 of SEQ ID NO: 3, LCDR2 of SEQ ID NO: 4, and LCDR3 of SEQ ID NO: 5, A method of administration that reduces serum IgG in a patient by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of baseline serum IgG.

[0233] 2. The method according to Embodiment 1, wherein the heavy chain comprises an amino acid sequence having at least 90% identity with the sequence of SEQ ID NO: 2, and the light chain comprises an amino acid sequence having at least 90% identity with the sequence of SEQ ID NO: 1.

[0234] 3. The method according to Embodiment 1, wherein the heavy chain comprises an amino acid sequence having at least 95% identity with the sequence of SEQ ID NO: 2, and the light chain comprises an amino acid sequence having at least 95% identity with the sequence of SEQ ID NO: 1.

[0235] 4. The method according to Embodiment 1, wherein the heavy chain comprises an amino acid sequence having at least 99% identity with the sequence of SEQ ID NO: 2, and the light chain comprises an amino acid sequence having at least 99% identity with the sequence of SEQ ID NO: 1.

[0236] 5. The method according to Embodiment 1, wherein the heavy chain comprises a variable region heavy chain having an amino acid sequence having at least 90% identity with the sequence of SEQ ID NO: 10, and the light chain comprises a variable region light chain having an amino acid sequence having at least 90% identity with the sequence of SEQ ID NO: 9.

[0237] 6. The method according to Embodiment 1, wherein the heavy chain comprises a variable region heavy chain having an amino acid sequence having at least 95% identity with the sequence of SEQ ID NO: 10, and the light chain comprises a variable region light chain having an amino acid sequence having at least 95% identity with the sequence of SEQ ID NO: 9.

[0238] 7. The method according to Embodiment 1, wherein the heavy chain comprises a variable region heavy chain containing an amino acid sequence having at least 99% identity with the sequence of SEQ ID NO: 10, and the light chain comprises a variable region light chain containing an amino acid sequence having at least 99% identity with the sequence of SEQ ID NO: 9.

[0239] 8. The method according to Embodiment 1, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 2 and the light chain comprises the amino acid sequence of SEQ ID NO: 1.

[0240] 9. The method according to Embodiment 1, wherein the heavy chain comprises a variable region heavy chain containing the amino acid sequence of SEQ ID NO: 10, and the light chain comprises a variable region light chain containing the amino acid sequence of SEQ ID NO: 9.

[0241] 10. The method according to any one of Embodiments 1 to 9, wherein the patient is suffering from generalized myasthenia gravis.

[0242] 11. The method according to any one of Embodiments 1 to 10, wherein the patient is an adult patient or a pediatric patient.

[0243] 12. The method according to any one of Embodiments 1 to 11, wherein the administration is intravenous or subcutaneous.

[0244] 13. The method according to any one of Embodiments 1 to 12, wherein the administration comprises administering a pharmaceutical composition comprising approximately 10 mg / ml to approximately 60 mg / ml of anti-FcRn antibody, approximately 20 mM to approximately 30 mM of sodium phosphate, approximately 20 mM to approximately 30 mM of sodium chloride, approximately 80 mg / ml to approximately 100 mg / ml of trehalose, and approximately 0.1% w / v to approximately 0.005% w / v of polysorbate 80.

[0245] 14. The method according to any one of Embodiments 1 to 13, wherein the initial loading dose is approximately 60 mg / kg or approximately 30 mg / kg.

[0246] 15. The method according to any one of Embodiments 1 to 14, wherein the initial loading dose is approximately 60 mg / kg.

[0247] 16. The method according to any one of Embodiments 1 to 14, wherein the initial loading dose is approximately 30 mg / kg.

[0248] 17. The method according to any one of Embodiments 1 to 16, wherein the maintenance dose is approximately 15 mg / kg, approximately 30 mg / kg, approximately 45 mg / kg, or approximately 60 mg / kg.

[0249] 18. The method according to any one of Embodiments 1 to 17, wherein the maintenance dose is approximately 15 mg / kg.

[0250] 19. The method according to any one of Embodiments 1 to 17, wherein the maintenance dose is approximately 30 mg / kg.

[0251] 20. The maintenance dose is, One week, two weeks, three weeks, or four weeks after the initial loading dose, and The method according to any one of Embodiments 1 to 19, administered one week, two weeks, three weeks, four weeks after the administration of a preceding maintenance dose, or monthly thereafter.

[0252] 21. The method according to any one of Embodiments 1 to 20, wherein the maintenance dose is administered one week, two weeks, three weeks, or four weeks after the administration of the initial loading dose.

[0253] 22. The method according to any one of Embodiments 1 to 21, wherein the maintenance dose is administered one week, two weeks, three weeks, or four weeks after the administration of the preceding maintenance dose.

[0254] twenty three. The initial loading dose is administered to the subject over a period of approximately 30 to 90 minutes. The method according to any one of Embodiments 1 to 22, wherein the maintenance dose is injected into the subject over a period of approximately 15 to 60 minutes.

[0255] 24. The method according to any one of Embodiments 1 to 23, wherein the initial loading dose is injected into the subject over a period of approximately 30 to 90 minutes.

[0256] 25. The method according to any one of Embodiments 1 to 24, wherein the maintenance dose is injected into the subject over a period of approximately 15 to 60 minutes.

[0257] 26. The method according to any one of Embodiments 1 to 25, wherein serum IgG is IgG1, IgG2, IgG3, or IgG4, or any combination thereof, and the reduction is at least 80% of baseline, or at least 70% of baseline.

[0258] 27. The method according to any one of Embodiments 1 to 26, wherein administration of an anti-FcRn antibody reduces serum IgG in a patient by at least 20% from baseline.

[0259] 28. The method according to any one of Embodiments 1 to 26, wherein administration of an anti-FcRn antibody reduces serum IgG in the patient by at least 30% from baseline.

[0260] 29. The method according to any one of Embodiments 1 to 28, wherein administration of an anti-FcRn antibody reduces serum albumin by up to 18%, up to 16%, up to 14%, up to 12%, up to 10%, up to 8%, up to 6%, up to 4%, or up to 2% of baseline serum albumin.

[0261] 30. Administration reduces serum autoantibodies, The autoantibodies were selected from the group consisting of anti-acetylcholine receptor (AChR), anti-muscle-specific kinase (MuSK), anti-low-density lipoprotein receptor-related protein 4 (LRP4), anti-agrin, anti-titin, anti-Kv1.4, anti-ryanodine receptor, anti-collagen Q, and anti-cortactin. The method according to any one of embodiments 1 to 29, wherein the reduction is at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 50%, or at least 25% of the baseline serum autoantibody.

[0262] 31. The method according to embodiment 30, wherein administration of the anti - FcRn antibody reduces the anti - AChR antibody by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 50%, or at least 25% of the baseline anti - AChR antibody.

[0263] 32. The method according to embodiment 30 or 31, wherein administration of the anti - FcRn antibody reduces the anti - MuSK antibody by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 50%, or at least 25% of the baseline anti - MuSK antibody.

[0264] 33. The method according to any one of embodiments 1 to 32, wherein the patient achieves a change from baseline in the MG - ADL score, QMG score, MG - QoL - 15r score, MGFA score, or any combination thereof.

[0265] 34. The method according to any one of embodiments 1 to 33, wherein administration of the anti - FcRn antibody to the subject does not significantly increase the levels of total cholesterol, HDL, calculated LDL, and triglycerides in the subject as compared to the levels before administration of the anti - FcRn antibody.

[0266] 35. A method of treating myasthenia gravis in a patient who needs treatment for myasthenia gravis, comprising administering an initial loading dose of an anti - FcRn antibody of about 30 mg / kg to about 60 mg / kg, followed by administering a maintenance dose of an anti - FcRn antibody of about 15 mg / kg to about 30 mg / kg, wherein the anti - FcRn antibody comprises a heavy chain comprising HCDR1 of SEQ ID NO: 6, HCDR2 of SEQ ID NO: 7, and HCDR3 of SEQ ID NO: 8, and A light chain comprising LCDR1 of SEQ ID NO: 3, LCDR2 of SEQ ID NO: 4, and LCDR3 of SEQ ID NO: 5, A method in which administration reduces baseline serum autoantibodies by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 50%, or at least 25%.

[0267] 36. The method according to embodiment 35, wherein the heavy chain comprises an amino acid sequence having at least 90% identity to the sequence of SEQ ID NO: 2, and the light chain comprises an amino acid sequence having at least 90% identity to the sequence of SEQ ID NO: 1.

[0268] 37. The method according to embodiment 35, wherein the heavy chain comprises an amino acid sequence having at least 95% identity to the sequence of SEQ ID NO: 2, and the light chain comprises an amino acid sequence having at least 95% identity to the sequence of SEQ ID NO: 1.

[0269] 38. The method according to embodiment 35, wherein the heavy chain comprises an amino acid sequence having at least 99% identity to the sequence of SEQ ID NO: 2, and the light chain comprises an amino acid sequence having at least 99% identity to the sequence of SEQ ID NO: 1.

[0270] 39. The method according to embodiment 35, wherein the heavy chain comprises a variable region heavy chain comprising an amino acid sequence having at least 90% identity to the sequence of SEQ ID NO: 10, and the light chain comprises a variable region light chain comprising an amino acid sequence having at least 90% identity to the sequence of SEQ ID NO: 9.

[0271] 40. The method according to embodiment 35, wherein the heavy chain comprises a variable region heavy chain comprising an amino acid sequence having at least 95% identity to the sequence of SEQ ID NO: 10, and the light chain comprises a variable region light chain comprising an amino acid sequence having at least 95% identity to the sequence of SEQ ID NO: 9.

[0272] 41. The method according to Embodiment 35, wherein the heavy chain comprises a variable region heavy chain having an amino acid sequence having at least 99% identity with the sequence of SEQ ID NO: 10, and the light chain comprises a variable region light chain having an amino acid sequence having at least 99% identity with the sequence of SEQ ID NO: 9.

[0273] 42. The method according to Embodiment 35, wherein the variable region heavy chain comprises the amino acid sequence of SEQ ID NO: 10 and the variable region light chain comprises the amino acid sequence of SEQ ID NO: 9.

[0274] 43. The method according to Embodiment 35, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 2 and the light chain comprises the amino acid sequence of SEQ ID NO: 1.

[0275] 44. The method according to any one of embodiments 35 to 43, wherein the patient is suffering from generalized myasthenia gravis.

[0276] 45. The method according to any one of embodiments 35 to 44, wherein the patient is an adult patient or a pediatric patient.

[0277] 46. ​​The method according to any one of Embodiments 35 to 45, wherein the administration is intravenous or subcutaneous.

[0278] 47. The method according to any one of Embodiments 35 to 46, wherein the administration comprises administering a pharmaceutical composition comprising approximately 10 mg / ml to approximately 60 mg / ml of anti-FcRn antibody, approximately 20 mM to approximately 30 mM of sodium phosphate, approximately 20 mM to approximately 30 mM of sodium chloride, approximately 80 mg / ml to approximately 100 mg / ml of trehalose, and approximately 0.1% w / v to approximately 0.005% w / v of polysorbate 80.

[0279] 48. The method according to any one of embodiments 35 to 47, wherein the initial loading dose is approximately 60 mg / kg.

[0280] 49. The method according to any one of embodiments 35 to 47, wherein the initial loading dose is approximately 30 mg / kg.

[0281] 50. The method according to any one of embodiments 35 to 49, wherein the maintenance dose is about 15 mg / kg, about 30 mg / kg, about 45 mg / kg, or about 60 mg / kg.

[0282] 51. The method according to any one of embodiments 35 to 50, wherein the maintenance dose is about 15 mg / kg.

[0283] 52. The method according to any one of embodiments 35 to 50, wherein the maintenance dose is about 30 mg / kg.

[0284] 53. The method according to any one of embodiments 35 to 52, wherein the maintenance dose is administered 1 week, 2 weeks, 3 weeks, or 4 weeks after the administration of the initial loading dose.

[0285] 54. The method according to any one of embodiments 35 to 53, wherein the initial loading dose is infused into the subject over about 30 minutes to about 90 minutes.

[0286] 55. The method according to any one of embodiments 35 to 54, wherein the maintenance dose is infused into the subject over about 15 minutes to about 60 minutes.

[0287] 56. The method according to any one of embodiments 35 to 55, wherein the autoantibody is selected from the group consisting of anti-acetylcholine receptor (AChR), anti-muscle specific kinase (MuSK), anti-low density lipoprotein receptor-related protein 4 (LRP4), anti-agrin, anti-tyitin, anti-Kv1.4, anti-ryanodine receptor, anti-collagen Q, and anti-cortactin.

[0288] 57. The method according to any one of embodiments �5 to 56, wherein the autoantibody is an anti-AChR antibody or an anti-MuSK antibody.

[0289] 58. The method according to any one of embodiments 35 to 57, wherein the administration of the anti-FcRn antibody reduces the anti-AChR antibody by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 50%, or at least 25% of the baseline anti-AChR antibody.

[0290] 59. The method according to any one of Embodiments 35 to 57, wherein administration of an anti-FcRn antibody reduces the anti-MuSK antibody by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 50%, or at least 25% of the baseline anti-MuSK antibody.

[0291] 60. The method according to any one of embodiments 35 to 59, wherein the administration reduces serum IgG by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of baseline serum IgG.

[0292] 61. The method according to any one of embodiments 35 to 60, wherein the serum IgG is IgG1, IgG2, IgG3, or IgG4.

[0293] 62. The method according to any one of embodiments 35 to 61, wherein the administration reduces serum albumin by up to 18%, up to 16%, up to 14%, up to 12%, up to 10%, up to 8%, up to 6%, up to 4%, or up to 2% of baseline serum albumin.

[0294] 63. A method for treating myasthenia gravis in a subject or reducing its severity, comprising administering an initial loading dose of anti-FcRn antibody at approximately 30 mg / kg to approximately 60 mg / kg, followed by a maintenance dose of anti-FcRn antibody at approximately 15 mg / kg to approximately 30 mg / kg, wherein the anti-FcRn antibody is A heavy chain containing HCDR1 (SEQ ID NO: 6), HCDR2 (SEQ ID NO: 7), and HCDR3 (SEQ ID NO: 8), A method comprising a light chain containing LCDR1 of SEQ ID NO: 3, LCDR2 of SEQ ID NO: 4, and LCDR3 of SEQ ID NO: 5.

[0295] 64. The method according to Embodiment 63, wherein the heavy chain comprises an amino acid sequence having at least 90% identity with the sequence of SEQ ID NO: 2, and the light chain comprises an amino acid sequence having at least 90% identity with the sequence of SEQ ID NO: 1.

[0296] 65. The method according to Embodiment 63, wherein the heavy chain comprises an amino acid sequence having at least 95% identity with the sequence of SEQ ID NO: 2, and the light chain comprises an amino acid sequence having at least 95% identity with the sequence of SEQ ID NO: 1.

[0297] 66. The method according to Embodiment 63, wherein the heavy chain comprises an amino acid sequence having at least 99% identity with the sequence of SEQ ID NO: 2, and the light chain comprises an amino acid sequence having at least 99% identity with the sequence of SEQ ID NO: 1.

[0298] 67. The method according to Embodiment 63, wherein the heavy chain comprises a variable region heavy chain having an amino acid sequence having at least 90% identity with the sequence of SEQ ID NO: 10, and the light chain comprises a variable region light chain having an amino acid sequence having at least 90% identity with the sequence of SEQ ID NO: 9.

[0299] 68. The method according to Embodiment 63, wherein the heavy chain comprises a variable region heavy chain having an amino acid sequence having at least 95% identity with the sequence of SEQ ID NO: 10, and the light chain comprises a variable region light chain having an amino acid sequence having at least 95% identity with the sequence of SEQ ID NO: 9.

[0300] 69. The method according to Embodiment 63, wherein the heavy chain comprises a variable region heavy chain having an amino acid sequence having at least 99% identity with the sequence of SEQ ID NO: 10, and the light chain comprises a variable region light chain having an amino acid sequence having at least 99% identity with the sequence of SEQ ID NO: 9.

[0301] 70. The method according to Embodiment 63, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 2 and the light chain comprises the amino acid sequence of SEQ ID NO: 1.

[0302] 71. The method according to Embodiment 63, wherein the heavy chain comprises a variable region heavy chain containing the amino acid sequence of SEQ ID NO: 10, and the light chain comprises a variable region light chain containing the amino acid sequence of SEQ ID NO: 9.

[0303] 72. The method according to any one of embodiments 63 to 71, wherein the patient is suffering from generalized myasthenia gravis.

[0304] 73. The method according to any one of embodiments 63 to 72, wherein the patient is an adult patient or a pediatric patient.

[0305] 74. The method according to any one of embodiments 63 to 73, wherein the administration is intravenous or subcutaneous.

[0306] 75. The method according to any one of Embodiments 63 to 74, wherein the administration comprises administering a pharmaceutical composition comprising approximately 10 mg / ml to approximately 60 mg / ml of anti-FcRn antibody, approximately 20 mM to approximately 30 mM of sodium phosphate, approximately 20 mM to approximately 30 mM of sodium chloride, approximately 80 mg / ml to approximately 100 mg / ml of trehalose, and approximately 0.1% w / v to approximately 0.005% w / v of polysorbate 80.

[0307] 76. The method according to any one of embodiments 63 to 75, wherein the initial loading dose is approximately 60 mg / kg.

[0308] 77. The method according to any one of embodiments 63 to 75, wherein the initial loading dose is approximately 30 mg / kg.

[0309] 78. The method according to any one of Embodiments 63 to 77, wherein the maintenance dose is approximately 15 mg / kg, approximately 30 mg / kg, approximately 45 mg / kg, or approximately 60 mg / kg.

[0310] 79. The method according to any one of embodiments 63 to 78, wherein the maintenance dose is approximately 15 mg / kg.

[0311] 80. The method according to any one of embodiments 63 to 78, wherein the maintenance dose is approximately 30 mg / kg.

[0312] 81. The method according to any one of embodiments 63 to 80, wherein the maintenance dose is administered one week, two weeks, three weeks, or four weeks after the administration of the initial loading dose.

[0313] 82. The method according to any one of embodiments 63 to 81, wherein the initial loading dose is injected into the subject over a period of approximately 30 to 90 minutes.

[0314] 83. The method according to any one of embodiments 63 to 82, wherein the maintenance dose is injected into the subject over a period of approximately 15 to 60 minutes.

[0315] 84. The method according to any one of embodiments 63 to 83, wherein the subject exhibits a reduction in one or more serum immunoglobulin isotypes or total IgG.

[0316] 85. The method according to any one of embodiments 63 to 84, wherein the isotype is IgG1, IgG2, IgG3, or IgG4.

[0317] 86. The method according to any one of embodiments 63 to 85, wherein the reduction in serum IgG is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of baseline serum IgG.

[0318] 87. The method according to any one of embodiments 63 to 86, wherein the administration reduces serum albumin by up to 18%, up to 16%, up to 14%, up to 12%, up to 10%, up to 8%, up to 6%, up to 4%, or up to 2% of baseline serum albumin.

[0319] 88. The method according to any one of embodiments 63 to 87, wherein the subject has a reduction in autoantibodies.

[0320] 89. The method according to any one of embodiments 63 to 88, wherein the autoantibody is selected from the group consisting of anti-acetylcholine receptor (AChR), anti-muscle-specific kinase (MuSK), anti-low-density lipoprotein receptor-related protein 4 (LRP4), anti-agrin, anti-titin, anti-Kv1.4, anti-ryanodine receptor, anti-collagen Q, and anti-cortactin.

[0321] 90. The method according to any one of Embodiments 63 to 89, wherein the autoantibody is an anti-AChR antibody or an anti-MuSK antibody.

[0322] 91. The method according to any one of Embodiments 63 to 90, wherein administration of an anti-FcRn antibody reduces the anti-AChR antibody by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 50%, or at least 25% of the baseline anti-AChR antibody.

[0323] 92. The method according to any one of Embodiments 63 to 90, wherein administration of an anti-FcRn antibody reduces the anti-MuSK antibody by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 50%, or at least 25% of the baseline anti-MuSK antibody.

[0324] 93. The method according to any one of embodiments 63 to 92, wherein the treatment of myasthenia gravis treats or improves ocular myasthenia, ptosis, difficulty chewing, dysphagia, dysarthria, dysphonia, difficulty breathing, inability to keep the mouth closed, onset of sadness or drowsiness, difficulty keeping the head upright, double eyelids, dysarthria, dysphagia, facial changes, shortness of breath, weakness of the arms, weakness of the hands, weakness of the fingers, weakness of the legs, and weakness of the neck.

[0325] 93. The method according to any one of Embodiments 63 to 92, wherein the patient achieves a change from baseline in the MG-ADL, QMG, or MG-QoL15 scale, Neuro-QoL-Fatigue Score, EQ-5D-5L Score, MGFA Score, PGI-C Score, PGI-S Score, C-SSRS Score, and PedsQL Score.

[0326] 94. The method according to any one of embodiments 63 to 93, wherein a patient achieves a change from baseline on the MG-ADL scale.

[0327] 95. The method according to any one of embodiments 63 to 94, wherein the patient achieves a change from baseline in the MG-ADL scale of 2.0 points or more on the MG-ADL scale.

[0328] 96. The method according to any one of embodiments 63 to 95, wherein the patient achieves a change from baseline in the MG-ADL scale of 3.0 points or more on the MG-ADL scale.

[0329] 97. The method according to any one of embodiments 63 to 96, wherein the change from baseline in the MG-ADL scale lasts for at least 4 weeks.

[0330] 98. The method according to any one of embodiments 63 to 97, wherein a patient achieves a change from baseline on the QMG scale.

[0331] 99. The method according to any one of embodiments 63 to 98, wherein the patient achieves a change from baseline on the QMG scale, which is a reduction of at least 2, 3, 4, 5, 6, 7, or 8 points or more on the QMG score.

[0332] 100. The method according to any one of embodiments 63 to 99, wherein the patient achieves a change from baseline on the QMG scale, which is a reduction of at least 3 points on the QMG score.

[0333] 101. The method according to any one of embodiments 63 to 99, wherein the patient achieves a change from baseline on the QMG scale, which is a reduction of at least 4 points on the QMG score.

[0334] 102. The method according to any one of Embodiments 63 to 99, wherein the patient achieves a change from baseline on the QMG scale, which is a reduction of at least 5 points on the QMG score.

[0335] 103. The method according to any one of embodiments 63 to 102, wherein the patient achieves a change from baseline on the MG-QoL-15r scale.

[0336] 104. The method according to any one of embodiments 63 to 103, wherein the patient achieves a change from baseline on the MG-QoL-15r scale, which is a reduction of at least 3, 4, 5, or 6 points on the MG-QoL-15r score.

[0337] 105. The method according to any one of embodiments 63 to 104, wherein the patient achieves a change from baseline on the MG-QoL-15r scale, which is a reduction of at least 3 points on the MG-QoL-15r score.

[0338] 106. The method according to any one of embodiments 63 to 104, wherein the patient achieves a change from baseline on the MG-QoL-15r scale, which is a reduction of at least 6 points on the MG-QoL-15r score.

[0339] 107. The method according to any one of embodiments 63 to 106, wherein a patient achieves a change from baseline in the MGFA classification.

[0340] 108. The method according to any one of embodiments 63 to 107, wherein the change from baseline in the MGFA classification indicates improvement.

[0341] 109. The method according to any one of embodiments 63 to 108, wherein the patient achieves a change from baseline on the Neuro-QoL-Fatigue Scale 22, 23, and 24 weeks after treatment.

[0342] 110. The method according to any one of embodiments 63 to 109, wherein the change from baseline on the Neuro-QoL-Fatigue Scale indicates improvement.

[0343] 111. The method according to any one of embodiments 63 to 110, wherein the patient achieves a change from baseline on the EQ-5D-5L scale 22, 23, and 24 weeks after treatment.

[0344] 112. The method according to any one of embodiments 63 to 111, wherein the change from baseline on the EQ-5D-5L scale indicates improvement.

[0345] 113. The method according to any one of embodiments 63 to 112, wherein the patient achieves a change from baseline on the PGI-C scale 22, 23, and 24 weeks after treatment.

[0346] 114. The method according to any one of embodiments 63 to 113, wherein the change from baseline on the PGI-C scale indicates improvement.

[0347] 115. The method according to any one of embodiments 63 to 114, wherein the patient achieves a change from baseline on the PGI-S scale 22, 23, and 24 weeks after treatment.

[0348] 116. The method according to any one of embodiments 63 to 115, wherein the change from baseline on the PGI-S scale indicates improvement.

[0349] 117. The method according to any one of embodiments 63 to 116, wherein the patient achieves a change from baseline in C-SSRS 22, 23, and 24 weeks after treatment.

[0350] 118. The method according to any one of embodiments 63 to 117, wherein the change from baseline on the C-SSRS scale indicates improvement.

[0351] 119. The method according to any one of embodiments 63 to 118, wherein a pediatric patient achieves a change from baseline on the PedsQL scale after treatment.

[0352] 120. The method according to any one of embodiments 63 to 119, wherein the change from baseline in the PedsQL scale indicates improvement.

[0353] 121. The method according to any one of Embodiments 63 to 120, wherein administration of an anti-FcRn antibody to a subject does not significantly increase the levels of total cholesterol, HDL, calculated LDL, and triglycerides in the subject compared to the levels before administration of the anti-FcRn antibody.

[0354] 122. The method according to Embodiment 121, wherein the administration does not significantly increase the level of total cholesterol.

[0355] 123. The method according to Embodiment 121, wherein the administration does not significantly increase the level of total HDL.

[0356] 124. The method according to Embodiment 121, wherein the administration does not significantly increase the calculated LDL level.

[0357] 125. The method according to Embodiment 121, wherein the administration does not significantly increase triglyceride levels.

[0358] 126. The method according to any one of embodiments 121 to 125, further comprising administering an additional therapeutic agent to a target.

[0359] 127. The method according to any one of Embodiments 63 to 126, wherein the additional therapeutic agent is an acetylcholinesterase inhibitor, pyridostigmine, pyridostigmine bromide (Mestinon), neostigmine, prednisone, azathioprine (Imuran), mycophenylate mofetil (CellCept), tacrolimus (Prograf), methotrexate, cyclosporine (Sandimmune, Neoral), and cyclophosphamide (Cytoxan, Neosar), rituximab (Rituxan), eculizumab (Soliris), IVIg, or any combination thereof.

[0360] 128. The method according to any one of embodiments 63 to 127, wherein an additional therapeutic agent is administered simultaneously with or consecutively (before or after) the anti-FcRn antibody.

[0361] 129. A pharmaceutical composition comprising an anti-FcRn antibody for administration to a patient suffering from myasthenia gravis, Anti-FcRn antibodies are administered intravenously or subcutaneously to patients at an initial loading dose of approximately 30 mg / kg to approximately 60 mg / kg, followed by a maintenance dose of approximately 15 mg / kg to approximately 30 mg / kg of anti-FcRn antibodies. Anti-FcRn antibody, A heavy chain containing HCDR1 (SEQ ID NO: 6), HCDR2 (SEQ ID NO: 7), and HCDR3 (SEQ ID NO: 8), A pharmaceutical composition comprising a light chain including LCDR1 of SEQ ID NO: 3, LCDR2 of SEQ ID NO: 4, and LCDR3 of SEQ ID NO: 5.

[0362] 130. The pharmaceutical composition according to Embodiment 129, wherein the heavy chain comprises an amino acid sequence having at least 90% identity with the sequence of Sequence ID No. 2, and the light chain comprises an amino acid sequence having at least 90% identity with the sequence of Sequence ID No. 1.

[0363] 131. The pharmaceutical composition according to Embodiment 129, wherein the heavy chain comprises an amino acid sequence having at least 95% identity with the sequence of SEQ ID NO: 2, and the light chain comprises an amino acid sequence having at least 95% identity with the sequence of SEQ ID NO: 1.

[0364] 132. The pharmaceutical composition according to Embodiment 129, wherein the heavy chain comprises an amino acid sequence having at least 99% identity with the sequence of Sequence ID No. 2, and the light chain comprises an amino acid sequence having at least 99% identity with the sequence of Sequence ID No. 1.

[0365] 133. The pharmaceutical composition according to Embodiment 129, wherein the heavy chain comprises a variable region heavy chain having an amino acid sequence having at least 90% identity with the sequence of Sequence ID No. 10, and the light chain comprises a variable region light chain having an amino acid sequence having at least 90% identity with the sequence of Sequence ID No. 9.

[0366] 134. The pharmaceutical composition according to Embodiment 129, wherein the heavy chain comprises a variable region heavy chain having an amino acid sequence having at least 95% identity with the sequence of Sequence ID No. 10, and the light chain comprises a variable region light chain having an amino acid sequence having at least 95% identity with the sequence of Sequence ID No. 9.

[0367] 135. The pharmaceutical composition according to Embodiment 129, wherein the heavy chain comprises a variable region heavy chain having an amino acid sequence having at least 99% identity with the sequence of Sequence ID No. 10, and the light chain comprises a variable region light chain having an amino acid sequence having at least 99% identity with the sequence of Sequence ID No. 9.

[0368] 136. The pharmaceutical composition according to Embodiment 129, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 2 and the light chain comprises the amino acid sequence of SEQ ID NO: 1.

[0369] 137. The pharmaceutical composition according to Embodiment 129, wherein the heavy chain comprises a variable region heavy chain containing the amino acid sequence of SEQ ID NO: 10, and the light chain comprises a variable region light chain containing the amino acid sequence of SEQ ID NO: 9.

[0370] 138. A pharmaceutical composition according to any one of embodiments 129 to 137, wherein the patient is suffering from generalized myasthenia gravis.

[0371] 139. The pharmaceutical composition according to any one of Embodiments 129 to 138, wherein the patient is an adult patient or a pediatric patient.

[0372] 140. A pharmaceutical composition according to any one of Embodiments 129 to 139, wherein the administration is intravenous or subcutaneous.

[0373] 141. The pharmaceutical composition according to any one of Embodiments 129 to 140, wherein administration comprises administering a pharmaceutical composition comprising approximately 10 mg / ml to approximately 60 mg / ml of anti-FcRn antibody, approximately 20 mM to approximately 30 mM of sodium phosphate, approximately 20 mM to approximately 30 mM of sodium chloride, approximately 80 mg / ml to approximately 100 mg / ml of trehalose, and approximately 0.1% w / v to approximately 0.005% w / v of polysorbate 80.

[0374] 142. A pharmaceutical composition according to any one of Embodiments 129 to 141, wherein the initial loading dose is approximately 60 mg / kg.

[0375] 143. A pharmaceutical composition according to any one of Embodiments 129 to 142, wherein the initial loading dose is approximately 30 mg / kg.

[0376] 144. A pharmaceutical composition according to any one of Embodiments 129 to 143, wherein the maintenance dose is approximately 15 mg / kg, approximately 30 mg / kg, approximately 45 mg / kg, or approximately 60 mg / kg.

[0377] 145. A pharmaceutical composition according to any one of Embodiments 129 to 144, wherein the maintenance dose is approximately 15 mg / kg.

[0378] 146. A pharmaceutical composition according to any one of Embodiments 129 to 144, wherein the maintenance dose is approximately 30 mg / kg.

[0379] 147. The pharmaceutical composition according to any one of Embodiments 129 to 146, wherein the maintenance dose is administered one week, two weeks, three weeks, or four weeks after the administration of the initial loading dose.

[0380] 148. A pharmaceutical composition according to any one of embodiments 129 to 147, wherein the initial loading dose is injected into the subject over a period of approximately 30 to 90 minutes.

[0381] 149. A pharmaceutical composition according to any one of embodiments 129 to 148, wherein a maintenance dose is injected into the subject over a period of approximately 15 to 60 minutes.

[0382] 150. A pharmaceutical composition according to any one of Embodiments 129 to 149, wherein administration of the pharmaceutical composition achieves a reduction in one or more serum immunoglobulin isotypes or total IgG.

[0383] 151. A pharmaceutical composition according to any one of Embodiments 129 to 150, wherein the isotype is IgG1, IgG2, IgG3, or IgG4.

[0384] 152. A pharmaceutical composition according to any one of Embodiments 129 to 151, wherein the reduction in serum IgG is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of baseline.

[0385] 153. A pharmaceutical composition according to any one of embodiments 129 to 152, wherein administration of the pharmaceutical composition achieves a reduction of up to 18%, up to 16%, up to 14%, up to 12%, up to 10%, up to 8%, up to 6%, up to 4%, or up to 2% of baseline serum albumin.

[0386] 154. A pharmaceutical composition according to any one of embodiments 129 to 153, wherein administration of the pharmaceutical composition achieves a reduction in autoantibodies.

[0387] 155. A pharmaceutical composition according to any one of Embodiments 129 to 154, wherein the autoantibody is selected from the group consisting of anti-acetylcholine receptor (AChR), anti-muscle-specific kinase (MuSK), anti-low-density lipoprotein receptor-related protein 4 (LRP4), anti-agrin, anti-titin, anti-Kv1.4, anti-ryanodine receptor, anti-collagen Q, and anti-cortactin.

[0388] 156. The pharmaceutical composition according to any one of Embodiments 129 to 155, wherein the autoantibody is an anti-AChR antibody or an anti-MuSK antibody.

[0389] 157. A pharmaceutical composition according to any one of Embodiments 129 to 156, wherein administration of the pharmaceutical composition achieves a reduction of at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 50%, or at least 25% of the baseline level of anti-AChR antibodies.

[0390] 158. A pharmaceutical composition according to any one of Embodiments 129 to 156, wherein administration of the pharmaceutical composition achieves a reduction of at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 50%, or at least 25% of the baseline level of anti-MuSK antibodies.

[0391] 159. A pharmaceutical composition according to any one of Embodiments 129 to 158, wherein administration of the pharmaceutical composition achieves a change from baseline in the MG-ADL, QMG, or MG-QoL15 scale, Neuro-QoL-Fatigue Score, EQ-5D-5L Score, MGFA Score, PGI-C Score, PGI-S Score, C-SSRS Score, and PedsQL Score.

[0392] 160. A pharmaceutical composition according to any one of Embodiments 129 to 159, wherein administration of the pharmaceutical composition achieves a change from baseline on the MG-ADL scale.

[0393] 161. A pharmaceutical composition according to any one of Embodiments 129 to 160, wherein administration of the pharmaceutical composition achieves a change from baseline in the MG-ADL scale of 2.0 points or more on the MG-ADL scale.

[0394] 162. A pharmaceutical composition according to any one of Embodiments 129 to 160, wherein administration of the pharmaceutical composition achieves a change from baseline in the MG-ADL scale of 3.0 points or more on the MG-ADL scale.

[0395] 163. A pharmaceutical composition according to any one of Embodiments 129 to 162, wherein the change from baseline in the MG-ADL scale is sustained for at least four weeks.

[0396] 164. A pharmaceutical composition according to any one of embodiments 129 to 163, wherein administration of the pharmaceutical composition achieves a change from baseline on the QMG scale.

[0397] 165. A pharmaceutical composition according to any one of Embodiments 129 to 164, wherein administration of the pharmaceutical composition achieves a change from baseline on the QMG scale, which is a reduction of at least 2, 3, 4, 5, 6, 7, or 8 points or more on the QMG score.

[0398] 166. A pharmaceutical composition according to any one of embodiments 129 to 165, wherein administration of the pharmaceutical composition achieves a change from baseline on the QMG scale, which is a reduction of at least 3 points on the QMG score.

[0399] 167. A pharmaceutical composition according to any one of embodiments 129 to 165, wherein administration of the pharmaceutical composition achieves a change from baseline on the QMG scale, which is a reduction of at least 4 points on the QMG score.

[0400] 168. A pharmaceutical composition according to any one of Embodiments 129 to 165, wherein administration of the pharmaceutical composition achieves a change from baseline on the QMG scale, which is a reduction of at least 5 points on the QMG score.

[0401] 169. A pharmaceutical composition according to any one of Embodiments 129 to 168, wherein administration of the pharmaceutical composition achieves a change from baseline on the MG-QoL15 scale.

[0402] 170. A pharmaceutical composition according to any one of Embodiments 129 to 169, wherein administration of the pharmaceutical composition achieves a change from baseline on the MG-QoL-15r scale, which is a reduction of at least 3, 4, 5, or 6 points on the MG-QoL-15r score.

[0403] 171. A pharmaceutical composition according to any one of Embodiments 129 to 170, wherein administration of the pharmaceutical composition achieves a change from baseline on the MG-QoL-15r scale, which is a reduction of at least 3 points on the MG-QoL-15r score.

[0404] 172. A pharmaceutical composition according to any one of Embodiments 129 to 170, wherein administration of the pharmaceutical composition achieves a change from baseline on the MG-QoL-15r scale, which is a reduction of at least 6 points on the MG-QoL-15r score.

[0405] 173. A pharmaceutical composition according to any one of embodiments 129 to 172, wherein administration of the pharmaceutical composition achieves a change from baseline in the MGFA classification.

[0406] 174. A pharmaceutical composition according to any one of embodiments 129 to 173, wherein the change from baseline in the MGFA classification indicates improvement.

[0407] 175. A pharmaceutical composition according to any one of embodiments 129 to 174, wherein administration of the pharmaceutical composition achieves a change from baseline on the Neuro-QoL-Fatigue Scale 22, 23, and 24 weeks after treatment.

[0408] 176. A pharmaceutical composition according to any one of embodiments 129 to 175, wherein the change from baseline on the Neuro-QoL-Fatigue Scale indicates improvement.

[0409] 177. A pharmaceutical composition according to any one of embodiments 129 to 176, wherein administration of the pharmaceutical composition achieves a change from baseline on the EQ-5D-5L scale 22, 23, and 24 weeks after treatment.

[0410] 178. A pharmaceutical composition according to any one of embodiments 129 to 177, wherein the change from baseline on the EQ-5D-5L scale indicates improvement.

[0411] 179. A pharmaceutical composition according to any one of embodiments 129 to 178, wherein administration of the pharmaceutical composition achieves a change from baseline on the PGI-C scale 22, 23, and 24 weeks after treatment.

[0412] 180. A pharmaceutical composition according to any one of Embodiments 129 to 179, wherein the change from baseline on the PGI-C scale indicates improvement.

[0413] 181. A pharmaceutical composition according to any one of embodiments 129 to 180, wherein administration of the pharmaceutical composition achieves a change from baseline on the PGI-S scale 22, 23, and 24 weeks after treatment.

[0414] 182. A pharmaceutical composition according to any one of Embodiments 129 to 181, wherein the change from baseline on the PGI-S scale indicates improvement.

[0415] 183. A pharmaceutical composition according to any one of embodiments 129 to 182, wherein administration of the pharmaceutical composition achieves a change from baseline in C-SSRS after 22, 23, and 24 weeks of treatment.

[0416] 184. A pharmaceutical composition according to any one of embodiments 129 to 183, wherein the change from baseline on the C-SSRS scale indicates improvement.

[0417] 185. A pharmaceutical composition according to any one of Embodiments 129 to 184, wherein administration of the pharmaceutical composition achieves a change from baseline on the PedsQL scale.

[0418] 186. A pharmaceutical composition according to any one of Embodiments 129 to 185, wherein the change from baseline on the PedsQL scale indicates improvement.

[0419] 187. A pharmaceutical composition according to any one of Embodiments 129 to 186, wherein administration of the pharmaceutical composition to a subject does not significantly increase the levels of total cholesterol, HDL, calculated LDL, and triglycerides in the subject compared to the levels before administration of the pharmaceutical composition.

[0420] 188. The pharmaceutical composition according to Embodiment 187, wherein administration does not significantly increase the level of total cholesterol.

[0421] 189. The pharmaceutical composition according to Embodiment 187, wherein administration does not significantly increase the level of total HDL.

[0422] 190. The pharmaceutical composition according to Embodiment 187, wherein administration does not significantly increase the calculated LDL level.

[0423] 191. The pharmaceutical composition according to Embodiment 187, wherein administration does not significantly increase the level of triglycerides.

[0424] 192. The pharmaceutical composition according to Embodiments 129 to 191, wherein the pharmaceutical composition is administered concurrently with at least one additional therapeutic agent.

[0425] 193. A pharmaceutical composition according to any one of Embodiments 129 to 192, wherein at least one additional therapeutic agent is an acetylcholinesterase inhibitor, pyridostigmine, pyridostigmine bromide (Mestinon), neostigmine, prednisone, azathioprine (Imuran), mycophenylate mofetil (CellCept), tacrolimus (Prograf), methotrexate, cyclosporine (Sandimmune, Neoral), and cyclophosphamide (Cytoxan, Neosar), rituximab (Rituxan), eculizumab (Soliris), IVIg, or any combination thereof.

[0426] 194. The pharmaceutical composition according to any one of Embodiments 129 to 193, wherein at least one additional therapeutic agent is administered simultaneously with or consecutively (before or after) the anti-FcRn antibody. [Examples]

[0427] The various FcRn antibodies described herein and their properties are described in detail in International Publication No. 2019 / 118791 (International Application No. US2018 / 065568). In the following examples, nipocalimab (also known as M281) (the light chain and heavy chain amino acid sequences provided herein by SEQ ID NOs. 1 and 2, respectively) were used as the anti-FcRn antibody.

[0428] Example 1. Pharmacokinetic and pharmacodynamic data for M281. To evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of M281, a phase 1, single-center, randomized, double-blind, placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) (SAD / MAD) study was conducted in normal healthy volunteers (NHV). In the SAD study, five cohorts were administered either a single intravenous infusion of placebo (n=2 / cohort) or ascending doses of M281 at 0.3 (n=3), 3 (n=3), 10 (n=6), 30 (n=6), or 60 (n=6) mg / kg, and were followed up for 8 weeks for safety, PK, and PD. FcRn receptor occupancy (Figure 1) and IgG levels (Figure 2) were measured. In the MAD portion of the study, subjects received up to four weekly intravenous infusions of M281 or placebo and were followed for safety, PK, and PD for 10 weeks after the last dose. Subjects in the first cohort received 30 mg / kg of M281 or placebo. Results showed that complete FcRn receptor occupancy (RO) was achieved and maintained at 30 mg / kg (Figure 3A). A second cohort of subjects was enrolled to receive 15 mg / kg of M281 (or placebo) and it was determined that complete RO was not maintained at 15 mg / kg (Figure 3B). Mean serum M281 concentration data (Cmax and trough on day 1) were measured for subjects in the 30 mg / kg and 15 mg / kg cohorts. For 30 mg / kg M281, the 2-hour (Cmax) value after the initial dose was within the expected range of 500–700 μg / mL (based on SAD data), and the trough values ​​on days 7, 14, and 21 were in the range of 40–140 μg / mL. With repeated dosing, a steady state was established between 100–200 μg / mL, reducing group variability. For 15 mg / kg M281, the 2-hour (Cmax) value after the first dose was 200–400 μg / mL, and considerable trough concentration variability was observed. The majority of the data were below 10 μg / mL, which could explain the inability to maintain a complete RO in the 15 mg / kg group. At both dose levels, serum IgG was suppressed to a similar extent during the treatment period (Figures 4A and 4B). In this Phase I study, both the 15 mg / kg and 30 mg / kg doses were found to be safe and well-tolerated.

[0429] Example 2. Safety and tolerability of intravenous infusion of anti-FcRn antibody. A single-dose, sequential, randomized, double-blind (sponsor open-label), placebo-controlled, dose-escalation and infusion rate study of M281 was conducted. Healthy subjects were randomized and administered a single dose of 30 mg / kg or 60 mg / kg of antibody or placebo by intravenous infusion on day 1. Each of the five cohorts consisted of 6 subjects receiving antibody and 2 subjects receiving placebo, for a total of 40 subjects. The five cohorts consisted of: 30 mg / kg antibody administered over 60 minutes (6 subjects) or placebo (2 subjects); 30 mg / kg antibody administered over 30 minutes (6 subjects) or placebo (2 subjects); 30 mg / kg antibody administered over 15 minutes (6 subjects) or placebo (2 subjects); 30 mg / kg antibody administered over 7.5 minutes (6 subjects) or placebo (2 subjects); and 60 mg / kg antibody administered over 15 minutes (6 subjects) or placebo (2 subjects). The antibody concentration in intravenous infusion was 30 mg / ml. There were no deaths, serious adverse events (SAEs), or adverse events leading to withdrawal from the study. The most commonly reported adverse events under treatment were: Headache was reported by 6 (20%) of the active drug treatment group and by 1 (10%) of the placebo group, while nausea was reported by 3 (10%) of the active drug treatment group. Both 30 mg / kg infused over 7.5 minutes and 60 mg / kg infused over 15 minutes were tolerable, but appeared to have a higher rate of headache and nausea than the lower infusion rate.

[0430] Example 3. Modeling of intravenous medication. Various medication regimens for M281 were modeled based on clinical data. First, the effects of 15, 30, 45, and 60 mg / kg IV every four weeks (Q4W) and 15, 30, and 35 mg / kg IV every two weeks (Q2W) on baseline IgG reduction were modeled. The results of this analysis are shown in Figures 5A and 5B. Based on this modeling, the Q2W regimen provides a more sustained and overall stronger IgG reduction (30 mg / kg Q4W, mean IgG reduction of approximately 50-60% (approximately 40-80%) and 30 mg / kg Q2W, mean IgG reduction of approximately 79% (74-85%)). The effects of various medication regimens on activities of daily living (MG-ADL) in myasthenia gravis were modeled. The modeled doses were 30 mg / kg Q2W, 30 mg / kg Q4W, 60 mg / kg Q2W, and 60 mg / kg Q4W. As shown in Figure 6, based on this model, the medication interval is expected to have a greater impact than the dose. Next, we modeled the effects of 15 mg / kg IV Q2W or 30 mg / kg IV Q2W, administered two weeks after the initial (loading) dose of 60 mg / kg IV, on IgG reduction and changes in MG-ADL from baseline. As shown in Figures 7A and 7B, including the 60 mg / kg loading dose provides superior IgG reduction in weeks 1 and 2, suggesting the possibility of earlier efficacy. Figures 8A and 8B are enlarged views of the modeling results in Figures 7A and 7B for weeks 1 and 2, showing that including the loading dose is expected to provide superior results between weeks 1 and 2. The effects of various intravenous doses of M281 (30 mg / kg Q4W, 60 mg / kg Q4W, 30 mg / kg Q2W, 60 mg / kg Q2W) on serum albumin were modeled. As shown in Figure 9, all modeled doses suggest a reduction in serum albumin of less than 25%. The 15 mg / kg Q2W dose is expected to show a reduction in serum albumin similar to or less than that modeled for the 30 mg / kg Q2W dose.

[0431] Example 4. Clinical study protocol. A clinical study will be conducted to compare the efficacy of various drug regimens for alloimmune and / or autoimmune disorders in fetuses and neonates by injection of anti-FcRn antibodies described herein in pregnant subjects identified as having a fetus or neonate in need. As described above, diseases and disorders for which FcRn inhibition by isolated anti-FcRn antibodies described herein may be beneficial include diseases and disorders in the fetus and / or neonate caused by the transfer of maternal pathogenic antibodies (e.g., maternal pathogenic IgG antibodies) across the placenta from the pregnant subject to the fetus and / or neonate. Diseases and disorders for which FcRn inhibition by the isolated anti-FcRn antibodies described herein may be beneficial include fetal and neonatal alloimmune thrombocytopenia (FNAIT), fetal and neonatal hemolytic disease (HDFN), alloimmune panthrombocytopenia, congenital heart block, fetal joint contractures, neonatal myasthenia gravis, neonatal autoimmune hemolytic anemia, neonatal antiphospholipid syndrome, neonatal polymyositis, dermatomyositis, neonatal lupus, neonatal scleroderma, Behçet's disease, neonatal Graves' disease, neonatal Kawasaki disease, neonatal autoimmune thyroid disease, and neonatal type 1 diabetes mellitus. The medication regimen will be tested with a loading dose of 60 mg / kg, followed by a maintenance dose. One cohort will receive a maintenance dose of 15 mg / kg every two weeks, a second cohort will receive a maintenance dose of 30 mg / kg every two weeks, a third cohort will receive a maintenance dose of 15 mg / kg once a month, and a fourth cohort will receive a maintenance dose of 30 mg / kg once a month. In all cases, the schedule will continue until the birth of the infant. IgG and serum albumin levels will be measured weekly in pregnant subjects.

[0432] Example 5. M281 is safe and well-tolerated in patients with generalized myasthenia gravis (gMG). Sixty-eight patients with either anti-AChR or anti-MuSK autoantibodies were randomized in a 1:1:1:1:1 ratio to one of four M281 treatment groups or a placebo group. M281 doses were 5 mg / kg Q4W, 30 mg / kg Q4W, and 60 mg / kg Q2W. A single dose of 60 mg / kg was also included to evaluate the duration and efficacy of IgG reduction. To maintain study blinding, all patients received intravenous infusions (either M281 or placebo) every other week for a total of five infusions over an 8-week treatment period. After completion of the follow-up period, patients were able to enroll in a separate, open-label extension study to receive treatment with M281. M281 was generally well-tolerated. There were no treatment emergent adverse effects (TEAEs) or adverse effects (AEs) that led to discontinuation of treatment with M281. There was one serious adverse effect (SAE) in the M281 group (shoulder pain) and two SAEs in the placebo group (one ischemic stroke and one MG exacerbation). The infection rates in the M281 combination dose group and the placebo group were 33.3% and 21.4%, respectively, and there were no severe or serious infections. The percentage of headache with M281 was comparable to that with placebo. Therefore, M281 was safe and well-tolerated in patients with gMG.

[0433] Example 6. M281 reduces serum IgG and anti-AChR and anti-MuSK autoantibodies. Serum samples were collected from individuals on the day of infusion, as provided in Example 5, and analyzed for M281 concentration using enzyme-linked immunosorbent assay (ELISA). Blood samples were collected immediately before the start of infusion upon hospital visit, when the study drug was scheduled to be administered, and after infusion on days 1 and 57. Serum samples were also analyzed for changes in the concentrations of total IgG, IgG subclasses, IgA, IgM, and IgE, as well as pathogenic MG antibodies (anti-AChR and anti-MuSK). Serum total IgG levels were accessed using Roche Cobas® 8000. Serum IgG subclasses (IgG1, IgG2, IgG3, and IgG4) and IgA, IgM, and IgE levels were measured using a valid immunoturbidimetry (Siemens) platform on a Behring Nephelometer II (BN II). Serum levels of pathogenic anti-AChR and anti-MuSK autoantibodies were analyzed by ARUP Laboratories (UT, USA) and The Doctors Laboratory (London, UK), respectively. Median trough serum M281 concentrations (Ctrough) were below the lower limit of quantification (<0.15 μg / mL) in all 5 mg / kg Q4W and 30 mg / kg Q4W dose groups. However, the median Ctrough ranged from 4.01 to 36.33 μg / mL in the 60 mg / kg Q2W group. No accumulation of serum M281 concentration over time was observed across the 5 mg / kg Q4W, 30 mg / kg Q4W, and 60 mg / kg Q2W treatment groups. The overall incidence of antibodies against M281 up to day 113 (week 16) in subjects treated with M281 was 40.7% (n=22). Antibody responses to M281 were low titer (all titer levels ≤ 1:16). Of the 22 subjects who tested positive for antibodies against M281, 8 (34.4%) had antibodies capable of neutralizing the physiological activity of M281 in vitro. Treatment with nipocalimab showed a substantial, rapid, and dose-dependent reduction in serum total IgG levels.One week after the first nipocalimab infusion, serum total IgG showed a mean reduction from baseline of up to 40% at 5 mg / kg and 70% at doses of 30 mg / kg or higher (Figure 12). Maximum IgG reductions of 42%, 73%, and 80% were observed with 5 mg / kg q4w, 30 mg / kg q4w, and 60 mg / kg single dose or q4w (Figure 12). The q2w dosing regimen resulted in a sustained reduction in mean serum IgG, while the q4w dosing regimen resulted in reductions in the peak and lowest points of mean serum IgG levels, with the lowest point occurring approximately 2 weeks after nipocalimab administration and the peak occurring approximately 4 weeks after administration. Similar reductions were observed across all IgG subclasses in the nipocalimab treatment groups, and no changes were observed in total IgM, IgA, and IgE. Simultaneously with the reduction in total IgG, a dose-dependent reduction in pathogenic anti-AChR autoantibodies was also observed across the nipocalimab treatment groups (Figure 13). A reduction in anti-MuSK autoantibodies was observed in patients who were positive for anti-MuSK autoantibodies. A dose-dependent decrease in mean serum albumin from baseline was observed in the nipocalimab groups. In the highest dose group of 60 mg / kg q2w, the mean albumin reduction was approximately 20%. One patient in the 60 mg / kg q2w group had a grade 2 albumin reduction. No patients had symptoms attributable to albumin reduction. Except for one patient in the 60 mg / kg q2w group with a grade 2 reduction (albumin level of 27 g / L on day 43, baseline value: 40 g / L, normal range: 35-55 g / L), albumin levels were within the normal range. Asymptomatic, dose-dependent, and reversible increases in mean total cholesterol, LDL, and HDL at non-fasting levels were observed in the high-dose nipocalimab group. The cholesterol:HDL ratio was <5% across all dose groups. The maximum mean percentage increases in total cholesterol, LDL, and HDL were 9.3%, 8.4%, and 17.9% in the 30 mg / kg q4w group, 15.6%, 13%, and 23.3% in the 60 mg / kg single-dose group, and 23.1%, 28.1%, and 19.8% in the 60 mg / kg q2w group, respectively.In the 30 mg / kg q4w and 60 mg / kg single dose regimens, the maximum mean values ​​occurred primarily within one week of the initial infusion, but subsequent increases were of a lower magnitude. Therefore, M281 reduces serum IgG, as well as anti-AChR and anti-MuSK autoantibodies, in patients with gMG.

[0434] Example 7. M281 improves MG-ADL and QMG scores in patients with gMG. MG-ADL and QMG scores were measured in patients with gMG after administration of M281, as provided in Example 5. Patients who received M281 achieved substantial and rapid reductions in serum total IgG and anti-AChR IgG autoantibodies, correlated with improved MG-ADL.

[0435] As shown in Tables 1 and 2, patients treated with M281 achieved robust mean improvement from baseline in the MG-ADL score across the M281 continuous dosing arm compared to placebo at the end of the treatment period (day 57).

[0436] [Table 3]

[0437] The highest percentage of patients showing an improvement of 2, 3, 4, 5, 6, 7, or 8 points or more in the total MG-ADL score from baseline to day 57 was observed in the following treatment groups (Table 2): i) M281 30 mg / kg q4w (including 83.3% of patients with a 2-point improvement; 66.7% with a 3-point improvement; 41.7% with a 4-point improvement; 41.7% with a 5-point improvement; 25% with a 6-point improvement; 25% with a 7-point improvement; and 8.3% with an ≥8-point improvement), and ii) M281 60 mg / kg q2w (including 85.7% of patients with a 2-point improvement; 78.6% with a 3-point improvement; 50% with a 4-point improvement; 42.9% with a 5-point improvement; 21.4% with a 6-point improvement; 14.3% with a 7-point improvement; and 14.3% with an ≥8-point improvement). A reduction from baseline in the mean MG ADL total score was observed in all treatment groups (including placebo) at days 85 and 113, after the last dose administration on day 57. The largest and most consistent reductions were observed in subjects treated with M281 30 mg / kg q4w and 60 mg / kg q2w.

[0438] [Table 4]

[0439] A greater proportion of patients treated with M281 showed rapid improvement in MG-ADL (within 2 weeks of treatment) across all four dosing arms compared to placebo. 51.9% of patients receiving M281 (all doses) reported a sustained MG-ADL response (defined as an improvement of ≥2 points from baseline in MG-ADL over at least 4 consecutive weeks during the first 8 weeks of treatment) compared to 15.4% of patients receiving placebo (p=0.017). The rapid and sustained MG-ADL response demonstrates a clear clinical benefit with nipocalimab therapy and highlights its potential for long-term treatment. Observed changes from baseline in MG-ADL after nipocalimab administration at doses ranging from 5 mg / kg q4w to 60 mg / kg q2w were dose-dependent, rapidly onset, and closely associated with the onset and magnitude of IgG or anti-AChR autoantibody decline. These results suggest that IgG decline predicts MG efficacy in patients with gMG.

[0440] The duration of response was defined as the number of consecutive weeks during which a subject experienced an improvement of ≥2 in MG-ADL (Table 3). The median duration of response was longer among subjects treated with M281 (ranging from 29.0 to 36.0 days across dose groups) compared with subjects treated with placebo (15.0 days). The percentage of subjects with sustained response was higher in the M281 treatment group compared with the placebo treatment group. At day 57, the number of subjects with sustained response (defined as ≥4 consecutive weeks with an improvement of ≥2 in MG-ADL) was higher in the M281 treatment group compared with the placebo treatment group (14.3%) (42.9%, 46.2%, 53.9%, and 64.3% in the 5 mg / kg q4w, 30 mg / kg q2w, 60 mg / kg single dose, and 60 mg / kg q2w dose groups, respectively). The difference in treatment reached a p-value of 0.0461 for the 60 mg / kg single dose group and a p-value of 0.0183 for the 60 mg / kg q2w dose group. In addition, the 5 mg / kg q4w group showed a p-value of 0.2087, and the 30 mg / kg q4w group showed a p-value of 0.1032. The percentage of patients with rapid onset of sustained response (i.e., by the planned visit in week 2 [≤17 days from the initial administration of the study drug]) was higher among the M281 treatment groups compared to the placebo group, at 42.9% (p=0.2087) for the 5 mg / kg Q4W treatment group, 38.5% (p=0.2087) for the 30 mg / kg Q4W treatment group, 46.2% (p=0.1032) for the 60 mg / kg single-dose treatment group, 42.9% (p=0.2087) for the 60 mg / kg Q2W treatment group, and 14.3% for placebo.

[0441] [Table 5]

[0442] Time to response was defined as the time from the first infusion to the first time an improvement of ≥2 in MG ADL was observed. The median time to response ranged from 15.0 to 15.5 days across dose groups for the M281 treatment group and 16.0 days for the placebo treatment group.

[0443] On day 57 (before the final dose), the greatest reduction from baseline in the mean total QMG score was observed in subjects treated with M281 30 mg / kg q4w and 60 mg / kg q2w (Table 1).

[0444] Treatment with M281 resulted in the following changes from baseline on the QMG scale: -0.1 LS mean, p=0.9289 for the 5 mg / kg q4w treatment group; -0.5 LS mean, p=0.7304 for the 30 mg / kg q4w treatment group; 2.1 LS mean, p=0.1845 for the 60 mg / kg single dose group; and -1.8 LS mean, p=0.2344 for the 60 mg / kg q2w treatment group. A single dose of M281 60 mg / kg also resulted in a significant reduction in the mean total QMG score up to day 29 (week 4, mean change from baseline: -2.2), with the maximum reduction occurring at day 15 (mean change from baseline: -4.1). The highest percentage of patients showing an improvement of 3, 4, 5, 6, 7, or 8 points or more in the total QMG score from baseline to day 57 was observed in the following M281 treatment groups (Table 4): i) 30 mg / kg q4w (including 60% of patients with a 3-point improvement; 60% of patients with a 4-point improvement; 50% of patients with a 5-point improvement; 40% of patients with a 6-point improvement; 10% of patients with a 7-point improvement; and 10% of patients with an ≥8-point improvement), and ii) 60 mg / kg q2w (including 76.9% of patients with a 3-point improvement; 76.9% of patients with a 4-point improvement; 61.5% of patients with a 5-point improvement; 38.5% of patients with a 6-point improvement; 23.1% of patients with a 7-point improvement; and 23.1% of patients with an ≥8-point improvement). The mean reduction in the total QMG score after the last dose administration on day 57 was maintained across all treatment groups until day 113.

[0445] [Table 6]

[0446] Sustained response was defined as the number of consecutive days on which a subject had an improvement of ≥3 in OMG. At day 57, the percentage of subjects with a sustained response was higher in most M281 treatment groups compared to the placebo group (28.57%), including 35.7% (p=1) for 5 mg / kg q4w; 38.5% (p=0.6946) for 30 mg / kg q4w; 15.38% (p=0.6483) for 60 mg / kg single dose; and 42.9% (p=0.6946) for 60 mg / kg q2w (Table 5).

[0447] [Table 7]

[0448] The duration of response was defined as the number of consecutive weeks during which a subject experienced an improvement of ≥3 in QMG. The longest median duration of response was observed in the 60 mg / kg q2w group (31.0 days), followed by the 30 mg / kg q4w group (24.0 days). The shortest median duration of response was in the 60 mg / kg single-dose group (1.0 day), followed by the 5 mg / kg q4w group (15.0 days) and the placebo group (16.0 days). The highest percentage of subjects with sustained response was observed in the 60 mg / kg q2w dose group, followed by the 30 mg / kg q4w group and the 5 mg / kg q4w group. The median duration of sustained response ranged from 43.0 to 44.0 days across dose groups for subjects treated with M281, and 43.0 days for subjects treated with placebo. The percentage of patients with a sustained response within 17 days was higher in the 30 mg / kg q4w group (38.5%, p=0.6946) and the 60 mg / kg q2w group (35.7%, p=1) compared to the placebo group (28.6%), lower in the 60 mg / kg single dose group (15.4%, p=0.6483), and similar in the 5 mg / kg q4w group (28.6%, p=1). Time to response was defined as the time from the first infusion to the first time with an improvement of ≥3 in QMG. The median time to response among M281 treatment subjects (ranging from 15.0 to 16.0 days across dose groups) was shorter than that observed among placebo treatment subjects (22.0 days). The data demonstrate that M281 improves MG-ADL and QMG scores in patients with gMG.

[0449] Example 8. M281 improves MG-QoL-15r score and MGFA classification in patients with gMG. MG-QoL-15r and MGFA scores were measured in patients with gMG after administration of M281, as provided in Example 5. A time-dependent reduction in total MG-QoL-15r was observed after administration of the study drug in all treatment groups, including placebo. On day 57 (before the final dose), the greatest reduction from baseline in the mean total MG-QoL-15r score was observed in subjects treated with M281 30 mg / kg q4w and 60 mg / kg q2w, including the following scores: -2.1 LS mean, p=0.9008 for 5 mg / kg q4w; -6.9 LS mean, p=0.0054 for 30 mg / kg q4w; -1.3 LS mean, p=0.7540 for 60 mg / kg single dose; and -4.0 LS mean for the 60 mg / kg q2w treatment group. P=0.2135 (Table 1).

[0450] A single dose of M281 60 mg / kg also resulted in a significant reduction in the mean total MG-QoL-15r score up to day 29 (week 4), although the score subsequently increased. The time-dependent reduction in the mean total MG-QoL15r score after the final dose on day 57 was maintained across all treatment groups, including placebo, until visit on day 113. On day 57, the MGFA score showed a 21.4% improvement and 64.3% remaining unchanged (p=0.2156) in the 5 mg / kg q4w group; a 53.8% improvement, 23.1% remaining unchanged, and 7.7% worsening (p=0.3774) in the 30 mg / kg q4w group; a 30.8% improvement and 61.5% remaining unchanged (p=0.4176) in the 60 mg / kg single-dose group; and a 50% improvement, 28.6% remaining unchanged, and 7.1% worsening (p=0.4928) in the 60 mg / kg q2w group (Table 8).

[0451] [Table 8]

[0452] On day 57, the highest percentage of subjects with improved MGFA classification status on day 57 was observed in the 30 mg / kg q4w and 60 mg / kg q2w treatment groups. At baseline, most of the subjects had an MGFA classification status of <IIIa (range of 69.2% - 78.6% across all treatment groups). Most of these subjects had improved or maintained the same MGFA classification until day 57. Thus, M281 improves the MG-QoL15 score and MGFA classification.

[0453] Example 9. Treatment of myasthenia gravis with M281 does not significantly increase cholesterol. Elevations of total cholesterol and low-density lipoprotein (LDL) have recently been reported with another experimental anti-FcRn antibody, not M281, in the same pharmacological class of FcRn antagonists. This finding prompted a review of lipid data in sponsored completed and ongoing M281 studies. In Phase 1 healthy volunteer and Phase 2 generalized myasthenia gravis studies, asymptomatic dose-dependent, reversible increases in mean total cholesterol at non-fasting levels were observed up to 25% of baseline. At the highest dose of 60 mg / kg every two weeks (Q2W), the mean percentage change in total cholesterol increased to a stable maximum 21%–23% higher than baseline within one month of drug initiation and decreased to near baseline levels one–2 months after the last dose. In the 30 mg / kg q4w group, the maximum mean percentage increases in total cholesterol, LDL, and HDL were 9.3%, 8.4%, and 17.9%, respectively. In the 60 mg / kg single-dose group, these were 15.6%, 13%, and 23.3%, and in the 60 mg / kg q2w group, they were 23.1%, 28.1%, and 19.8%, respectively. In the 30 mg / kg q4w and 60 mg / kg single-dose groups, the maximum mean increases occurred mainly within one week of the first infusion, but subsequent increases were of a lower magnitude. The cholesterol:HDL ratio was <5% across all dose groups. As a result of these findings, the following evaluations are made: 1) evaluation of lipids (total cholesterol, HDL, calculated LDL, and triglycerides) in fasting and non-fasting states at multiple time points during and outside of treatment; 2) exclusion criteria for patients with recent significant cardiovascular events; and 3) recommendations for dyslipidemia management in accordance with local health guidelines.

[0454] Example 10. Phase 3 Study Design. This multicenter, randomized, double-blind, placebo-controlled study was designed to evaluate the safety, tolerability, efficacy, disease progression (PD), and immunogenicity of nipocalimab compared to placebo when administered intravenously (IV) to adults with gMG. After a screening period of up to 4 weeks, approximately 150 eligible autoantibody-positive (anti-AChR, anti-MuSK, and / or anti-LRP4) patients and 30 eligible autoantibody-negative patients were enrolled. Participants were randomized in a 1:1 ratio to one of two treatment groups. Randomization was stratified by baseline MG-ADL score (≤9, >9), region (East Asia, United States, and other countries worldwide), and autoantibody status (serogenous or serogenous). The treatment groups included: 1) placebo infusion once every two weeks (Q2W); and 2) infusion of nipocalimab with an initial loading dose of 30 mg / kg, followed by a maintenance dose of 15 mg / kg every two weeks (Q2W). The regimen of intravenous administration of a 30 mg / kg loading dose on day 1, followed by 15 mg / kg IV q2w maintenance doses from week 2 onward, was based on data observed from a phase 2 study, as well as extensive population PK / PD / efficacy modeling analyses and simulations to evaluate the relationship between PK, IgG reduction, and MG-ADL and other efficacy and safety endpoints (including serum albumin and total cholesterol). The results showed that 15 mg / kg q2w dosing provided the best safety with nearly equivalent sustained IgG reduction (73.8%) compared to 30 mg q4w dosing (79.4%), and was associated with minimal additional MG-ADL improvement in the steady-state trough. Therefore, the 15 mg / kg q2w dose regimen was selected as the single maintenance dose regimen studied for this Phase 3 study in gMG. Starting from baseline (Day 1), patients receive infusions of the investigational drug (placebo or nipocalimab) over 15–30 minutes at Q2W and undergo safety, efficacy, PD, and immunogenicity evaluations. Efficacy evaluations are collected every 2–4 weeks. Efficacy evaluations include MG-ADL, QMG, MG-QoL15r, and other patient-reported outcomes (PROs).All visits, except for those at weeks 1, 3, and 23 (conducted by telephone), will take place at the research center. At the week 24 visit, patients will have the option to participate in another open-label extension (OLE) study in which they will receive nipocalimab infusions every two weeks. Patients who do not wish to continue with OLE, or who are not eligible for OLE, or who discontinue the study early and are not eligible for OLE, will return to the research center 8 weeks after their last infusion to complete the safety follow-up assessment. Patients requiring rescue treatment may be eligible to participate in OLE at the discretion of the principal investigator. The safety assessment will include adverse events (AEs; including serious adverse events [SAEs] and particularly interesting adverse events [AESIs]), laboratory tests (including chemistry, hematology, coagulation, and urinalysis), vital signs, ECG, physical examination, and a complete Columbia-Suicide Severity Rating Scale (C-SSRS) assessment. An independent Drug Safety Monitoring Board (DSMB) is responsible for monitoring the safety of patients in the study.

[0455] Example 11. M281 is safe and well-tolerated in patients with gMG. Prior to treatment with M281, subjects of the Phase 3 study will be evaluated using one or more of the following: physical examination, C-SSRS, vital signs, 12-lead ECG, lipid panel, urinalysis (dipstick), urinalysis drug screening, pregnancy test (serum or urine), FSH (for menopausal women), HIV-1 and HIV, hepatitis B and C. In addition, blood and serum will be collected for exploratory biomarker analysis, IgG type analysis, and clinical laboratory evaluation. Subjects with myasthenia gravis or gMG who have an inadequate clinical response to ongoing, stable standard treatment will be evaluated prior to M281 treatment using physical examination, C-SSRS, vital signs, 12-lead ECG, lipid panel, urinalysis (dipstick), urinalysis drug screening, pregnancy test (serum or urine), FSH (for menopausal women), HIV-1 and HIV, and hepatitis B and C assessment tests to generate a baseline score. Subjects will receive M281 as a single dose or as a loading dose and maintenance dose every two weeks for 24 weeks. Subjects will be evaluated for changes in vital signs, laboratory values, and C-SSRS scores after 24 weeks and throughout the study.

[0456] Example 12. Treatment of myasthenia gravis with anti-FcRn antibodies results in a change from baseline on the MG-ADL scale. Participants in the Phase 3 study were assessed using the Myasthenia Gravis-Activities of Daily Living (MG-ADL) scale before treatment with M281. Participants with myasthenia gravis or gMG who have an inadequate clinical response to ongoing stable standard treatment were assessed using MG-ADL before treatment with M281 to generate an MG-ADL score. Participants were administered M281 as a single dose or as a loading dose and maintenance dose every two weeks for 24 weeks. After 24 weeks and throughout the study, participants were assessed for changes in their MG-ADL score. After 24 weeks and throughout the study, participants were assessed using the MG-ADL scale and found to have achieved a change from baseline on the MG-ADL scale.

[0457] Example 13. Treatment of myasthenia gravis with anti-FcRn antibodies results in changes from baseline on the QMG and MG-QoL-15r scales. Participants in the Phase 3 study will be evaluated using the QMG and MG-QoL-15r scales before treatment with M281. Participants with myasthenia gravis or gMG who have an inadequate clinical response to ongoing stable standard treatment will be evaluated using the QMG and MG-QoL-15r scales before treatment with M281 to generate QMG and MG-QoL-15r scores. Participants will be administered M281 as a single dose or as a loading dose and maintenance dose every two weeks for 24 weeks. After 24 weeks and throughout the study, participants will be evaluated for changes in their QMG and MG-QoL-15r scores. At 24 weeks and throughout the study, participants were assessed using the QMG and MG-QoL-15r scales, and were found to have achieved changes from baseline on the QMG and MG-QoL-15r scales.

[0458] Example 14. Treatment of myasthenia gravis with anti-FcRn antibodies results in changes from baseline on the Neuro-QoL-Fatigue, EQ-5D-5L, MGFA, PGI-C, and PGI-S scales. Participants in the Phase 3 study will be evaluated using the Neuro-QoL-Fatigue, EQ-5D-5L, MGFA, PGI-C, and PGI-S scales before treatment with M281. Participants with myasthenia gravis or gMG who have an inadequate clinical response to ongoing stable standard treatment will be evaluated using the Neuro-QoL-Fatigue, EQ-5D-5L, MGFA, PGI-C, and PGI-S scales before treatment with M281 to generate Neuro-QoL-Fatigue, EQ-5D-5L, MGFA, PGI-C, and PGI-S scores. Participants will be administered M281 as a single dose or as a loading dose and maintenance dose every two weeks for 24 weeks. At 24 weeks and throughout the study, participants will be assessed for changes in Neuro-QoL-Fatigue, EQ-5D-5L, MGFA, PGI-C, and PGI-S scores. At 24 weeks and throughout the study, participants will be assessed using the Neuro-QoL-Fatigue, EQ-5D-5L, MGFA, PGI-C, and PGI-S scales and will be found to have achieved changes from baseline in Neuro-QoL-Fatigue, EQ-5D-5L, MGFA, PGI-C, and PGI-S.

[0459] Example 15. Pediatric Study Design. This is an open-label, multicenter trial to evaluate the pharmacokinetics, pathological progression (PD), safety, tolerability, and efficacy of an investigational drug in pediatric subjects with gMG who have an inadequate clinical response to ongoing stable standard treatment. A screening period of up to 28 days will allow sufficient time to conduct screening evaluations and determine study eligibility. A total of 12 subjects were proposed, six in each of two age cohorts: Cohort 1) ≥12 to <18 years, and Cohort 2) ≥2 to <12 years. The active treatment phase will include Cohorts 1 and 2, which may be open-label and unblinded for all male and female pediatric subjects who meet study-specific inclusion and exclusion criteria. Cohort 1 will enroll adolescents (12 to under 18 years) to evaluate the pharmacokinetics, pathological progression, safety, and activity of the investigational drug treatment. Twelve weeks after all participants have been enrolled in Cohort 1, PK, PD, and safety data will be evaluated in an interim analysis, and if acceptable, the trial will be initiated in Cohort 2 (participants aged 2 to under 12 years). Once adolescents are enrolled, younger subjects aged 2 to under 12 years may be enrolled. All subjects will receive the investigational drug via IV infusion over 15–30 minutes every two weeks. Participants in Cohort 1 of the study will receive a single 30 mg / kg loading dose, followed by 15 mg / kg every two weeks [q2w]. Dosing in Cohort 2 will be modeled based on all existing PK and PD data available at the time of the interim analysis (including adult data from Phase 1–3 studies and adolescent data from Cohort 1 of this study). A total of at least 12 subjects will be studied, with at least 6 in each of the two age cohorts (adolescents and younger children). The study period is 24 weeks, with the option to participate in a long-term extension (LTE) after completion. Participants who discontinue early or do not participate in the LTE after completing the study will undergo a safety assessment 8 weeks after the end of enrollment. The LTE is expected to last approximately 104 weeks (about 2 years). All Cohort 1 participants in the LTE phase of the study will have the option, at the discretion of the principal investigator, to receive nipocalimab infusions q2w (15 mg / kg) or q4w (30 mg / kg), or to change their background concomitant medications.The options for modifying the dose and regimen of Cohort 2 participants during the LTE phase will be modeled based on all existing PK and PD data available at the time of the interim analysis (including adult data from Phase 1-3 studies and adolescent data from Cohort 1 of this study). Other medication regimens should not be used. Participants who discontinue early or do not participate in the LTE after completing the study will have a safety follow-up visit 8 weeks after the last infusion of the study intervention.

[0460] Blood samples will be collected at selected visits in this study to evaluate the pharmacokinetic (PK) and disease progression (PD) of the investigational drug in pediatric participants with gMG. Serum samples for immunogenicity assessment will be collected at selected visits in this study. Biomarker samples may be collected to evaluate the mechanism of action of the investigational drug or to help identify subgroups of the population that respond differently to the intervention. The duration of the active treatment phase (24 weeks) is expected to be sufficient to evaluate the mechanism of action of nipocalimab and its activity and safety based on the results of the adult phase 2 study, which demonstrated efficacy against MG-ADL as early as week 2 and persisted until day 57 (the primary evaluation point in the adult phase 2 study). The maintenance of the effect of nipocalimab and its long-term safety will be further evaluated in the LTE phase. Safety assessments include collection of AEs and SAEs, use of concomitant medications, clinical laboratory tests (including chemistry, hematology, lipid profiles, urinalysis, and testing of total serum IgG and diphtheria / tetanus vaccine titers), ECG, vital signs, physical examination, and Tanner staging. Urinary pregnancy tests are performed only in girls who may be pregnant. In addition, the occurrence of suicidal ideation is assessed using the Columbia Suicide Severity Scale (C-SSRS). Severe or critical infections, hypoalbuminemia (<20 g / L), and opportunistic infections are considered particularly interesting adverse events (AESIs).

[0461] Example 16. Nipocalimab is safe and well-tolerated in pediatric patients with gMG. Pediatric subjects are evaluated using one or more of the following before treatment with nipocalimab: physical examination, C-SSRS, vital signs, 12-lead ECG, and urinalysis. In addition, blood and serum are collected for exploratory biomarker analysis, Ig type analysis, and clinical laboratory evaluation. Subjects with myasthenia gravis or gMG who have an inadequate clinical response to ongoing stable standard treatment are evaluated using physical examination, C-SSRS, vital signs, 12-lead ECG, urinalysis, and blood and serum evaluation tests before treatment with nipocalimab to generate a baseline score. Subjects are administered nipocalimab as a single dose or as a loading dose and maintenance dose every two weeks for 24 weeks. After 24 weeks and throughout the study, subjects are evaluated for changes in vital signs, clinical laboratory values, and C-SSRS scores.

[0462] Example 17. Modeling of intravenous medication for use in pediatric patients. Various medication regimens for M281 are modeled based on clinical data from adolescent patients. The effects of various medication regimens on activities of daily living (MG-ADL) in myasthenia gravis were modeled. Modeled doses include approximately 5 mg / kg, 10 mg / kg, 15 mg / kg, 20 mg / kg, 25 mg / kg, 30 mg / kg, 40 mg / kg, 45 mg / kg, 50 mg / kg, 55 mg / kg, and 60 mg / kg. Based on this modeling, medication regimens for younger patients are derived.

[0463] Example 18. Treatment of myasthenia gravis with anti-FcRn antibodies results in a change from baseline in the MG-ADL scale in pediatric patients. Pediatric subjects were assessed using the Myasthenia Gravis-Activities of Daily Living (MG-ADL) scale prior to treatment with nipocalimab. Subjects with myasthenia gravis or gMG who have an inadequate clinical response to ongo...

Claims

1. 1. A pharmaceutical composition for use in a method of treating myasthenia gravis in a patient in need of such treatment, comprising an anti-FcRn antibody, said method comprising administering an initial loading dose of about 30 mg / kg to about 60 mg / kg of said anti-FcRn antibody, followed by a maintenance dose of about 15 mg / kg to about 30 mg / kg of said anti-FcRn antibody, wherein said anti-FcRn antibody is a heavy chain comprising an HCDR1 of SEQ ID NO:6, an HCDR2 of SEQ ID NO:7, and an HCDR3 of SEQ ID NO:8; a light chain comprising an LCDR1 of SEQ ID NO:3, an LCDR2 of SEQ ID NO:4, and an LCDR3 of SEQ ID NO:5; The pharmaceutical composition, wherein said administration reduces serum IgG in said patient by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of baseline serum IgG.

2. 2. The pharmaceutical composition of claim 1, wherein the heavy chain comprises an amino acid sequence having at least 95% identity to the sequence of SEQ ID NO:2 and the light chain comprises an amino acid sequence having at least 95% identity to the sequence of SEQ ID NO:

1.

3. 2. The pharmaceutical composition of claim 1, wherein the heavy chain comprises a variable region heavy chain comprising an amino acid sequence having at least 95% identity to the sequence of SEQ ID NO: 10, and the light chain comprises a variable region light chain comprising an amino acid sequence having at least 95% identity to the sequence of SEQ ID NO:

9.

4. 2. The pharmaceutical composition of claim 1, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO:2 and the light chain comprises the amino acid sequence of SEQ ID NO:

1.

5. The pharmaceutical composition of claim 1 , wherein the heavy chain comprises a variable region heavy chain comprising the amino acid sequence of SEQ ID NO: 10, and the light chain comprises a variable region light chain comprising the amino acid sequence of SEQ ID NO:

9.

6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the administration is intravenous or subcutaneous.

7. 7. The pharmaceutical composition of any one of claims 1-6, wherein said administering comprises administering a pharmaceutical composition comprising about 10 mg / ml to about 60 mg / ml of said anti-FcRn antibody, about 20 mM to about 30 mM sodium phosphate, about 20 mM to about 30 mM sodium chloride, about 80 mg / ml to about 100 mg / ml of trehalose, and about 0.1% w / v to about 0.005% w / v of polysorbate 80.

8. The pharmaceutical composition of any one of claims 1 to 7, wherein the initial loading dose is about 60 mg / kg or about 30 mg / kg.

9. The pharmaceutical composition of any one of claims 1 to 8, wherein the maintenance dose is about 15 mg / kg or about 30 mg / kg.

10. The maintenance dose is After administration of the loading dose, every week, every two weeks, every three weeks, every four weeks, or every month; and 10. The pharmaceutical composition of any one of claims 1 to 9, which is administered weekly, every two weeks, every three weeks, every four weeks, or monthly following administration of a preceding maintenance dose.

11. the loading dose is injected into the subject over about 30 minutes to about 90 minutes; The pharmaceutical composition of any one of claims 1 to 10, wherein the maintenance dose is infused into the subject in about 15 to about 60 minutes.

12. 12. The pharmaceutical composition of any one of claims 1 to 11, wherein the serum IgG is IgG1, IgG2, IgG3, or IgG4, or any combination thereof, and the reduction is at least 20% from baseline, or at least 30% from baseline.

13. 13. The pharmaceutical composition of any one of claims 1-12, wherein said administration of said anti-FcRn antibody reduces serum albumin by up to 18%, up to 16%, up to 14%, up to 12%, up to 10%, up to 8%, up to 6%, up to 4%, or up to 2% of baseline serum albumin.

14. said administering reducing serum autoantibodies; the autoantibody is selected from the group consisting of anti-acetylcholine receptor (AChR), anti-muscle specific kinase (MuSK), anti-low density lipoprotein receptor-related protein 4 (LRP4), anti-agrin, anti-titin, anti-Kv1.4, anti-ryanodine receptor, anti-collagen Q, and anti-cortactin; 14. The pharmaceutical composition of any one of claims 1 to 13, wherein the reduction is at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 50%, or at least 25% of baseline serum autoantibodies.

15. 15. The pharmaceutical composition of claim 14, wherein said administration of said anti-FcRn antibody reduces anti-AChR antibodies by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 50%, or at least 25% of baseline anti-AChR antibodies.

16. 16. The pharmaceutical composition of claim 14 or 15, wherein said administration of said anti-FcRn antibody reduces anti-MuSK antibodies by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 50%, or at least 25% of baseline anti-MuSK antibodies.

17. 17. The pharmaceutical composition of any one of claims 1-16, wherein the patient achieves a change from baseline in MG-ADL score, QMG score, MG-QoL-15r score, MGFA score, or any combination thereof.

18. 18. The pharmaceutical composition of any one of claims 1 to 17, wherein said administration of said anti-FcRn antibody to said subject does not significantly increase total cholesterol, HDL, calculated LDL, and triglyceride levels in said subject compared to levels prior to said administration of said anti-FcRn antibody.

19. The pharmaceutical composition of any one of claims 1 to 18, wherein the loading dose is a single dose.

20. The pharmaceutical composition of any one of claims 1 to 19, wherein the serum IgG is IgG1, IgG2, IgG3, or IgG4, or any combination thereof, and the decrease is at least 20% from baseline, or at least 30% from baseline.

21. The pharmaceutical composition of claim 20, wherein the use reduces serum IgG in the patient by at least 70% of baseline serum IgG.

22. A pharmaceutical composition described in any one of claims 1 to 21, wherein the patient is 18 years of age or older.

23. The pharmaceutical composition of claim 1, wherein the patient is seropositive for anti-acetylcholine receptor (AChR) autoantibodies, anti-muscle specific kinase (MuSK) autoantibodies, and / or anti-low density lipoprotein receptor-related protein 4 (LRP4) autoantibodies, or any combination thereof.

24. The pharmaceutical composition of claim 23, wherein the patient is seropositive for anti-AChR autoantibodies.

25. The pharmaceutical composition of claim 23, wherein the patient is seropositive for anti-MuSK autoantibodies.

26. The pharmaceutical composition of claim 23, wherein the patient is seropositive for anti-LRP4 antibodies.

27. The pharmaceutical composition of any one of claims 1 to 26, wherein the patient achieves at least a 3 point reduction in MG-ADL score from baseline by 24 weeks after receiving the initial loading dose.

28. A pharmaceutical composition described in any one of claims 1 to 27, wherein the patient achieves a reduction in QMG score of at least 4 points from baseline by 24 weeks after receiving the initial loading dose.

29. The pharmaceutical composition of any one of claims 1 to 28, wherein the patient achieves at least a 3 point reduction from baseline in MG-ADL score and at least a 4 point reduction from baseline in QMG score by 24 weeks after receiving the initial loading dose.

30. 1. A pharmaceutical composition for administration to a patient suffering from myasthenia gravis, comprising an anti-FcRn antibody, the anti-FcRn antibody is administered intravenously or subcutaneously to the patient at an initial loading dose of about 30 mg / kg to about 60 mg / kg, followed by a maintenance dose of about 15 mg / kg to about 30 mg / kg of the anti-FcRn antibody; The anti-FcRn antibody, a heavy chain comprising an HCDR1 of SEQ ID NO:6, an HCDR2 of SEQ ID NO:7, and an HCDR3 of SEQ ID NO:8; and a light chain comprising an LCDR1 of SEQ ID NO:3, an LCDR2 of SEQ ID NO:4, and an LCDR3 of SEQ ID NO:

5.

31. 31. The pharmaceutical composition of claim 30, wherein the loading dose is about 60 mg / kg or about 30 mg / kg and the maintenance dose is about 15 mg / kg or about 30 mg / kg.